Top

Henry M. Kuerer, M.D., Ph.D., F.A.C.S., CMQ

Department of Breast Surgical Oncology, Division of Surgery

About Dr. Kuerer

Dr. Kuerer plays a leading role in MD Anderson’s world-renowned breast care group as a recognized cancer surgeon and researcher who specializes in the multidisciplinary care of patients with breast cancer. Recruited back to MD Anderson to help establish a premier program to train breast cancer surgeons of the future, he became the founding Director of the Breast Surgical Oncology Training Program, and is now the Robinson Endowed Distinguished Professor of Surgery and Cancer Research, and the Executive Director of the MD Anderson Cancer Network Breast programs. He maintains a busy clinical research program and is also a Co-Principal Investigator for the expanded national cooperative group NRG Oncology at MD Anderson and serves as a member of the NRG Breast Committee, is on the editorial board of several clinical journals, and is the Chair of the Publications Committee for American Society of Breast Surgeons. Dr. Kuerer is heavily involved with the MD Anderson Cancer Network clinical expansion in terms of comprehensive assessment, benchmarking, and review of potential new partners and ongoing member hospital and programmatic relationships nationally and internationally. Dr. Kuerer is a regularly invited speaker at academic, national, and international meetings and has authored or coauthored more than 500 peer-reviewed scientific reports, editorials/commentaries, and text chapters. Dr. Kuerer is Editor-in-Chief of the definitive McGraw-Hill textbook, Breast Surgical Oncology.

Surgery may not be necessary to treat invasive breast cancer

Breast biopsies after neoadjuvant chemotherapy accurately predict presence of residual breast cancer

MD Anderson study evaluates need for biopsies during follow-up care in women with early breast cancer

Present Title & Affiliation

Primary Appointment

Professor and Executive Director Breast Programs, MD Anderson Cancer Network, Department of Breast Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor and Executive Director Breast Programs, MD Anderson Cancer Network, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

PH and Fay Etta Robinson Distinguished Professor in Cancer Research, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1992	SUNY Health Science Center, Brooklyn, New York, US, Medical Scientists Training Program, Ph.D
1992	SUNY Health Science Center, Brooklyn, New York, US, MD
1985	Rutgers College, New Brunswick, New Jersey, US, Biological Sciences, BA

Postgraduate Training

2015-2015	Leadership, Harvard Executive Leadership Strategies for Evolving Health Care, Boston, Massachusetts
2014-2014	Healthcare Delivery Program, Value Based Health Care, Strategy for Healthcare Delivery Program, Harvard Business School Texas Medical Center Collaborative, Houston, Texas
1997-1998	Clinical Fellowship, Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
1992-1997	Clinical Residency, General Surgery, The Mount Sinai School of Medicine, New York, New York

Licenses & Certifications

1998	Diplomate of the American Board of Surgery
1998	American Board of Medical Quality, Certified in Medical Quality
1998	California Physicians and Surgeons License to Practice Medicine
1997	Texas State Board of Medical Examiners Licensure
1993	National Board of Medical Examiners
1993	New York State License to Practice Medicine and Surgery

Experience & Service

Faculty Academic Appointments

Associate Professor of Surgery with Tenure, Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 2003 - 2007

Assistant Professor, Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 2000 - 2003

Assistant Professor in Residence, Department of Surgery, University of California at San Francisco, San Francisco, CA, 1998 - 2000

Fellow, Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 1997 - 1998

Junior Faculty Associate, Department of Surgery, The Mount Sinai School of Medicine, New York, NY, 1996 - 1997

Administrative Appointments/Responsibilities

Executive Director, Department of Breast Programs, The University of Texas MD Anderson Cancer Center, MD Anderson Cancer Network, Houston, TX, 2015 - Present

Medical Director, Department of Clinical Expansion, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2015

Co-Program Director, MD Anderson and Susan G. Komen Interdisciplinary Breast Fellowship Program, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2002 - 2009

Director, Breast Surgical Oncology Fellowship Training Program, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2001 - 2019

Director, UCSF Ongoing Breast Cancer Surveillance Program, University of California at San Francisco, San Francisco, CA, 1999 - 2000

Other Professional Positions

Member - Breast Standard Working Group, The International Consortium for Health Outcomes Measurement (ICHOM), Cambridge, MA, 2015 - Present

Subject Matter Expert, 2012 - Present

Panel member, National Oncology Alliance, unknown, 2006 - 2009

Reviewer, National Comprehensive Cancer Network, Unknown, 2001 - Present

Member, Regional Cancer Foundation, San Francisco, CA, 1999 - 2000

Extramural Institutional Committee Activities

Member, Chief Academic Officer Sub-committee on faculty engagement, The University of Texas MD Anderson Cancer Center, 2020 - Present

Member, MD Anderson Cancer Network Adjunct Appointment Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present

Member, MD Anderson Expansion Strategy Team, The University of Texas MD Anderson Cancer Center, 2017 - Present

Member, American Association of Cancer Research Program Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2018

Member, Office of the Deputy President, Career, Resilience, Engagement, Wellbeing, and Sustainability Task Force, The University of Texas MD Anderson Cancer Center, 2017 - Present

Co-Chair, Faculty Health and Wellbeing, Office of the Chief Academic Officer, The University of Texas MD Anderson Cancer Center, 2017 - Present

Chair, General Oncology Search Committee, The University of Texas MD Anderson Cancer Center, 2016 - 2017

Member, Promotions and Tenure Committee, Academic Affairs, MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, 2016 - 2018

Member, Banner MD Anderson Cancer Center (BMDACC) Relationship Committee, The University of Texas MD Anderson Cancer Center, 2015 - Present

Member, Cancer Network Operations Committee, The University of Texas MD Anderson Cancer Center, 2014 - Present

Member, Executive Committee, National Clinical Trials Network Lead Academic Participating Site (LAPS) Grant, The University of Texas MD Anderson Cancer Center, 2014 - Present

Chair, Pathology Department Chair Search Committee, Office of the Provost, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2014 - 2015

Member, Cancer Network Steering Committee, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2014 - Present

Member, MD Anderson Patient and Provider Outcomes Development Group, Office of the Senior VP Clinical Operations, The University of Texas MD Anderson Cancer Center, 2013 - Present

Member, MD Anderson Cancer Network Research Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present

Member, Education Council, Educational Resources Committee, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2012 - Present

Member, Chair Search Committee, Breast Medical Oncology, Office of the Provost, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2011 - 2013

Member, Vice President of Education Search Committee, Office of the Provost, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2011 - 2012

Member, Breast Cancer Clinical Research Program Committee, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2010 - 2014

Member, Breast and Surgical Oncology Education Committee, The University of Texas MD Anderson Cancer Center, 2009 - Present

Member, Faculty Health Committee, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2008 - Present

Member, Advisory Committee: Program for Interpersonal Communication and Relationship Enhancement, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2007 - Present

Member, Scientific Publications Advisory Group, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2006 - Present

Member, Cancer and Pregnancy MD Anderson Cancer Center Guidelines Development Task Force, The University of Texas MD Anderson Cancer Center, 2005 - Present

Member, Institutional Review Subcommittee of Graduate Medical Education, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2003 - Present

Member, Abnormal Results Task Force, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2003 - 2004

Member, Surgical Oncology Clinical Research Committee, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2002 - Present

Member, Graduate Medical Education Committee, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2002 - Present

Member, Medical Practice Committee, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2001 - 2004

Member, Multidisciplinary Telemedicine Planning Clinic Surgery Representative, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2000 - 2011

Member, Clinical Research Committee Protocol Scientific Reviewer, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2000 - Present

Member, Finance Committee, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2000 - 2003

Member, Faculty Senate, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2000 - 2003

Member, Breast Cancer Practice Outcomes Committee, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2000 - 2009

unknown, UCSF Third Year Medical Student Formal Surgery Advisor, The University of Texas MD Anderson Cancer Center, 1999 - 2000

Member, UCSF Cancer Center Data Monitoring Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2000

Surgeon Representative, Healing Choices, Bridging Communities: Breast Cancer and Integrative Medicine, The University of Texas MD Anderson Cancer Center, 1998 - 1999

Member, UCSF Breast Oncology Program, The University of Texas MD Anderson Cancer Center, 1998 - 2000

Member, UCSF Surgery Resident Recruitment and Selection Committee, The University of Texas MD Anderson Cancer Center, 1998 - 2000

Member, UCSF Cancer Center Steering Committee, The University of Texas MD Anderson Cancer Center, 1998 - 2000

Member, UCSF Perioperative Collaborative Practice Committee, The University of Texas MD Anderson Cancer Center, 1998 - 2000

Member, UCSF Critical Care Planning Committee, The University of Texas MD Anderson Cancer Center, 1998 - 2000

Member, UCSF Campus Wide Breast Pathology Working Group, The University of Texas MD Anderson Cancer Center, 1998 - 2000

Member, UCSF Cancer Center, The University of Texas MD Anderson Cancer Center, 1998 - 2003

Editorial Activities

Editor, Annals Surgical Oncology, 2019 - 2021

Editor, Breast Cancer, Society of Surgical Oncology, SOSAP: Surgical Oncology Self-Assessment Program, 2015 - Present

Editorial Advisory Board Member, Current Cancer Therapy Reviews, 2015 - Present

Editor, Cancer Management, American Society of Breast Surgeons Breast Education and Self-Assessment Program, 2013

Editor, American Society of Cllinical Oncology Education Book, 2013 - 2014

Editor, UpToDate, Wolters Kluwer Health, Waltham, MA, 2012 - Present

Associate Editor, New England Journal of Medicine, Journal Watch Oncology/Hematology, 2006 - Present

Editor, Journal of Clinical Oncology, 2006 - 2008

Editorial Board, The Breast Journal, 2005 - Present

Editorial Board, The Cancer Journal, 2005 - Present

Editorial Board, Annals of Surgical Oncology, 2004 - Present

Editorial Board, American Journal of Oncology Review, 2003 - Present

Editor, Women’s Oncology Review, 2002

Honors & Awards

2021	Excellence in Research Mentorship Award, The UT MD Anderson Cancer Center Department of Breast Surgical Oncology
2019	American Society of Breast Surgeons Scientific Impact Award for Research Mentor
2019	MD Anderson Distinguished Educator Award, The University of Texas MD Anderson Cancer Center, Academy of Health Science Education
2018 - 2024	Honorary Member Sociedad de Cirujanos de Chile
2017	Master Educator Award in Surgical Oncology, State University of New York, Health Sciences Center at Brooklyn
2017	National Top 1% Patient Care Experience
2017	Top Doctors Award and Top Surgeon, awarded multiple years, Castle Connolly Medical, Ltd
2016	ASCO Advocacy Champion
2016	MD Anderson Cancer Center Outstanding Graduate Medical Education Program Director Award
2015	Outstanding Teacher Award, The UT MD Anderson Cancer Center Department of Surgical Oncology
2014	Harvard Business School Texas Medical Center Collaborative, Value Based Health Care, Strategy for Healthcare Delivery Invited Participant
2014	NEJM Group-Harvard Business Review Innovation in Health Care Leadership Invited Participant
2014	Regent's Outstanding Teaching Award
2010	Royal Australasian College of Surgeons Distinguished Visitor
2009	Honorary Induction, Societe Internationale de Senologie
2006 - 2024	Best Doctors in America
2005 - 2008	Faculty Scholars Award, The UT MD Anderson Cancer Center
2004	Honorary Permanent Membership in the Sociedad Mexicana de Oncologia
2001 - 2024	Susan G. Komen Breast Cancer Foundation Study Section Scientific Reviewer
1998	American Society of Clinical Oncology Merit Award
1998	MD Anderson Associates-Kanojia Clinical Fellow Award
1995	American College of Surgeons Resident's Paper Competition
1992	Association for Academic Surgery Research Award
1992	Who's Who in Science and Engineering
1987	Medical Scientists Award, Engle Foundation
1986 - 1987	NIH Research Foundation Summer Fellowship
1985	The Ralph Defalco Award for Excellence in the Biological Sciences
1981	Rutgers Scholars Program

Professional Memberships

ASCO Annual Meeting Scientific Program Committee

2019 - 2022

American Association of Cancer Research Program Committee

2017 - 2018

Alliance for clinical trials. COMET: Comparison of Medical Endocrine Therapy with Surgery for Low – Risk DCIS, a randomized multi-center and cooperative group study

2016 - 2021

International Consortium of Health Outcomes Measures (ICHOM), Harvard Business School

2016 - Present

NRG Oncology

2015 - Present

American Association of Physician Leadership Institute

2014

Alliance for Clinical Trials in Oncology

2011 - Present

SIS International Scientific Centers Network

2009 - Present

NSABP Breast Committee Working Group

2007 - 2010

New England Journal of Medicine, Journal Watch Oncology and Hematology

2006 - Present

International Society of Cancer Risk Assessment and Management

2004 - Present

Sociedad Mexicana de Oncologia

2004 - Present

Western Surgical Association

2003 - Present

American College of Radiology Imaging Network (ACRIN), Breast Committee

2003 - 2008

Texas Medical Association

2000 - Present

American College of Surgeons Oncology Group

2000 - 2011

National Comprehensive Cancer Network (NCCN) Breast Cancer Treatment and Prevention Guidelines

1999 - Present

Susan G. Komen Breast Cancer Foundation

1999 - 2000

American College of Surgeons Commission

1999 - 2000

American Society of Breast Surgeons

1998 - Present

American Society of Clinical Oncology

1998 - Present

Bay Area Breast Cancer Forum

1998 - 2000

Society of Surgical Oncology

1998 - Present

American Society of Breast Disease

1997 - Present

New York Academy of Sciences

1995 - 1997

New York Metropolitan Breast Cancer Group

1993 - 1997

Association for Academic Surgery

1992 - Present

American College of Surgeons

1992 - Present

Medical Society of the State of New York

1985 - 1997

Selected Presentations & Talks

Local Presentations

2024. De-escalating surgical therapy after neoadjuvant chemotherapy in breast cancer (exceptional responders). Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2023. Review of NCCN Guidelines. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2022. De-escalating surgical therapy after neoadjuvant chemotherapy in breast cancer (exceptional responders). Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2021. De-escalating surgical therapy after neoadjuvant chemotherapy in breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2021. Journal Club: Duchess Trial. Moderator. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2021. Review of NCCN guidelines. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2021. De-escalating surgical therapy after neoadjuvant chemotherapy in breast cancer (exceptional responders). Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2020. De-escalating surgical therapy after neoadjuvant chemotherapy in breast cancer (exceptional responders). Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2019. Pre-op Radiation Therapy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2019. First job search and negotiations. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2019. Introduction to Breast Surgical Oncology and Review of NCCN guidelines. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2019. Wellness and resiliency in a breast surgical oncology career. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2018. De-escalating surgical therapy after neoadjuvant chemotherapy in breast cancer (exceptional responders). Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2018. Stress and Burnout in Medical Professionals at MD Anderson; Identification and Management. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2018. Biologic and genomic tools for determining DCIS local-recurrence risk with and without radiotherapy after breast conserving surgery. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2018. Eliminating Breast Surgery in Exceptional Responders with Neoadjuvant Systemic Therapy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2018. Surgical trials – COMET and no surgery for exceptional responders. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2018. Targeted Axillary Dissection: New Surgical and Radiologic Method to Avoid Axillary Dissection. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2018. Surgical issues regarding DCIS and research opportunities. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2018. Integrating neoadjuvant systemic therapy with breast cancer surgery: predictors of response and progression outcomes. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2017. Career Planning: Selection and Negotiating your First Position. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2017. Local-Therapy Implications following Neoadjuvant Systemic Therapy for Breast Cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2017. Long-term Results after Oncoplastic Surgery for Breast Cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2017. Leveraging the neoadjuvant platform in breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2017. Imaging and determination of pathologic response in the breast and nodes after neoadjuvant systemic therapy: clinical trial implications. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2017. Eliminating Breast Cancer Surgery in Exceptional Responders with Neoadjuvant Systemic Therapy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2016. Guidelines for Consideration of Contralateral Prophylactic Mastectomy- New American Society of Breast Surgeons. Conference. The University of Texas MD Anderson Cancer Cancer. Houston, TX, US.
2016. MD Anderson Cancer Network Overview and Opportunities for Breast Program Clinical and Translational Research. Conference. The University of Texas MD Anderson Cancer Cancer. Houston, TX, US.
2016. Multidisciplinary Care of the Cancer Patient. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2016. Multidisciplinary care of the cancer patient. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2016. Common Benign Breast Disorders and Their Management. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2016. Improving breast surgery with oncoplastic reconstruction. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2015. Breast Cancer Regional Nodal Irradiation: MD Anderson Multidisciplinary Clinical Practice implications of MA.20 and EORTC 22922 Trial Results. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2015. Integrating breast cancer clinical standards and research. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2015. Incidence and Predictors of Breast Cancer Local-regional Recurrence in 2015. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2015. Local control in breast assessment. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2015. American Society of Breast Surgeons New Performance & Practice Guidelines & Quality Monitoring. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2014. Regional nodal radiation in sentinel node positive patients. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2014. 2014 National Comprehensive Cancer Network Guidelines for Diagnosis, Genetic Testing, and Treatment. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2013. Intraoperative radiotherapy for breast cancer: ready for prime time?. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2012. Update on DCIS trials at MD Anderson and opportunities for prevention research. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2012. Elimination of axillary surgery for invasive breast cancer: update on clinical trials past, present, and future. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2012. Update on breast cancer management. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2012. Surveillance and invasive procedures following standard breast conserving surgery. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2012. Maintaining work life balance and preventing burnout at MD Anderson Cancer Center and results of completed and ongoing studies. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2011. Current and future research priorities. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2011. Evidence based management of ductal carcinoma in situ. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2011. Occult metastases in sentinel nodes and bone marrow in breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2011. Gene expression profiling in breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2011. Triple negative breast cancer and local regional control. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2010. Biomarker expression and risk of local-regional recurrence from breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2010. What's new with intraoperative radiotherapy for breast cancer?. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2010. Influence of biology, therapy, and tumor burden on local and regional recurrence from breast cancer: role of margin evaluation and control of surgery. Conference. The University of Texas MD Anderson Cancer Center, Department of Breast Medical Oncology. Houston, TX, US.
2010. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Conference. The University of Texas MD Anderson Cancer Center, Department of Breast Medical Oncology. Houston, TX, US.
2010. NIH consensus conference: update on management and necessary future research steps. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2009. Novel therapies for early stage breast cancer: current state-of-the art. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2009. Role of Post-mastectomy radiation in early breast cancer: Update of the EBCTCG randomized meta-analysis of 23,000 patients and current treatment implications. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2009. HER-2 Overexpression as a Predictor for Cancer Transition from In situ to Invasive Breast Cancer and Mechanism of Action of Trastuzumab. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2009. Technical aspects and considerations in axillary lymph node dissection. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2009. Advances in breast surgical oncology. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2008. Prognostic significance of occult axillary metastases in breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2008. Role of axillary surgery in patients with DCIS. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2008. Recent advances in the local therapy of breast cancer. burnout. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2008. Optimizing career satisfaction in surgical oncology and practical tips to avoid burnout. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2007. Fifty-three years of landmark studies by the NSABP and their currently planned trials. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2007. Clinical assessment and selection of patients for neoadjuvant systemic therapy for breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2007. Role of accelerated partial breast radiation in the management of breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2007. Role contralateral breast MRI at diagnosis of breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2007. Surgery for inoperable breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2007. Diagnosis and management of local recurrences following breast conserving surgery or mastectomy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2006. The clinical management and current investigator initiated trials for ductal carcinoma in situ of the breast. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2006. NSABP landmark local therapy clinical trials. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2006. DCIS: Current and development of the next pivotal trials. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2006. Surgery after Neoadjuvant Therapy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2006. Diagnosis and management of phyloides tumors. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2006. Implications of breast cancer surgery for radiation oncologists. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2006. Breast cancer and reconstructive considerations. Invited. Baylor College of Medicine. Houston, TX, US.
2006. Breast Cancer: What the scientist needs to know. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2006. Techniques for reconstruction of the partial mastectomy defect. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2006. Clinical trial results and novel perspectives on non-invasive breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2006. New insights into optimizing local control. Conference. Four Seasons Hotel. Houston, TX, US.
2006. Randomized data to support a survival advantage with local control of breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2005. Herceptin for primary breast cancer: current and planned clinical trial for DCIS. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2005. Integrating multidisciplinary breast cancer care with reconstructive surgery. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2005. Role of bone marrow aspiration in early breast cancer staging. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2005. Role of lymph node assessment in patients at high-risk receiving prophylactic mastectomy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2004. Minimally invasive procedures for breast disease and cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2004. Integration of lymphatic mapping and sentinel lymph node biopsy for breast cancer in developing countries. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2004. Molecular Determinates of Breast Cancer Risk. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2004. M D Anderson Investigator Initiated Multicenter Phase II Study of Repeat Breast Conserving Surgery for Local In-Breast Recurrence. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2003. Molecular determinants of breast cancer risk. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2003. Breast cancer. The End of Cancer as We Know it. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2003. Initiation of accelerated partial breast irradiation protocols at M.D. Anderson Cancer Center: rationale and surgical considerations. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2002. Current New Choices in Breast Cancer Management. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2002. M. D. Anderson Inaugural Presidential Opening. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2002. Proteomics. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2002. What you and every patient needs to know about breast cancer: Focus on surgery. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2002. The role of ductal fluid cellular and protein analyses in breast cancer risk stratification and biomarker discovery. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2001. Role of ductal fluid analyses in our understanding of the biology and risk stratification of breast carcinoma. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2001. Radiofrequency ablation of small invasive breast cancers: M. D. Anderson Cancer Center Protocols. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2001. Role of intraductal technology in the prevention, detection, and treatment of breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2001. Advances in Surgical Oncology. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2001. Nipple aspirate proteins in breast cancer biomarker discovery. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2000. What’s new in breast cancer?. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2000. Anthracycline and taxane resistant breast carcinoma. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2000. Pitfalls of chemotherapy prior to surgery for breast cancer. Conference. Kelsey Seybold Clinic. Houston, TX, US.
1998. Role of axillary dissection in the multimodality treatment approach to locally advanced breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
1996. Early results of conservative surgical treatment of invasive breast cancer associated with pregnancy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.

Regional Presentations

2018. American Joint Committe on Cancer (AJCC) 8th Edition Staging for Breast Cancer. Conference. Citizens Medical Center. Victoria, TX, US.
2013. Evidence based management strategies for nodal micrometastases in breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, US.
2013. Long-term outcomes in patients with radiation-association angiosarcomas of the breast following surgery and radiotherapy for breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, US.
2013. Landmark breast cancer cooperative group trials: Preoperative chemotherapy and surgical trials. Conference. The University of Texas MD Anderson Cancer Center. Houston, US.
2011. New Breast Cancer AJCC7th Edition Revised Staging System: implications for clinical multidisciplinary practice. Conference. Citizens Medical Center. Victoria, TX, US.

National Presentations

2025. Exceptional Responders to Breast Cancer Therapy: Eliminating Surgery Altogether. Invited. Clinical Congress. Chicago, IL, US.
2024. Transformational potential of selective elimination of breast cancer surgery among patients with exceptional responses to neoadjuvant systemic therapy. Invited. American Association for Cancer Research, Session SY47-Surgical Innovations in Breast Cancer. San Diego, CA, US.
2022. Integrating the no surgery and radiation paradigm after neoadjuvant systemic therapy in the MD Anderson clinical trials portfolio. Invited. MD Anderson Cancer Center, US.
2021. Surgical Care in women with breast cancer: The OR and beyond. Invited. 6th Annual Breast Health Symposium. New York, New York (Virtual), US.
2021. De-escalation of Breast Surgery. Invited. 10th Global Breast Cancer Conference. Seoul (Virtual).
2021. Local Management of the Primary Tumor in Stage IV Breast Cancer. Invited. 38th Annual Miami Breast Cancer Conference. (Virtual), US.
2021. Utilizing Preoperative Radiotherapy (RT) to Facilitate Immediate Autologous Breast Reconstruction. Invited. 38th Annual Miami Breast Cancer Conference. (Virtual), US.
2020. What’s new with decreasing and eliminating breast and axillary surgery after neoadjuvant systemic therapies?. Invited. 10th Global Breast Cancer Conference (Virtual via YouTube). Seoul.
2020. Surgical Considerations for the Axilla. Invited. School of Breast Oncology. (Virtual), US.
2020. Elimination of Breast Cancer Surgery in exceptional responders. Live CMB. Invited. 1st Free online event with everyday clincial cases.
2020. Moderator, Virtual Plenary Scientific Sessions. Invited. The American Society of Breast Surgeons. Las Vegas (V), NV, US.
2020. Male Breast Cancer: Sugical Perspective. Invited. The NYMBCG 47th Annual Breast Cancer Symposium. New York, NY, US.
2020. Angiosarcoma: Where are we now?. Invited. The NYMBCG 47th Annual Breast Cancer Symposium. New York, NY, US.
2020. Eliminating breast cancer surgery in exceptional responders after neoadjuvant chemotherapy. Invited. The NYMBCG 47th Annual Breast Cancer Symposium. New York, NY, US.
2020. Panel Discussion & Closing Remarks: Updates from MD Anderson. Invited. The NYMBCG 47th Annual Breast Cancer Symposium. New York, NY, US.
2019. Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict the presence of residual cancer: a multi-institutional pooled analysis. Conference. San Antonio Breast Cancer Symposium. San Antonio, TX, US.
2019. Surgical Considerations for the Axilla. Invited. 17th Annual School of Breast Oncology. Atlanta, GA, US.
2019. Surgical Considerations for the Axilla. Invited. 17th Annual School of Breast Oncology. Atlanta, GA, US.
2019. De-Escalation of breast and axillary surgery after neoadjuvant systemic therapy. Invited. Emerging Treatment Options in the management of early stage triple negative (TNBC) and HER2 positive breast cancer. The role of neoadjuvant and post-neoadjuvant therapies. Chicago, IL, US.
2019. Percutaneous management of breast cancer after pCR following neoadjuvant chemotherapy. Invited. 20th Annual Meeting. Dallas, TX, US.
2019. Work Life Balance, What Makes You Happy?. Invited. The National Consortium of Breast Centers. Las Vegas, NV, US.
2019. Since My Cancer Has Disappeared with Neoajuvant Chemotherapy - Do I Still Need Surgery?. Invited. The National Consortium of Breast Centers. Las Vegas, NV, US.
2019. De-Escalation of Breast and Axillary Surgery After Neoadjuvant Systemic Therapy. Invited. Keck School of Medicine of USC. Los Angeles, CA, US.
2018. Medical Advisory Board. Invited. Breast Cancer Network. Las Vegas, NV, US.
2018. Take the Lead in Breast Cancer Care, Roundtable Symposium. Invited. Breast Cancer Network. Las Vegas, NV, US.
2018. Surgical Considerations for the Axilla. Invited. 16th Annual Meeting. Atlanta, GA, US.
2018. Breast Lymphatic Mapping and Sentinel Node Biopsy. Invited. Advisory Board. Chicago, IL, US.
2018. Breast Cancer Surgery Present and Future. Invited. Zeta Tau Alpha Grand Rounds. Indianapolis, IN, US.
2018. Breast Cancer Surgery Update: Present and Future. Invited. The Lefcourt Family Cancer Treatment and Wellness Center. Englewood, NJ, US.
2018. Patient Reported Outcomes for Breast Patients. Q&A. Invited. The American Society of Breast Surgeons. Grande Lakes, Orlando, FL, US.
2018. Quickshot Presentations. Invited. The American Society of Breast Surgeons. Grande Lakes, Orlando, FL, US.
2018. No Surgery in pCR Patients After Neoadjuvant Therapy. Invited. The John Wayne Critical Issues in Breast Cancer Forum: The Changing Paradigm for Breast Cancer Surgery.Supported by an educational grant from the John Wayne Cancer Foundation. Grande Lakes, Orlando, FL, US.
2018. Burnout in Oncology-Related Physicians: Incidence and Roadmap for Mitigation. Invited. 35th Annual Miami Breast Cancer Conference. Miami Beach, FL, US.
2018. Breast Cancer Management in Exceptional Responders to Neoadjuvant Systemic Therapy. Invited. 35th Annual Miami Breast Cancer Conference. Miami Beach, FL, US.
2018. DCIS: What Is the Evidence for a 2-MM Margin?. Invited. 35th Annual Miami Breast Cancer Conference. Miami Beach, FL, US.
2018. Nonoperative management of DCIS. Invited. The 23rd Annual Multidisciplinary Symposium on Breast Disease. Amelia Island, FL, US.
2018. Management of the Axilla after Neoadjuvant Therapy. Invited. The 23rd Annual Multidisciplinary Symposium on Breast Disease. Amelia Island, FL, US.
2018. Eliminating Breast Cancer Surgery after Neoadjuvant Therapy: Will it be a New Trend?. Invited. The 23rd Annual Multidisciplinary Symposium on Breast Disease. Amelia Island, FL, US.
2018. Nodal Downstaging a New Indication for Neoadjuvant Therapy. Invited. The 23rd Annual Multidisciplinary Symposium on Breast Disease. Amelia Island, FL, US.
2018. Advances in Wireless Approaches to BCT #2. Invited. The 23rd Annual Multidisciplinary Symposium on Breast Disease. Amelia Island, FL, US.
2017. Defining and negotiating your first job. Conference. SSO Fellows Institute at the Methodist Institute for Technology, Innovation, and Education (MITIE). Houston, TX, US.
2017. Sentinel Lymph Node Biopsy and Axillary Dissection. Invited. School of Breast Oncology. Atlanta, GA, US.
2017. De-escalating and Eliminating Surgery for Invasive Breast Cancer After Neoadjuvant Systemic Therapy. Invited. 7th Annual Breast Cancer Symposium. Poughkeepsie, NY, US.
2017. De-escalating and elimination of breast and nodal surgery for invasive breast cancer after neoadjuvant systemic therapy. Invited. Northwell Health Multi-Hospital Combined Multidisciplinary Breast Program Lecture and Visiting Professorship Program. New York, NY, US.
2017. Hot Topics and Challenging Dogma: No surgery after neoadjuvant chemotherapy with biopsy. Invited. The American Society of Breast Surgeons. Las Vegas, NV, US.
2017. General Session: Tumor Board Participation, Surgery. Invited. The American Society of Breast Surgeons. Las Vegas, NV, US.
2017. Genomic Profiling for Neoadjuvant Treatment? Is Pre-treatment Genomic Profiling Ready for Prime Time?. Invited. The American Society of Breast Surgeons. Las Vegas, NV, US.
2017. Surgical Management of Breast Cancer. Invited. 2017 State of The Science Summit. Dallas, TX, US.
2016. MD Anderson Breast Surgical Guidelines. Invited. National MD Anderson Physician's Network Site Video Lecture. Houston, TX, US.
2016. Feasibility Trial for Identification of Patients for Eliminating Breast Cancer Surgery Following Neoadjuvant Systemic Therapy. Conference. 2016 San Antonio Breast Cancer Symposium. San Antonio, TX, US.
2016. How to Select the Right Job and Integrating Work-Life Balance. Invited. SSO Fellows Institute at the Methodist Institute for Technology, Innovation, and Education (MITIE). Houston, TX, US.
2016. Sentinel Lymph Node Biopsy and Axillary Dissection. Invited. 14th Annual School of Breast Oncology. Atlanta, GA, US.
2016. Randomized trial of endocrine therapy alone versus guideline concordant care for DCIS. Invited. NRG Cooperative Group National Meeting. Dallas, TX, US.
2016. DCIS Discussion: Alliance Trial. Conference. NRG Oncology Semiannual Meeting. Dallas, TX, US.
2016. Overview of how clinical trials have shaped the management of breast cancer 1960 to date. Invited. ASBrS 17th Annual Meeting. Dallas, TX, US.
2016. Optimal Surgical Management Lymph Node Positive Breast Cancer 2016. Invited. 26th Annual Interdisciplinary Breast Cancer Conference. Las Vegas, NV, US.
2016. Surgical Management DCIS. Invited. 26th Annual Interdisciplinary Breast Cancer Conference. Las Vegas, NV, US.
2016. Multidiciplinary Approach Boarder line Lesions (Surgeon). Invited. 26th Annual Interdisciplinary Breast Cancer Conference. Las Vegas, NV, US.
2016. Update on the Surgical Management of Breast Cancer: What Happens After Imaging?. Invited. SBI Breast Imaging Symposium. Austin, TX, US.
2016. Feasibility Trial for Eliminating Breast Cancer Surgery in Exceptional Responders. Invited. 33rd Annual Miami Breast Cancer Conference. Miami Beach, FL, US.
2016. Treatment vs Observation in DCIS. Invited. 33rd Annual Miami Breast Cancer Conference. Miami Beach, FL, US.
2016. Selective Management of DCIS: Future Directions. Invited. Susan G. Komen Lecture and Symposium. Boston, MA, US.
2016. Targeted Axillary Dissection for Node-Positive Breast Cancer. Invited. 33rd Annual Miami Breast Cancer Conference. Miami Beach, FL, US.
2016. Stress and Burnout of Medical Health Professionals: Recognizing the Syndrome and Avoiding the Adverse Consequences. Invited. 27th Annual Cancer Update 2016 Conference. San Antonio, TX, US.
2016. Maintaining Career Satisfaction, Well-being and Preventing Burnout for Oncology Providers. Invited. Institutional Cancer Center Grand Rounds. Gilbert, AZ, US.
2015. Pearls for Picking the Right Job –What’s Important to You. Invited. 2015 SSO Fellow's Institute. Houston, TX, US.
2015. Sentinel Lymph Node Biopsy and Axillary Dissection. Invited. 13th Annual School of Breast Oncology®. Atlanta, GA, US.
2015. Ethics Lecture and Discussion: Work Life Integration and Preventing Burnout Among Oncology Specialists. Invited. 13th Annual School of Breast Oncology. Atlanta, GA, US.
2015. Evaluation and Management of Non-Invasive Breast Cancers. Invited. Translating Molecular Biology into Individualized Cancer Care. National Harbor, MD, US.
2015. Eliminating breast cancer surgery: Clinical trials to set new paradigms. Invited. Institutional Grand Rounds. Tampa, FL, US.
2015. Pre-operative and intra-operative decision making in the neoadjuvant setting. Invited. Society of Surgical Oncology Annual Cancer Symposium. Houston, TX, US.
2015. Neoadjuvant therapy in the modern era. Invited. Society of Surgical Oncology. Houston, TX, US.
2014. The role of sentinel lymph node biopsy and axillary dissection. Invited. School of Breast Oncology. Atlanta, GA, US.
2014. Breast cancer as a high-stress and high-volume career choice: Identifying and managing burnout. Invited. 10th Annual Pacific Northwest Excellence in Breast and Gynecologic Care. Portland, OR, US.
2014. Neoadjuvant Strategies in DCIS. Invited. 10th Annual Pacific Northwest Excellence in Breast and Gynecologic Care. Portland, OR, US.
2014. Presidential symposium debate: regional nodal irradiation in the SLN era. Plenary session. 56th Annual Meeting. Invited. American Society for Radiation Oncology (ASTRO). San Francisco, CA, US.
2014. Presidential symposium debate: regional nodal irradiation in the SLN era. Plenary session. Invited. American Society for Radiation Oncology (ASTRO) 56th Annual Meeting. San Francisco, CA, US.
2014. Should we still be performing axillary lymph node dissection in breast cancer?. Invited. MD Anderson Physicians Network Annual Symposium. Boston, MA, US.
2014. When should we use MRI in breast cancer treatment?. Invited. MD Anderson Physicians Network Annual Symposium. Boston, MA, US.
2014. Current Controversies: Axillary Dissection: RIP?, Can XRT Improve Survival in Early-Stage Breast Cancer? General Session Moderator. Invited. American Society of Breast Surgeons 15th Annual Meeting. Las Vegas, NV, US.
2014. Community Tumor Board: Surgery. Invited. American Society of Breast Surgeons 15th Annual Meeting. Las Vegas, NV, US.
2014. MD Anderson Cancer Center breast surgery practices and clinical trials. Invited. Hackensack University Medical Center, Department of Surgery, Morbidity and Mortality Conference. Hackensack, NJ, US.
2014. Neoadjuvant strategies in DCIS. Invited. 31st Annual Miami Breast Cancer Conference. Miami Beach, FL, US.
2014. Strategies for neoadjuvant chemotherapy: Sentinel node clipping for post-chemotherapy identification. Invited. 31st Annual Miami Breast Cancer Conference. Miami Beach, FL, US.
2014. Breast cancer as a high stress and high volume career choice: Identifying and managing burnout. Invited. 31st Annual Miami Breast Cancer Conference. Miami Beach, FL, US.
2013. Development of national curriculum and evaluation of breast surgical oncology programs in the USA. Invited. Annual American College of Surgeons Meeting. Washington, DC, US.
2013. Integrating preoperative systemic therapy with local regional treatments. Invited. Bringing the Future of Oncology to Practice Now. MD Anderson Physicians Network Symposium, Peabody Hotel. Orlando, FL, US.
2013. Update on DCIS. Invited. Bringing the Future of Oncology to Practice Now. MD Anderson Physicians Network Symposium, Peabody Hotel. Orlando, FL, US.
2013. Nomograms: How useful are they. Invited. American Society of Breast Surgeons. Chicago, IL, US.
2012. New trials evidence and emerging controversies in cancer care. Invited. American College of Surgeons Centennial Meeting and Celebration. Chicago, IL, US.
2012. The role of sentinel lymph node biopsy and axillary dissection. Invited. School of Breast Oncology. Atlanta, GA, US.
2012. Oncoplastic surgery: Does it improve breast cancer outcomes?. Invited. Frontiers of Interdisciplinary Personalized Cancer Therapy. Chicago, IL, US.
2012. New directions in the management of DCIS. Invited. Frontiers of Interdisciplinary Personalized Cancer Therapy. Chicago, IL, US.
2012. Coordinating reconstruction with post-mastectomy XRT: The MD Anderson Experience. Invited. Breast Cancer Coordinated Care (BC3) 2nd Annual Symposium. Washington, DC, US.
2012. Breast conservation and oncoplastic surgery: The MD Anderson Experience. Invited. Breast Cancer Coordinated Care (BC3) 2nd Annual Symposium. Washington, DC, US.
2012. Papillary lesions of the breast: diagnostic and management. Invited. American Society of Breast Surgeons. Phoenix, AZ, US.
2012. Biology of DCIS: More questions than answers?. Invited. Plenary session, American Society of Breast Surgeons. Phoenix, AZ, US.
2012. Update and clinical trials for DCIS of the breast. Invited. Grand Rounds, Department of Surgery. Chicago, IL, US.
2012. Genetic profiling of in situ breast carcinoma. Invited. University of Miami, Sylvester Comprehensive Cancer Center, Grand Rounds. Miami, FL, US.
2012. Clinical trials update and current understanding of ductal carcinoma in situ of the breast. Invited. Roswell Park Cancer Institute. Buffalo, NY, US.
2011. Sentinel lymph nodes and detecting micrometastatic disease. Invited. Emory University. Atlanta, GA, US.
2011. Improving targeted therapy in the future. Invited. 13th Annual Lynn Sage Breast Cancer Symposium. Chicago, IL, US.
2011. Educational programs of the American College of Surgeons Oncology Group and opportunities for the new Alliance and Commission on Cancer. Invited. American College of Surgeons. Chicago, IL, US.
2011. Ipsilateral breast cancer recurrence: predictors, diagnosis, and management. Invited. American Society of Breast Surgeons. Washington, DC, US.
2011. Histologic and biologic markers to differentiate indolent from aggressive DCIS. Invited. 28th Annual Miami Breast Cancer Conference. Miami Beach, FL, US.
2011. Tumor Board Symposium: Participant. Invited. 64th Annual Cancer Symposium of the Society of Surgical Oncology. San Antonio, TX, US.
2011. Is there a role for preoperative therapy for DCIS?. Invited. 28th Annual Miami Breast Cancer Conference. Miami Beach, FL, US.
2011. Nipple discharge and gynecomastia. Invited. 28th Annual Miami Breast Cancer Conference. Miami Beach, FL, US.
2011. New Breast Cancer AJCC 7th Edition Revised Staging System: Implications for clinical multidisciplinary practice. Invited. Citizens Medical Center. Victoria, TX, US.
2010. Utility of sentinel lymph node biopsy for breast cancer. Invited. Emory Conference Center, School of Breast Oncology. Atlanta, GA, US.
2010. Moderator: Advances in cancer surgery and update on ACOSOG clinical trials. Invited. American College of Surgeons Annual Congress. Washington, DC, US.
2010. Ductal carcinoma in situ: Update on biology and treatment. Invited. The University of Texas M. D. Anderson Cancer Center and M. D. Anderson Physicians Network Sixth Annual Symposium, Personalized Interdisciplinary Cancer Treatment: The Importance of Timing. New York, NY, US.
2010. Improving surgical outcomes with preoperative systemic therapy for breast cancer. Invited. The University of Texas M. D. Anderson Cancer Center and M. D. Anderson Physicians Network Sixth Annual Symposium, Personalized Interdisciplinary Cancer Treatment: The Importance of Timing. New York, NY, US.
2010. Educational Programs of the American College of Surgeons Oncology Group. Invited. NIH Subcommittee H Presentation. Bethesda, MD, US.
2010. Advances in DCIS. Breakfast Workshop. Invited. 11th Annual Meeting of the American Society of Breast Surgeons. Las Vegas, NV, US.
2010. Stress, burnout, and career satisfaction in surgical oncologists: Results from the SSO Survey. Invited. Society of Surgical Oncology. St. Louis, MO, US.
2010. RTOG 1014: Repeat breast conservation following local recurrence using 3D-confirmal re-irradiation. Invited. American College of Surgeons Oncology Group Meeting. Chicago, IL, US.
2010. Update on educational activities for ACOSOG. Invited. American College of Surgeons Executive Committee Meeting. Chicago, IL, US.
2009. Controversies in sentinel lymph node biopsy. Invited. School of Breast Oncology. Atlanta, GA, US.
2009. DCIS: Update on management and roadmap to advance the field. Invited. University of Michigan 7th Annual Breast Cancer Management Symposium. Ann Arbor, MI, US.
2009. Moderator: The surgeon’s role in novel cancer diagnostics and minimally invasive procedures. Invited. American College of Surgeons Annual Clinical Congress. Chicago, IL, US.
2009. Molecular mechanisms of transformation of in situ to invasive breast cancer: opportunities for clinical trials for DCIS. Invited. University of Louisville. Louisville, KY, US.
2009. Panel discussant: NIH Consensus Conference on the Diagnosis and Management of Ductal Carcinoma In Situ (DCIS). Invited. National Institute of Health. Bethesda, MD, US.
2009. Neoadjuvant therapy for DCIS: Who, Why, and When?. Invited. American College of Surgeons Oncology Group Annual Meeting. Weston, FL, US.
2009. First report of patient demographics, pathologic factors, and immune response to administration of trastuzumab for patients with DCIS. Invited. American College of Surgeons Oncology Group Annual Meeting. Weston, FL, US.
2009. Surgery in the era of biologic therapy for breast cancer. Invited. 9th Annual New Strategies in Breast Cancer Conference. Philadelphia, PA, US.
2009. Molecular classification of breast cancer. Opening plenary session, moderator. Invited. American Society of Breast Surgeons. San Diego, CA, US.
2009. Sentinel lymph node biopsy. Invited. St. Dominics Hospital Regional Cancer Symposium. Jackson, MS, US.
2009. Clinical trials and tissue resources for DCIS: SPORE in breast cancer programs consortium. Invited. Dana Farber Cancer Institute. Boston, MA, US.
2008. Detection and management of lymph node metastases in breast cancer. Invited. School of Breast Oncology. Atlanta, GA, US.
2008. ACOSOG: Update on controversies in breast and colorectal cancer surgery and clinical trials. Invited. American College of Surgeons Annual Clinical Congress. San Francisco, CA, US.
2008. Plenary Debate: The timing of sentinel node biopsy (SN BX) in the patient receiving neoadjuvant treatment -- AFTER chemotherapy (opponent: Dr. Jay Harris, Department of Radiation Oncology, Harvard Medical School). Invited. Tenth Annual Lynn Sage Breast Cancer Symposium. Chicago, IL, US.
2008. Randomized trial of whole breast versus partial breast radiation for breast cancer: trial update. Invited. American College of Surgeons Group Meeting. Chicago, IL, US.
2008. Multidisciplinary integration of neoadjuvant therapy into breast cancer treatment and clinical trials. Invited. New York Breast Imaging Society, Memorial Sloan Kettering Cancer Center. New York, NY, US.
2008. Plenary Session Basic Translational Science: Moderator. Invited. American Society of Breast Surgeons. New York, NY, US.
2008. Advances in local management of breast cancer. Conference. Current Trends in Breast Cancer Symposium. Dallas, TX, US.
2008. Advances in local management of breast cancer. Invited. Current Trends in Breast Cancer Symposium. Dallas, TX, US.
2008. Advances in the local management of breast cancer. Invited. Current Trends in Breast Cancer Symposium. New York, NY, US.
2007. Multidisciplinary Discovery and Advancement of Breast Cancer Care: Pre-operative therapy as a practice model and guide for pivotal clinical trials. Invited. Institutional Grand Rounds. Tampa, FL, US.
2007. Detection and management of lymph node metastases in breast cancer. Invited. School of Breast Oncology, Emory Conference Center. Atlanta, GA, US.
2007. Not all patients with a positive sentinel lymph node need an axillary lymph node dissection. Invited. Controversies in Breast Cancer Adjuvant and Neoadjuvant Therapy 2007. New York, NY, US.
2007. Advancing our understanding of DCIS with targeted pre-operative therapy. Invited. Stratified Cancer Prevention Symposium: Identifying predictive epithelial markers in breast cancer risk and risk reduction. Bethesda, MD, US.
2007. Preoperative therapy for breast cancer. Invited. 5th Annual Contemporary Issues in Multidisciplinary Breast Cancer. Ann Arbor, MI, US.
2007. Update on randomized trial of partial breast irradiation. Invited. American College of Surgeons Oncology Group. St. Louis, MO, US.
2007. What's new in breast cancer surgery 2007?. Invited. National Medical Association. Honolulu, HI, US.
2007. American College of Surgeons Education Committee: Report on advances and future directions. Invited. NIH-NCI Sub-Committee H Reverse Site Visit. Washington, DC, US.
2007. Opening Address. Invited. 60th Annual Society of Surgical Oncology Meeting. Washington, DC, US.
2007. MammoSite: Cost, timing, technique. Invited. 24th Annual Miami Breast Cancer Conference. Miami Beach, FL, US.
2007. Novel clinical trial designs for DCIS. Invited. Ductal Carcinoma in Situ: Strategies for Integrating Tumor Biology and Population Sciences. San Francisco, CA, US.
2007. Optimizing local control of breast cancer. Invited. Current Concepts Symposium for Breast Cancer. Boston, MA, US.
2007. Palliative surgery for inoperable breast cancer. Invited. 24th Annual Miami Breast Cancer Conference. Miami Beach, FL, US.
2007. Meet the Professor. Invited. 24th Annual Miami Breast Cancer Conference. Miami Beach, FL, US.
2007. Decision analysis and outcome of surgery for young versus older breast cancer patients. Invited. 24th Annual Miami Breast Cancer Conference. Miami Beach, FL, US.
2007. What's new in local therapy for breast cancer?. Invited. University of Cincinnati, Departments of Hematology/Oncology and Surgical Oncology. Cincinnati, OH, US.
2007. Optimizing local control in breast cancer. Invited. 2007 Current Trends in Breast Cancer Symposium. Seattle, WA, US.
2006. Detection of breast cancer metastases. Invited. School of Breast Oncology, Emory Conference Center. Atlanta, GA, US.
2006. Update on partial breast irradiation and accrual goals on the randomized NSABP study. Invited. Breast Committee Plenary Session. Chicago, IL, US.
2006. Trans-disciplinary behavioral studies of surgeon and patient communication regarding trial accrual. Invited. American College of Surgeons. Chicago, IL, US.
2006. ACTION: Accrual to Clinical Trials in Oncology Networks. American College of Surgeons Oncology Group: Opportunities for Increasing Communication and Accrual of Patients on Surgical Clinical Trials. Biopsychosocial Processes and Treatment Decision Making. Conference. NIH, American College of Surgeons Oncology Group. Detroit, MI, US.
2006. New directions in breast surgery. Invited. Sixth Annual Strategies in Breast Cancer. Philadelphia, PA, US.
2006. Optimizing local therapy for breast cancer. Invited. Current Trends in Breast Cancer Symposium. Denver, CO, US.
2006. Advances and clinical trials in breast cancer. Invited. Surgery Grand Rounds. New York, NY, US.
2006. Advancing our understanding of local therapy for breast cancer. Invited. American School of Oncology. Philadelphia, PA, US.
2005. Integrating neoadjuvant systemic therapy into clinical trials and practice for breast cancer. Invited. Dana-Farber Cancer Institute and Brigham and Women's Hospital, Integrative Breast Cancer Program. Boston, MA, US.
2005. Facts and controversies: sentinel lymph node biopsy for breast cancer. Invited. School of Breast Oncology. Atlanta, GA, US.
2005. Sentinel lymph nodes and detecting micrometastatic disease. Invited. School of Breast Oncology. Atlanta, GA, US.
2005. Novel clinical trial designs for the therapy of ductal carcinoma of the breast. Invited. Massachusetts General Hospital, Department of Surgery and Multidisciplinary Breast Program, Harvard Medical School. Boston, MA, US.
2005. Percutaneous ablation procedures for breast cancer. Invited. Third Annual Contemporary Issues in Multidisciplinary Breast Cancer Management. Ann Arbor, MI, US.
2005. Ductal lavage, ductoscopy, and molecular analyses of ductal fluids. Invited. American College of Surgeons Annual Clinical Congress. San Francisco, CA, US.
2005. Moderator: Evidence-based decisions in cancer management. Invited. American College of Surgeons Annual Clinical Congress. San Francisco, CA, US.
2005. Overview American College of Surgeons Oncology Group: Opportunities for increasing Communication and accrual of patients on surgical clinical trials. NIH roadmap initiative. ACTION: Accrual to Clinical Trials in Oncology Networks. Invited. Karmanos Cancer Center. Detroit, MI, US.
2005. Partial breast irradiation: the surgical oncologist perspective. Invited. Society of Surgical Oncology. Atlanta, GA, US.
2005. Advances in neoadjuvant and adjuvant treatment for women with hormone receptor-positive early breast cancer. Invited. American Society of Breast Surgeons. Los Angeles, CA, US.
2005. First Plenary Session Moderator: Hormonal issues for women. Invited. American Society of Breast Surgeons. Los Angeles, CA, US.
2005. Innovations in breast conservation surgery. Invited. Society of Surgical Oncology, Dinner Symposium. Atlanta, GA, US.
2005. Symposium Moderator: Clinical innovations in radiation oncology: What the surgical oncologist needs to know. Invited. Society of Surgical Oncology, Dinner Symposium. Atlanta, GA, US.
2005. Ductal lavage, ductoscopy, molecular analysis of ductal fluids. Invited. 22nd Annual Miami Breast Cancer Conference. Miami Beach, FL, US.
2005. Meet the Professor: Breast Surgery Management. Invited. 22nd Annual Miami Breast Cancer Conference. Miami Beach, FL, US.
2005. Ductal lavage, surgical issues related to partial breast irradiation. Invited. 22nd Annual Miami Breast Cancer Conference. Miami Beach, FL, US.
2005. Ductal lavage, integration of sentinel lymph node biopsy in breast cancer patients undergoing neoadjuvant therapy and the concept of neoadjuvant therapy for DCIS. Invited. 22nd Annual Miami Breast Cancer Conference. Miami Beach, FL, US.
2005. Oncologic implications of immediate reconstruction of partial mastectomy defects: what's on the horizon?. Invited. American Society of Reconstructive Microsurgery Annual Meeting. Farjardo, PR, US.
2005. Upcoming partial breast radiation cooperative group trials. Invited. American College of Surgeon’s Oncology Group. San Antonio, TX, US.
2005. Integration of Clinical Trials in Advancing the Future of Cancer Surgery. Invited. Surgery Grand Rounds. Savannah, GA, US.
2004. Lymphatic mapping and sentinel lymph node biopsy: Its role in axillary lymph node management. Invited. Breast Cancer: What’s on the Horizon. Stonegate Conference Center Alexian Brothers Medical Center. Elks Grove Village, IL, US.
2004. Key Note Address: The current status and future of breast cancer management. Invited. Breast Cancer: What’s on the Horizon. Stonegate Conference Center, Alexian Brothers Medical Center. Elks Grove Village, IL, US.
2004. Sentinel lymph node biopsy for breast cancer. Invited. School of Breast Oncology, Emory University. Atlanta, GA, US.
2004. Discrimination of pre- and post-treatment breast cancer serum using SELDI-TOF MS (Surface-Enhanced Laser Desorption/Ionization-Time of Flight Mass Spectrometry). Invited. Surgical Forum, American College of Surgeons Annual Symposium. New Orleans, LA, US.
2004. Scientific reviewer. NCI mock site visit. Conference. Scientific reviewer. NCI mock site visit. Houston, TX, US.
2004. Multidisciplinary integration in breast cancer surgery and clinical trials. Invited. Grand Rounds, PA, US.
2004. Sentinel lymph node controversies: panel discussion. Invited. American Society of Breast Surgeons. Las Vegas, NV, US.
2004. Lumpectomy following neoadjuvant chemotherapy: is it wise?. Invited. American Society of Breast Surgeons. Las Vegas, NV, US.
2004. Accelerated partial breast radiation therapy-Current state of the art. Invited. Society of Surgical Oncology. New York, NY, US.
2004. Advancing the standard of breast cancer care: the emerging role of neoadjuvant therapy in clinical trial development. Invited. Current Trends in Breast Cancer. Santa Monica, CA, US.
2004. Novel preoperative strategies for breast cancer treatment. Invited. Current Trends in Breast Cancer. Boston, MA, US.
2004. Development of phase II and III randomized clinical trials for conservative surgery and partial breast irradiation. Invited. American College of Surgeons Oncology Group Breast Committee. Miami, FL, US.
2004. Key Note Speaker: The M.D. Anderson Experience with Breast Conservation after Neoadjuvant Chemotherapy. Invited. Comprehensive Breast Cancer Review. Pittsburgh, PA, US.
2003. Neoadjuvant therapy for solid organ tumors: breast cancer. Invited. American College of Surgeons 89th Annual Clinical Congress. Chicago, IL, US.
2003. Alternative radiation sources and devices for use in partial breast irradiation. Conference. M D Anderson Multidisciplinary Oncology Symposium. Houston, TX, US.
2003. What's new in breast cancer treatment. Invited. University of Michigan Medical School 2003 Cancer Update. Mackinac Island, US.
2003. New advances in the surgical management of breast cancer. Invited. 27th Annual Advances in Internal Medicine Conference- Oncology Day. Orlando, FL, US.
2002. Ductal lavage in the management of high-risk women. Invited. Fourth Annual Lynn Sage Breast Cancer Conference. Chicago, IL, US.
2002. Image guided diagnosis and surgical removal of non-palpable breast lesions. Invited. 8th Annual Perspectives in Breast Cancer. Atlanta, GA, US.
2002. Controversies in sentinel lymph node biopsy. Invited. Current Issues in Breast Cancer Management. Dayton, OH, US.
2002. New technology in breast cancer surgery. Invited. Current Issues in Breast Cancer Management. Dayton, OH, US.
2002. The M. D. Anderson Cancer Center surgical experience in breast cancer treated with preoperative chemotherapy: benefits and potential pitfalls. Invited. The M. D. Anderson Cancer Center surgical experience in breast cancer treated with preoperative chemotherapy: benefits and potential pitfalls. New Orleans, LA, US.
2002. Emerging breast cancer immunodiagnostic techniques: breast cancer discovery. Invited. American Association of Clinical Chemistry. Orlando, FL, US.
2002. Future Approaches in Surgical Treatment of the Primary Tumor. Invited. American Radium Society. Las Croabas, PR, US.
2002. Minimal Access Surgery. Invited. 4th Annual National Sisters Network Conference. Detroit, MI, US.
2002. Detection/Prognostic Assessment. Invited. New Strategies in Breast Cancer 2002. Las Vegas, NV, US.
2002. Detection of Premalignant and Malignant Breast Cancer Cells by Ductal Lavage. Invited. New Strategies in Breast Cancer 2002. Las Vegas, NV, US.
2002. Utility of Sentinel Node Biopsy. Invited. New Strategies in Breast Cancer. Las Vegas, NV, US.
2002. Title not provided. Conference. 19th Annual Miami Breast Cancer Conference on Intraductal Technology and Cancer Risk Stratification. Miami Beach, FL, US.
2002. The critical need for the early integration of patient advocates in developing and performing cancer clinical trials. Invited. Intercultural Cancer Council 8th Biennial Symposium on Minorities, the Medically Underserved & Cancer. Washington, US.
2002. Introductory talk. Invited. 19th Annual Miami Breast Cancer Conference on Intraductal Technology and Cancer Risk Stratification. Miami Beach, FL, US.
2002. Ductal lavage for breast cancer risk stratification. Invited. Second Annual Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
2001. Controversies in sentinel node biopsy for breast cancer. Invited. M. D. Anderson Orlando Joint Symposium Teleconference, US.
2001. Reconstruction after mastectomy: The patient perspective. Invited. Surgical Forum, Invited commentary, American College of Surgeons. New Orleans, LA, US.
2001. Treatment options for breast cancer. Invited. Texas Academy of Family Physicians. Primary Care 2001 Summit. Houston, TX, US.
2001. Breast cancer lymphatic mapping and sentinel node biopsy: Standard of care?. Invited. BJC Missouri Baptist Medical Center. St. Louis, MO, US.
2001. Expanding the role of neoadjuvant chemotherapy to early stage breast cancer: What are the risks and benefits?. Conference. Symposium on chemotherapy for breast cancer. Houston, TX, US.
2001. Increasing accrual rates to ACOSOG trial Z11 with patient-centered brochures and a video. Invited. Breast Organ Site Committee, American College of Surgeons Oncology Group. Chicago, IL, US.
2001. Development of educational materials for current and future ACOSOG trials. Invited. Education Committee Meeting, American College of Surgeons Oncology Group. Chicago, IL, US.
2001. Breast Session. Conference. Society of Surgical Oncology 54th Annual Cancer Symposium. Washington, US.
2001. Moderator, Breast Session. Invited. Society of Surgical Oncology 54th Annual Cancer Symposium. Washington, DC, US.
2001. Establishing a multidisciplinary breast surgical oncology fellowship at M.D. Anderson Cancer Center. Invited. Susan G. Komen Breast Cancer Foundation Fellowship Director’s Meeting at the Society of Surgical Oncology 54th Annual Cancer Symposium. Washington, US.
2001. Axillary sentinel lymph node biopsy for breast cancer patients: The impact on immediate breast reconstruction. Conference. Advances in Breast Reconstruction. Houston, TX, US.
2000. Surgical issues regarding the use of induction chemotherapy in operable breast cancer. Conference. Bristol-Myers Squibb Oncology Breast Cancer Forum. Houston, TX, US.
1999. Management of locally advanced breast cancer. Invited. UCSF Surgery Chief Rounds. San Francisco, CA, US.
1999. Neoadjuvant chemotherapy in breast cancer: indications and fundamental surgical Issues. Conference. Department of Surgery Grand Rounds. San Francisco, CA, US.
1999. The M. D. Anderson Cancer Center experience with neoadjuvant chemotherapy for breast cancer. Conference. Surgery Grand Rounds. San Francisco, CA, US.
1999. What’s new in breast cancer? Recent results and current national UCSF initiated breast cancer research trials. Conference. UCSF Staff Forum. San Francisco, CA, US.
1999. Axillary lymph node dissection in breast cancer: why do it. Conference. Bay Area Breast Cancer Forum. San Francisco, CA, US.
1999. Neoadjuvant chemotherapy in breast cancer. Conference. The Department of Surgery and the Howard C. Naffziger Surgical Society. San Francisco, CA, US.
1999. Breast cancer treatment and prevention in the new millennium. Conference. The Susan G. Komen Breast Cancer Foundation. San Francisco, CA, US.
1999. Current fundamental issues regarding the neoadjuvant approach to breast cancer management. Conference. The UCSF-Stanford Tumor Board at Silverado: A Multidisciplinary Approach to Cancer Treatment. Napa, CA, US.
1999. Integrating the oncologic surveillance program with the education, quality assurance, informatics, and clinical trials core. Conference. UCSF Cancer Center 1999 Breast Oncology Program Retreat. Yountville, CA, US.
1999. Neoadjuvant chemotherapy for locally advanced breast cancer: A surgeon’s perspective of the M. D. Anderson experience. Invited. 18th Annual Current Approaches to Radiation Oncology, Biology, and Physics. San Francisco, CA, US.
1999. Tumor biology: what the surgeon needs to know about molecular biology in the coming millennium. Conference. UCSF Surgery Education Series, US.
1999. Establishing sentinel lymph node biopsy as the standard of care in women with breast cancer and a clinically negative axilla. Conference. UCSF Breast Oncology Program, US.
1998. Stage III breast cancer as a model for implementing new technology and novel therapeutics. Conference. UCSF Breast Oncology Program, US.
1998. Developing a novel breast cancer neoadjuvant clinical trial. Conference. UCSF Clinical Trials Committee, US.
1997. Skin-sparing mastectomy: report to the editorial panel and CPT advisory committee. Invited. American Medical Association. Chicago, IL, US.

International Presentations

2023. Post-NACT Axillary management. Conference. MBN2023 Oncoplastic Breast Meeting. Masters and Promises. Milan, IT.
2023. De-escalation of surgery. Conference. MBN2023 Oncoplastic Breast Meeting. Masters and Promises. Milan, IT.
2023. Debate: Is Robotic Nipple Sparing Mastectomy Ready for Prime Time?. Invited. 42nd Congress of the European Society of Surgical Oncology. Florence, IT.
2023. Breast Debate: TAD Is the Most Accurate Axillary Staging Technique for CN+ After Neoadjuvant Treatment. Invited. 42nd Congress of the European Society of Surgical Oncology. Florence, IT.
2023. Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: Three-year preplanned primary-endpoint on a phase II multicentre prospective trial. Conference. European Society of Medical Oncology. Madrid, ES.
2023. Plenary lecture: Eliminating Breast Surgery After Neoadjuvant Systemic Therapy. Invited. XVI Argentine and International Congress of Mastology. Buenos Aires, AR.
2023. Plenary lecture: Adapting axillary surgery in node-positive patients. Invited. XVI Argentine and International Congress of Mastology. Buenos Aires, AR.
2023. Pre-Mastectomy Radiation Therapy to Facilitate Immediate Breast Reconstruction. Invited. XVI Argentine and International Congress of Mastology. Buenos Aires, AR.
2022. Update on the eliminating surgery paradigm and early trial result publication in Lancet Oncology. International Umberto Veronesi Academy; Breast cancer management controversies 2022. Invited. Update on the eliminating surgery paradigm and early trial result publication in Lancet Oncology. International Umberto Veronesi Academy; Breast cancer management controversies 2022. Milan, IT.
2021. Eliminating breast cancer surgery or radiotherapy in exceptional responders to neoadjuvant systemic therapy: Clinical trials update; Virtual Key Note Lecture. Invited. Umberto Veronesi Academy. Milan, IT.
2021. Personalized surgery for breast cancer through a standardized approach. Invited. Concord Medical Group and MD Anderson Cancer Network Joint Academic Conference. Shanghai, CN.
2021. Surgical Treatment of Highly Responsive Patients. Invited. International Multidisciplinary Course on Breast Cancer. (Virtual), PE.
2021. Adjuvant Radiation: When to Omit. Invited. SSO2021 Annual International Conference. (Virtual), US.
2020. Omitting Surgery After Pathologic Complete Response: Where Are We and Where Are We Going?. Invited. 19th Annual International Congress on the Future of Breast Cancer West. San Diego (V), US.
2019. Will surgery be part of breast cancer treatment in the future?. Invited. Oncoplastic Breast Meeting. Milan, IT.
2019. Integrating breast reconstruction techniques when post-mastectomy radiation. Invited. Oncoplastic Breast Meeting. Milan, IT.
2019. Management of locally recurrent breast cancer: re-lumpectomy, re-sentinel node biopsy, re-radiation (In-breast recurrences: is re-lumpectomy adequate?). Invited. Oncoplastic Breast Meeting. Milan, IT.
2019. Eliminación de la Cirugía de mama posterior a respuesta completa a la Neoadyuvancia. Invited. VIII Congreso Nacional De Mastologia. Cartagena, CO.
2019. Controversias en CDIS. Invited. VIII Congreso Nacional De Mastologia. Cartagena, CO.
2019. Manejo de la axila positiva posterior a tratamiento neoadyuvante. Invited. VIII Congreso Nacional De Mastologia. Cartagena, CO.
2019. Discussion | Breast Cancer II: Local therapy - axilla surgery. Management: Clinical lymph-nodepositive situations in the era of post-neoadjuvant approaches. MD Anderson experience. Invited. Master of Disaster with Live Surgery. Essen, DE.
2019. Take-home Message: Axillar Surgery. Invited. Master of Disaster with Live Surgery. Essen, DE.
2019. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Invited. 2019 Annual Meeting. Chicago, US.
2019. Surgery: Breast and axilla in the age of primary systemic therapy. Invited. Hirslanden Klinik St. Anna. Luzern, CH.
2018. Could we skip surgery in some patients undergoing chemotherapy neoadjuvant? Exploring a potential new paradigm. Invited. 91st Congress of the Chilean Society of Surgery. Santiago, CL.
2018. Strategies to reduce burnout and improve well-being in oncologists. Invited. 91st Congress of the Chilean Society of Surgery. Santiago, CL.
2018. Controversies and clinical studies for the management of Carcinoma in situ: Margins and active monitoring. Invited. 91st Congress of the Chilean Society of Surgery. Santiago, CL.
2018. Management of the armpit in breast cancer with positive lymph nodes after neoadjuvant chemotherapy. Update of clinical studies. Invited. 91st Congress of the Chilean Society of Surgery. Santiago, CL.
2018. Is bilateral mastectomy overtreatment of breast cancer. Invited. European Society of Surgical Oncology [ESSO] 2018. Budapest, HU.
2018. The role of sentinel node in the era of neaoadjuvant therapy. Invited. European Society of Surgical Oncology [ESSO] 2018. Budapest, HU.
2018. Current directions for breast and axillary surgery after neoadjuvant systemic therapy. Invited. 2018 Annual Meeting. Vienna, AT.
2018. This House Believes That Targeted Approaches to the Axilla in cN+ After PST are Oncologically Safe and Will Reduce Axillary Dissection [Debate - For]. Invited. 11th European Breast Cancer Conference. Barcelona, ES.
2018. Axillary lymph node dissection should be performed after mastectomy and a positive sentinel lymph node? [Debate - Against]. Invited. 11th European Breast Cancer Conference. Barcelona, ES.
2017. Controversy and Margins for Ductal Carcinoma in Situ of the Breast. Invited. 2017 BASO~ACS and NCRI Cancer Conference. Liverpool, GB.
2017. Identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy. Invited. 2017 BASO~ACS and NCRI Cancer Conference. Liverpool, GB.
2017. Clinical trials and Update on the Management of DCIS. Invited. 20th Brazilian Congress of Mastology. Porto de Galinhas, BR.
2017. Limiting Axillary Surgery for Lymphnode Positive Breast Cancer Patients. Invited. 20th Brazilian Congress of Mastology. Porto de Galinhas, BR.
2017. Feasibility Trial for Elimination of Breast Cancer Surgery for Exceptional Responders to Noeadjuvant Chemotherapy. Invited. 20th Brazilian Congress of Mastology. Porto de Galinhas, BR.
2017. Early Results and Current Clinical Trials for Omission of Breast Cancer Surgery after Neoadjuvant Systemic Therapy. Invited. 14th National Congress of Mastology, 11th International Reunion. Guadalajara, MX.
2017. Targeted Axillary Dissection for Node Positive Breast Cancer after Neoadjuvant Systemic Therapy. Invited. 14th National Congress of Mastology, 11th International Reunion. Guadalajara, MX.
2017. Decreasing Surgery, less is more in DCIS. Invited. 14th National Congress of Mastology, 11th International Reunion. Guadalajara, MX.
2017. Eliminating Surgery in Patients with Invasive Breast Cancer and those with DCIS: Is it Feasible?. Invited. 16th Annual International Congress on the Future of Breast Cancer. San Diego, US.
2017. Eliminating Surgery in Patients with Invasive Breast Cancer and in Those with DCIS: Is It Feasible?. Invited. 16th Annual International Congress on the Future of Breast Cancer West. San Diego, US.
2017. Program Chair: Optimal breast adjuvant radiation and the upstream and downstream treatment implications. Educational Session. Invited. The American Society of Clinical Oncology. Chicago, US.
2017. How planned radiation will impact management of the axilla in patients who undergo mastectomy and breast conservation. Invited. The American Society of Clinical Oncology. Chicago, US.
2017. Targeted Axillary Dissection for Breast Cancer: Less is More. Invited. Cancer Metastasis through the Lymphovascular System: Biology & Treatment. San Francisco, US.
2016. Clinical trials for eliminating breast cancer surgery in exceptional responders. Invited. Spandidos Publications. Athens, GR.
2016. Risk reduction mastectomy and surgical options for deleterious mutation carriers diagnosed with breast cancer. Invited. The International Symposium of Assessment and Management of Patients High Oncologic Risk, CL.
2016. De-escalating Breast Surgery. Invited. 15th Annual International Congress on the Future of Breast Cancer. New York, US.
2016. Sentinel node biopsy directed postneoadyuvancia. Invited. 5th AECIMA Annual Meeting. Gran Canaria, ES.
2016. Are we overtreating patients with carcinoma in situ?. Invited. 5th AECIMA Annual Meeting. Gran Canaria, ES.
2016. Complete to neoadjuvant breast cancer in Answer: Is it possible to avoid surgery. Invited. 5th AECIMA Annual Meeting. Gran Canaria, ES.
2015. Outcome of multimodal tailored therapy. Invited. Oncoplastic and Reconstructive Breast Surgery Annual International Symposium (ORBS). Nottingham, GB.
2015. Who needs post-mastectomy radiotherapy - a surgical oncology perspective. Invited. Oncoplastic and Reconstructive Breast Surgery Annual International Symposium (ORBS). Nottingham, GB.
2015. Why are the rates of contralateral mastectomy increasing?. Invited. Oncoplastic and Reconstructive Breast Surgery Annual International Symposium (ORBS). Nottingham, GB.
2015. What would be your approach with this cancer?. Invited. Oncoplastic and Reconstructive Breast Surgery Annual International Symposium (ORBS). Nottingham, GB.
2015. What predicts local reccurence these days?. Invited. Oncoplastic and Reconstructive Breast Surgery Annual International Symposium (ORBS). Nottingham, GB.
2015. Surgical burn out and how to avoid it. Invited. Oncoplastic and Reconstructive Breast Surgery Annual International Symposium (ORBS). Nottingham, GB.
2015. Preoperative and Intraoperative Decision Making in the Neoadjuvant Setting. Invited. XII Congreso National de Mastologia. Monterrey, MX.
2015. Changes in surgical management of axillary disease. Invited. SMEO Summit 2015. Guadalajara, MX.
2015. Update on DCIS and new clinical trials for active surveillance. Invited. SMEO Summit 2015. Guadalajara, MX.
2014. The necessity for treating ductal carcinoma in situ. Invited. American Society of Clinical Oncology (ASCO) Breast Cancer Symposium 2014. San Francisco, US.
2014. Biology, treatment, and outcome of women with DCIS. Invited. Breast Cancer 2014: Advances and Perspectives, Hospital Sirio-Libanes and Memorial Sloan Kettering Cancer Center. Sao Paulo, BR.
2014. Presidential Key Note Address: Tailoring local-regional treatment of breast cancer in the genomic era. Invited. Breast Cancer 2014: Advances and Perspectives, Hospital Sirio-Libanes and Memorial Sloan Kettering Cancer Center. Sao Paulo, BR.
2014. Targeted axillary surgery for node positive breast cancer. Invited. Breast Cancer 2014: Advances and Perspectives, Hospital Sirio-Libanes and Memorial Sloan Kettering Cancer Center. Sao Paulo, BR.
2014. Indications for prophylactic mastectomy. Invited. 6th International Scientific Conference Cancer Forum 2014, “Multidisciplinary Approach”. Dammam, SA.
2014. Sentinel lymph node (SLN) biopsy for breast cancer. Invited. 6th International Scientific Conference Cancer Forum 2014, “Multidisciplinary Approach”. Dammam, SA.
2014. Risk reducing breast surgery: Update. Invited. Recife Breast Cancer Symposium. Recife, BR.
2014. Targeted surgery for nodal metastasis. Invited. Recipe Breast Cancer Symposium. Recife, BR.
2013. Targeting nodal metastases in breast cancer and update on cooperative group and MD Anderson Cancer Center trials. Invited. The Royal Marsden Hospital. London, GB.
2013. Selection of patients for local-regional management in the presence of stage IV breast cancer. Plenary Session. Invited. XXXI National Congress of Oncology. Cancun, MX.
2013. Prevalence and avoidance of burnout in oncology practice. Plenary Session. Invited. XXXI National Congress of Oncology. Cancun, MX.
2013. Targeted axillary surgery for node positive breast cancer. Plenary Session. Invited. XXXI National Congress of Oncology. Cancun, MX.
2013. Contralateral prophylactic mastectomy. Invited. Association of Breast Surgeons of Indian International Conference. Chandigarh, IN.
2013. Circulating tumor cells in breast cancer-ready for prime time?. Invited. Association of Breast Surgeons of India International Conference. Chandigarh, IN.
2013. Surgery for breast cancer in metastatic disease. Invited. Association of Breast Surgeons of India International Conference. Chandigarh, IN.
2013. Update on breast cancer surgery. Invited. International Multidisciplinary Breast Cancer Management Symposium. Houston, US.
2012. Management of the axilla after a positive sentinel lymph node in breast cancer. Invited. Grand Rounds. Mexico City, MX.
2012. Is there an indication for local regional therapy in stage IV breast cancer?. Invited. Cancer Center Grand Rounds. Mexico City, MX.
2012. Directrices en el tratamiente del cancer de mama. Invited. Sociedad de Cancerologia de Guadalajara A.C. Guadalajara, MX.
2012. Axillary management in local regional recurrence. Invited. VIIIth Simposio Internacional de Cancer de Mama de Santiago. Santiago, CL.
2012. Repeat conservative surgery for local recurrence of breast cancer: Trial update. Invited. VIIIth Simposio Internacional de Cancer de Mama de Santiago. Santiago, CL.
2011. Improving surgical outcomes with preoperative systemic therapy for breast cancer. Invited. Sociedad Mexicana de Oncologia. Ixtapa, Zihuantanejo, MX.
2011. Ipsilateral breast cancer recurrence: Predictors, diagnosis, and new management strategies. Invited. Sociedad Mexicana de Oncologia. Ixtapa, Zihuantanejo, MX.
2011. Ductal carcinoma in situ: Update on biology and treatment. Invited. Sociedad Mexicana de Oncologia. Ixtapa, Zihuantanejo, MX.
2011. The MD Anderson Cancer Center Approach to sentinel node biopsy. Invited. Sociedad Mexicana de Oncologia. Ixtapa, Zihuantanejo, MX.
2011. The MD Anderson Cancer Center approach to prophylactic mastectomy. Invited. Sociedad Mexicana de Oncologia. Ixtapa, Zihauntanejo, MX.
2010. Integrating reconstruction and radiation in breast cancer. Invited. Philippine College of Surgeons 66th Annual Clinical Congress. Mandaluyong City, PH.
2010. Plenary session: NCCN Guidelines for Breast Cancer: Applicability in the Philippines. Invited. Philippine College of Surgeons 66th Annual Clinical Congress. Mandaluyong City, PH.
2010. Plenary session: Integration neoadjuvant systemic therapy with surgery. Invited. Philippine College of Surgeons 66th Annual Clinical Congress. Mandaluyong City, PH.
2010. Plenary session: Ductal carcinoma in situ. Invited. Philippine College of Surgeons 66th Annual Clinical Congress. Mandaluyong City, PH.
2010. Plenary session. Clinical and translational research update: Ductal carcinoma in situ. Invited. XXVII Congreso Nacional Y II Internacional De Oncologia. Cancun, MX.
2010. Conservative treatment: 30 years of follow-up. Invited. 16th World Congress Societe Internationale de Senologie. Valencia, ES.
2010. Plenary session. Integrating immediate breast reconstruction in patients potentially needing post-mastectomy radiotherapy: Results of local regional recurrence rates in women with one to three positive nodes. Invited. XXVII Congreso Nacional Y II Internacional De Oncologia. Cancun, MX.
2010. Plenary session. Controversies in sentinel node biopsy for breast cancer. Invited. XXVII Congreso Nacional Y II Internacional De Oncologia. Cancun, MX.
2010. Reconstruction and radiotherapy: The MD Anderson Approach. Invited. The Royal Australasian College of Surgeons, Perth '10 Annual Scientific Congress. Perth, AU.
2010. Satisfaction and balance in surgical oncology. Invited. The Royal Australasian College of Surgeons, Perth '10 Annual Scientific Congress. Perth, AU.
2010. DCIS: State of science, current controversies and planned clinical trials. Invited. The Royal Australasian College of Surgeons, Perth '10 Annual Scientific Congress. Perth, AU.
2010. The role of preoperative systemic therapy in breast cancer management. Invited. The Royal Australasian College of Surgeons, Perth '10 Annual Scientific Congress. Perth, AU.
2009. Biomarkers of risk in nipple aspirate fluid and ductal lavage: Plenary Session Moderator. Invited. Dr. Susan Love Research Foundation 6th International Symposium on the Intraductal Approach to Breast Cancer. Santa Monica, US.
2008. Plenary session: No axillary dissection for patient with a positive sentinel lymph node: what is the evidence and where are the controversies. Breast Cancer Update. Invited. XXVII Congreso Nacional De Cirugia. Madrid, ES.
2008. Plenary session: Breast Cancer Update. Invited. XXVII Congreso Nacional De Cirugia. Madrid, ES.
2008. Is axillary dissection always indicated for a positive SLN?. Invited. International Consensus Conference on Local Treatment of Early Breast Cancer. Frankfurt/Biedenkopf, DE.
2008. Optimizing sentinel lymph node biopsy in breast cancer patients receiving preoperative therapy. Invited. Interdisciplinary Breast Group Preoperative Therapy in Breast Cancer Optimal Approach: Controversies Clinical Research. Leoban, AT.
2007. Update and advancements in interdisciplinary breast training at the M D Anderson Cancer Center. Invited. Susan G. Komen International Ignite the Promise Meeting. Washington, DC, US.
2007. Surgical Oncology. Invited. ASCO-Chinese Society of Clinical Oncology Multidisciplinary Clinical Cancer Management Course. Shanghai, CN.
2007. Management of early stage breast cancer. Invited. ASCO-Chinese Society of Clinical Oncology Multidisciplinary Clinical Cancer Management Course. Shanghai, CN.
2007. New insights on the local therapy for breast cancer. Invited. Seventh Annual International New Strategies in to Breast Cancer Conference. Philadelphia, US.
2007. The use of ductal fluids as a potential screening method. Plenary Session Moderator. Invited. The 5th Annual International Symposium on the Intraductal Approach to Breast Cancer. Santa Monica, US.
2006. Clinical significance and management of the positive sentinel lymph node. Invited. Fifth International Congress on the Future of Breast Cancer. Kohala, US.
2006. Surgery after neoadjuvant therapy. Invited. Plenary Lecture, Toronto Breast Cancer Symposium 2006. Toronto, CA.
2006. What is new in breast cancer clinical trials and practice. Invited. Sixth International Peruvian Society of Mastology. Lima, PE.
2006. Ductal lavage and ductoscopy. Invited. Sixth International Peruvian Society of Mastology. Lima, PE.
2006. Integration of neoadjuvant therapy into surgical practice. Invited. Sixth International Peruvian Society of Mastology. Lima, PE.
2006. The surgical management of young versus older patients with breast cancer. Invited. Eleventh Annual International Portugal Breast Symposium on Breast Cancer. Lisbon, PT.
2005. Special Symposium: Randomized trials evaluating aromatase inhibitors in early post-menopausal breast cancer. Invited. International Breast and Melanoma Cancer Congress. Bogota, CO.
2005. The role of ductal analyses in ongoing breast cancer research and clinical practice. Invited. International Breast and Melanoma Cancer Congress. Bogota, CO.
2005. Advances in neoadjuvant therapy for breast cancer. Invited. International Breast and Melanoma Cancer Congress. Bogota, CO.
2005. Technical aspects of the collection and analysis of ductal fluids and analyzing nipple aspirate fluid: the M D Anderson Cancer Center trial. Invited. Fourth International Symposium on the Intraductal Approach to Breast Cancer. Santa Barbara, US.
2005. Sentinel Node Biopsy for DCIS. Invited. 2005 International Consensus Conference: Image Detected Breast Cancer: State of the Art Diagnosis and Treatment. Miami, US.
2005. Neoadjuvant therapy for DCIS. Invited. 2005 International Consensus Conference: Image Detected Breast Cancer: State of the Art Diagnosis and Treatment. Miami, US.
2005. Percutaneous ablation of breast carcinoma. Invited. 2005 International Consensus Conference: Image Detected Breast Cancer: State of the Art Diagnosis and Treatment. Miami, US.
2005. Segmental resection following neoadjuvant chemotherapy. Invited. 2005 International Consensus Conference: Image Detected Breast Cancer: State of the Art Diagnosis and Treatment. Miami, US.
2005. Intraductal Technology and Ductoscopy. Invited. 2005 International Consensus Conference: Image Detected Breast Cancer: State of the Art Diagnosis and Treatment. Miami, US.
2004. Multidisciplinary of Early Stage Breast Cancer. Conference. ASCO International Multidisciplinary Cancer Management Course. Alexandria, US.
2004. Management of Locally Advanced Breast Cancer. Conference. ASCO International Multidisciplinary Cancer Management Course. Alexandria, US.
2004. Breast conserving surgery for locally advanced breast cancer. Invited. Sociedad Mexicana de Oncologia, XIII National Congress in Oncology. Merida, MX.
2004. Controversies in Breast Cancer: Sentinel lymph node biopsy in DCIS and after neoadjuvant chemotherapy. Invited. Sociedad Mexicana de Oncologia, XIII National Congress in Oncology. Merida, MX.
2004. Local therapy strategies for DCIS: future perspectives. Invited. The future of breast cancer: an international breast cancer congress. Southampton, BM.
2004. Chair, Breast Cancer II Session. Invited. American Society of Clinical Oncology. New Orleans, US.
2004. Current and planned breast cancer clinical trials in the United States of America. Invited. National Cancer Institute. Bangkok, TH.
2004. Advances in breast cancer care. Invited. Siriaj Hospital, Special Symposium. Bangkok, TH.
2004. Techniques for local ablation of breast cancer. Invited. IV Santiago International Breast Cancer Symposium. Santiago, US.
2004. The present and future of breast cancer surgery. Invited. IV Santiago International Breast Cancer Symposium. Santiago, US.
2003. Neoadjuvant therapy for breast cancer: new approaches and technical considerations. Invited. Canadian Society of Surgical Oncology. Vancouver, CA.
2003. Breast cancer proteomic signatures. Invited. 3rd International Santa Barbara Symposium: The Intraductal Approach to Breast Cancer. Santa Barbara, US.
2002. The future of breast cancer surgery. Invited. The Future of Breast Cancer: An International Breast Cancer Congress. Paradise Island, BS.
2001. Breast conservation after neoadjuvant chemotherapy: surgical planning in women with stage II and Operable stage III breast cancer. Invited. Southwestern Surgical Congress. Cancun, MX.

Formal Peers

2022. What Is the Role for Surgery After NST? Potential for Elimination. Visiting. Santa Barbara, CA, US.
2019. Limiting and Eliminating Breast Cancer Surgery in Exceptional Responders to Systemic Therapy. Visiting. Amsterdam, NL.
2018. Breast Cancer Surgery Present and Future. Visiting. Indianapolis, IN, US.
2018. Breast Cancer Surgery Update: Present and Future. Visiting. Englewood, NJ, US.
2017. Northwell Health Multi-Hospital Combined. Visiting. New York, NY, US.
2015. Lean Facility Design Seminar. Invited. Seattle, WA, US.
2015. Moffitt Cancer Center. Visiting, FL, US.
2013. The Royal Marsden Hospital. Visiting, England, GB.
2012. University of Illinois. Visiting. Chicago, IL, US.
2012. Instituto Nacional de Cancerologia. Visiting, MX.
2012. Roswell Park Cancer Institute. Visiting. Buffalo, NY, US.
2009. Management strategies for ductal carcinoma in situ. Invited. Dearborn, MI, US.
2008. Emory University. Visiting. Atlanta, GA, US.
2007. Moffitt Cancer Center and Research Institute. Visiting. Tampa, FL, US.
2006. Memorial Sloan Kettering Hospital. Visiting. New York, NY, US.
2006. The Mount Sinai School of Medicine. Visiting. New York, NY, US.
2005. Dana-Farber Cancer Institute and Brigham and Women’s Hospital. Visiting. Boston, MA, US.
2005. Massachusetts General Hospital, Harvard Medical School. Visiting. Boston, MA, US.
2005. Fundacion Santa Fe de Bogota. Visiting. Bogota, CO.
2005. Memorial Health University Medical Center. Visiting. Savannah, GA, US.
2004. H.M. National Cancer Institute. Invited. Bangkok, TH.
2004. Mahidol University, Siriaj Hospital. Visiting. Bangkok, TH.
2004. Allegheny Western. Visiting, PA, US.
2004. University of Pittsburgh Medical Center. Visiting. Pittsburgh, PA, US.
2003. Molecular characterization of ductal fluids. Invited. Bethesda, MD, US.
2003. Primary tumor ablation. Advances in Multidisciplinary Breast Cancer Care. Invited. Ann Arbor, MI, US.
2003. What’s new in the local therapy of breast cancer- a multidisciplinary perspective of care. Invited. St. Augustine, FL, US.
2002. Wayne State University. Visiting. Dayton, US.
2001. Neoadjuvant chemotherapy in breast cancer: Indications and fundamental surgical issues. Invited. Houston, TX, US.
1999. Role of neoadjuvant chemotherapy in the management of breast cancer. Invited, US.
1998. Diagnosis and current treatment of breast cancer. Invited, US.
1998. Surgical considerations in breast cancer patients treated with primary chemotherapy. Invited. Philadelphia, PA, US.
1997. Carcinoma of the breast associated with pregnancy and lactation. Invited. New York, NY, US.
1996. Conservative management of breast carcinoma: origins, outcome, and the future. Invited. Queens, NY, US.

Less

Grant & Contract Support

Date:	2017 - 2019
Title:	Multimodal microscope for intraoperative assessment of breast surgical margins
Funding Source:	NIH/NCI
Role:	Co-I
ID:	2R44CA173998 - 03A1

Date:	2014 - 2019
Title:	UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAPS)
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 U10 CA180858-01

Date:	2014 - 2016
Title:	Impact of the Oncotype DX DCIS Score on Treatment Decision Making in Patients with Ductal Carcinoma In Situ
Funding Source:	Genomic Health
Role:	PI
ID:	2013-0849

Date:	2011 - 2016
Title:	Co-Investigator and Chair, Education Committee, NIH
Funding Source:	NIH Alliance Committee Chair Funds
Role:	Co-I
ID:	7 U10 CA076001

Date:	2009 - 2010
Title:	American College of Surgeons Oncology Group ACOSOG Education Committee Chair
Funding Source:	American College of Surgeons Oncology Group
Role:	Co-I
ID:	5 U10 CA76001 14

Date:	2009 - 2014
Title:	Komen Promise Grant
Funding Source:	Susan G. Komen Breast Cancer Foundation
Role:	Co-I
ID:	KG 091020

Date:	2009 - 2020
Title:	NO TITLE PROVIDED
Funding Source:	NSABP Cooperative Trial Group B-43 TFED/TIND
Role:	Principal Investigator-MDACC
ID:	U10 CA01202738

Date:	2009 - 2020
Title:	NO TITLE PROVIDED
Funding Source:	NIH - NSABP Cooperative Trials Group B-35 TFED/TIND
Role:	PI
ID:	1 U10 CA037377 01

Date:	2008 - 2014
Title:	The LAPIS Clinical Trial: Neoadjuvant Trial of Lapatinib for the Treatment of Women with DCIS Breast Cancer
Funding Source:	Breast Cancer Research Foundation
Role:	Co-I
ID:	2008-0086

Date:	2008 - 2010
Title:	Viruses in Breast Fluid: Biomarkers for Breast Cancer?
Funding Source:	Avon Foundation/University of California-San Francisco
Role:	Co-I
ID:	07-2007-073

Date:	2007 - 2009
Title:	Breast Fluid Band-aid Test
Funding Source:	Dr. Susan Love Research Foundation
Role:	Co-I

Date:	2007 - 2020
Title:	NO TITLE PROVIDED
Funding Source:	National Surgical Adjuvant Breast and Bowel Project, 5U10-CA012027-37
Role:	PI

Date:	2005 - 2006
Title:	Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast
Funding Source:	Genentech, Inc., San Francisco, CA
Role:	PI

Date:	2005 - 2008
Title:	Fluorescence imaging for sentinel lymph node mapping
Funding Source:	National Cancer Institute
Role:	Collaborator
ID:	CA99048-01

Date:	2005 - 2007
Title:	Improving Early Detection of Breast Cancer with a Blood Test, Biomarker study of nipple aspirate fluid
Funding Source:	Fred Hutchinson Cancer Research Center
Role:	Co-I

Date:	2004 - 2007
Title:	NO TITLE PROVIDED
Funding Source:	National Surgical Adjuvant Breast and Bowel Project
Role:	PI

Date:	2004 - 2007
Title:	NO TITLE PROVIDED
Funding Source:	Southwest Oncology Group (SWOG), National Cancer Institute, U10 Full Member Application
Role:	Co-I

Date:	2003 - 2011
Title:	Breast and Colorectal Cancer Cooperative Trials Group
Funding Source:	National Surgical Adjuvant Breast and Bowel Project
Role:	PI
ID:	1 U10 CA037377 01

Date:	2003 - 2008
Title:	Radiation Dosimetry of Intratumoral Injection of Radionuclides in Human Breast Cancer
Funding Source:	Department of Defense
Role:	Collaborator
ID:	BC020808

Date:	2003 - 2006
Title:	Role of ductal lavage in monitoring risk reduction strategies for breast cancer
Funding Source:	National Cancer Institute
Role:	Co-I

Date:	2002 - 2006
Title:	Development of an Interdisciplinary Breast Fellowship Program
Funding Source:	The Susan G. Komen Breast Cancer Foundation
Role:	PI

Date:	2001 - 2006
Title:	Education Committee, American College of Surgeons Oncology Group
Funding Source:	National Cancer Institute
Role:	Co-I
ID:	5U10-CA76001-05

Date:	2001 - 2002
Title:	Prospective investigation to determine the ability to obtain, cytologically characterize, and biochemically analyze nipple aspiration fluid in women with carcinoma of the breast
Funding Source:	M. D. Anderson Clinical Translational Research
Role:	PI

Date:	1998 - 1999
Title:	Impact of occult axillary lymph node micrometastases in breast cancer patients with complete histopathologic axillary response to neoadjuvant chemotherapy
Funding Source:	Biogenex Corporation, San Ramon, CA
Role:	PI

Selected Publications

Peer-Reviewed Articles

Wanis, K, Dong, W, Shen, Y, Meric-Bernstam, F, Adesoye, T, Kuerer, HM, Caudle, AS, Tamirisa, N, DeSnyder, SM, Sun, SX, Bedrosian, I, Singh, P, Cox, SE, Hunt, KK, Hwang, RF. Predicting pathologic ≥N2 disease in women with breast cancer. npj Breast Cancer 11(1), 2025. e-Pub 2025. PMID: 40404657.
Mukhtar, RA, Dimitroff, K, Yau, C, Chien, AJ, Connolly, E, Howard-McNatt, M, Rao, R, Ladores, V, Golshan, M, Sauder, C, Ahmed, KA, Lancaster, RB, Fox, J, Gutnik, L, Lee, MC, Tchou, J, Prionas, ND, Arciero, CA, Reyna, C, Kuerer, HM, Switalla, K, Taunk, NK, Tuttle, TM, Moran, MS, Postlewait, LM, Perlmutter, J, DeMichele, A, Yee, D, Hylton, NM, Symmans, WF, Rugo, H, Shatsky, R, Isaacs, C, Esserman, L, van‘t Veer, LJ, Boughey, JC. Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer. Annals of surgical oncology 32(11):8243-8253, 2025. e-Pub 2025. PMID: 40705266.
Van Hassel, J, Dimitroff, K, Yau, C, Mukhtar, RA, Boughey, JC, Ladores, V, Howard-McNatt, M, Jaskowiak, NT, Perlmutter, J, DeMichele, A, Yee, D, Hylton, NM, Symmans, WF, Veer, Lt, Rugo, H, Esserman, L, Shatsky, R, Isaacs, C, Kuerer, HM, Wallace, A, Prionas, ND, Tseng, JF, Reyna, C, Taunk, NK, Kesmodel, SB, Lee, MC, Fox, J, Piltin, MA, Tchou, J, Arciero, CA, Postlewait, LM, Sauder, C, Rao, R. Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes. Annals of surgical oncology 32(11):8113-8126, 2025. e-Pub 2025. PMID: 40849380.
Kaur, M, Dimitroff, K, Boughey, JC, Esserman, L, Yau, C, Tchou, J, Quirarte, A, Lee, MC, Howard-McNatt, M, Switalla, K, Kuerer, HM, Sauder, C, Postlewait, LM, Arciero, CA, Rao, R, Wallace, A, Reyna, C, Ahmed, KA, Gutnik, L, Taunk, NK, Perlmutter, J, DeMichele, A, Yee, D, Hylton, NM, Symmans, WF, Rugo, H, Shatsky, R, Isaacs, C, Rudra, S, Pohlmann, PR, Ewing, CA, Wong, JM, Alvarado, M, Jaskowiak, NT, Prionas, ND, Golshan, M, Piltin, MA, Olopade, OI, Mukhtar, RA. Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial. Annals of surgical oncology 32(11):8211-8219, 2025. e-Pub 2025. PMID: 40699532.
Schaverien MV, Singh P, Kuerer HM, Akay CL, Chavez-MacGregor M, Chu CK, Clemens MW, Qiao W, Smith BD, Hoffman KE. Comparison of Outcomes of Microsurgical Breast Reconstruction after Premastectomy and Postmastectomy Radiation Therapy. J Am Coll Surg 241(4):535-549, 2025. e-Pub 2025. PMID: 40366003.
Huynh V, Glencer A, Yi M, Wingate E, Wingate H, Allassan N, Alameddine S, Singh P, Kuerer HM, Hunt KK, Refinetti AP. Impact of Pathologic Complete Response on Local-Regional Recurrence and Survival in Patients Undergoing Neoadjuvant Systemic Therapy and Breast-Conserving Surgery. Ann Surg Oncol 32(11):8160-8167, 2025. e-Pub 2025. PMID: 40762776.
Chen JH, Warneke CL, Middleton L, Singh P, Kuerer HM, Hunt KK, Martinez AL, Litton JK, Oke OC, Johnson HM. Complication Rates are Low After Invasive Procedures on the Lactating Breast in Patients Treated for Breast Cancer During Pregnancy. Ann Surg Oncol 32(11):8196-8206, 2025. e-Pub 2025. PMID: 40676422.
Yi M, Chavez-MacGregor M, Smith BD, Mitchell MP, Caudle AS, DeSnyder SM, Kuerer HM, Hunt KK. Comparing Survival Differences between Patients Undergoing Breast-Conserving Therapy Versus Total Mastectomy as a First Treatment for Early Stage Breast Cancer. Ann Surg Oncol, 2025. e-Pub 2025. PMID: 40789993.
Huynh, VD, Mouabbi, JA, Kuerer, HM, Wanis, K, Abdel-Salam, HM, Gutierrez, AM, Johnson, HM, Lucci, A, Hunt, KK, Arun, BK. Characterization of the Germline Pathogenic Mutational Landscape and Oncologic Outcomes Among 877 Patients with Invasive Lobular Carcinoma. Annals of surgical oncology 32(8):5477-5488, 2025. e-Pub 2025. PMID: 40314901.
Kuerer HM. Five Years After Pathologic Complete Response Without Surgery-Reply. JAMA Oncol, 2025. e-Pub 2025. PMID: 40705327.
Wanis, K, Mitchell, MP, Giordano, SH, Litton, J, Shaitelman, SF, Tamirisa, N, Bedrosian, I, Dong, W, Shen, Y, Hunt, KK, Singh, P, Sun, SX, Caudle, AS, Kuerer, HM, Meric-Bernstam, F, Hwang, RF, Adesoye, T. Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers. Cancer 131(11), 2025. e-Pub 2025. PMID: 40433858.
Kuerer HM, Valero V, Smith BD, Krishnamurthy S, Diego EJ, Johnson HM, Lin H, Shen Y, Lucci A, Shaitelman SF, Mitchell MP, Boughey JC, White RL, Hunt KK, Yang WT, Rauch GM. Selective Elimination of Breast Surgery for Invasive Breast Cancer: A Nonrandomized Clinical Trial. JAMA Oncol 11(5):529-534, 2025. e-Pub 2025. PMID: 40152443.
Montagna G, Laws A, Ferrucci M, Mrdutt MM, Sun SX, Bademler S, Balbaloglu H, Balint-Lahat N, Banys-Paluchowski M, Barrio AV, Benson J, Bese N, Boughey JC, Boyle MK, Diego EJ, Eden C, Eller R, Goldschmidt M, Hlavin C, Heidinger M, Jelinska J, Karadeniz Cakmak G, Kesmodel SB, King TA, Kuerer HM, Loesch J, Milardi F, Murawa D, Moo TA, Menes TS, Passeri D, Pastoriza JM, Perhavec A, Pislar N, Polidorio N, Rami A, Ryu JM, Schulz A, Sevilimedu V, Ugurlu MU, Uras C, van Hemert A, Wong SM, Yoo TR, Zhang JQ, Karanlik H, Cabioglu N, Peeters MV, Morrow M, Weber WP. Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study. J Clin Oncol 43(7):810-820, 2025. e-Pub 2025. PMID: 39509672.
So A, Yi M, Simons JM, Kuerer HM, Caudle A, DeSnyder SM, Bedrosian I, Nead KT, Chavez-MacGregor M, Teshome M, Hunt KK. Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy. Ann Surg Oncol 32(2):922-930, 2025. e-Pub 2025. PMID: 39441324.
So A, Yi M, Simons JM, Kuerer HM, Caudle A, DeSnyder SM, Bedrosian I, Nead KT, Chavez-MacGregor M, Teshome M, Hunt KK. ASO Visual Abstract: Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy. Ann Surg Oncol 32(2):977-978, 2025. e-Pub 2025. PMID: 39562423.
Ganz PA, Cecchini RS, White JR, Vicini FA, Arthur DW, Rabinovitch RA, Kuske RR, Julian TB, Parda DS, Scheier MF, Winter KA, Paik S, Kuerer HM, Vallow LA, Pierce LJ, Mamounas EP, McCormick B, Bear HD, Germain I, Gustafson GS, Grossheim L, Petersen IA, Hudes RS, Curran WJ Jr, Wolmark N. Quality-of-life outcomes from NRG Oncology NSABP B-39/RTOG 0413: whole-breast irradiation vs accelerated partial-breast irradiation after breast-conserving surgery. J Natl Cancer Inst 117(1):103-111, 2025. e-Pub 2025. PMID: 39254630.
Moore AM, Caudle AS, Sun SX, Yi M, Smith BD, Valero V, Yang W, Kuerer HM, Hunt KK, Teshome M. ASO Visual Abstract: Impact of Clipped Node as a Sentinel Lymph Node on Axillary Staging Following Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer. Ann Surg Oncol 32(1):123-124, 2025. e-Pub 2025. PMID: 39443343.
Moore AM, Caudle AS, Sun SX, Yi M, Smith BD, Valero V, Yang W, Kuerer HM, Hunt KK, Teshome M. Impact of Clipped Node as a Sentinel Lymph Node on Axillary Staging Following Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer. Ann Surg Oncol 32(1):84-91, 2025. e-Pub 2025. PMID: 39419889.
Mitchell MP, Shaitelman SF, Smith BD, Krishnamurthy S, Valero V, Rauch GM, Shen Y, Lin H, Kuerer HM. Feasibility of breast conserving surgery alone in HER2-positive exceptional responders to neoadjuvant systemic therapy. Eur J Surg Oncol 50(12):108613, 2024. e-Pub 2024. PMID: 39243728.
Huang ML, Lane DL, Chang Sen LQ, Candelaria RP, Kuerer HM, Hunt KK, Akay C, Lim B, Shaitelman S, Hwang RF, Chen H, Katta R, Santiago L. Defining Breast Cryoablation Treatment Success: A Guide for the Curative and Palliative Treatment of Breast Cancer. Acad Radiol 31(12):4759-4771, 2024. e-Pub 2024. PMID: 39107186.
Piltin MA, Norwood P, Ladores V, Mukhtar RA, Sauder CA, Golshan M, Tchou J, Rao R, Lee MC, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman LJ, Boughey JC, Working Group IL. Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial. Ann Surg Oncol 31(11):7420-7428, 2024. e-Pub 2024. PMID: 38980586.
Moore AM, Caudle AS, Sun SX, Yi M, Smith BD, Valero V, Yang W, Kuerer HM, Hunt KK, Teshome M. Residual Nodal Burden After Neoadjuvant Chemotherapy in cN1 Breast Cancer Patients with Positive Nodes at Targeted Axillary Dissection. Ann Surg Oncol 31(11):7264-7270, 2024. e-Pub 2024. PMID: 39044106.
Chen JH, Addanki S, Roy D, Bassett R, Kalashnikova E, Spickard E, Kuerer HM, Meas S, Sarli VN, Korkut A, White JB, Rauch GM, Tripathy D, Arun BK, Barcenas CH, Yam C, Sethi H, Rodriguez AA, Liu MC, Moulder SL, Lucci A. Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA. BMC Cancer 24(1):1016, 2024. e-Pub 2024. PMID: 39148033.
Moore AM, Caudle AS, Sun SX, Yi M, Smith BD, Valero V, Yang W, Kuerer HM, Hunt KK, Teshome M. ASO Visual Abstract: Residual Nodal Burden After Neoadjuvant Chemotherapy in cN1 Breast Cancer Patients with Positive Nodes on Targeted Axillary Dissection. Ann Surg Oncol, 2024. e-Pub 2024. PMID: 39090492.
Wanis KN, Kuerer HM, Sun SX, Hunt KK, Glencer AC, Teshome M, Lucci A, Weiser R, Johnson H, Smith BD, Gutierrez AM, Shaitelman SF, Arun BK. Clinical Outcomes for BRCA Pathogenic Variant Carriers With Breast Cancer Undergoing Breast Conservation. JAMA Netw Open 7(6), 2024. e-Pub 2024. PMID: 38916888.
Montagna G, Mrdutt MM, Sun SX, Hlavin C, Diego EJ, Wong SM, Barrio AV, van den Bruele AB, Cabioglu N, Sevilimedu V, Rosenberger LH, Hwang ES, Ingham A, Papassotiropoulos B, Nguyen-Strauli BD, Kurzeder C, Aybar DD, Vorburger D, Matlac DM, Ostapenko E, Riedel F, Fitzal F, Meani F, Fick F, Sagasser J, Heil J, Karanlik H, Dedes KJ, Romics L, Banys-Paluchowski M, Muslumanoglu M, Perez MDRC, Diaz MC, Heidinger M, Fehr MK, Reinisch M, Tukenmez M, Maggi N, Rocco N, Ditsch N, Gentilini OD, Paulinelli RR, Zarhi SS, Kuemmel S, Bruzas S, di Lascio S, Parissenti TK, Hoskin TL, Guth U, Ovalle V, Tausch C, Kuerer HM, Caudle AS, Boileau JF, Boughey JC, Kuhn T, Morrow M, Weber WP. Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy. JAMA Oncol 10(6):793-798, 2024. e-Pub 2024. PMID: 38662396.
Schaverien MV, Singh P, Smith BD, Qiao W, Akay CL, Bloom ES, Chavez-MacGregor M, Chu CK, Clemens MW, Colen JS, Ehlers RA, Hwang RF, Joyner MM, Largo RD, Mericli AF, Mitchell MP, Shuck JW, Tamirisa N, Tripathy D, Villa MT, Woodward WA, Zacharia R, Kuerer HM, Hoffman KE. Premastectomy Radiotherapy and Immediate Breast Reconstruction: A Randomized Clinical Trial. JAMA Netw Open 7(4):e245217, 2024. e-Pub 2024. PMID: 38578640.
Huang ML, Lane DL, Bomar H, Kuerer H. Breast cryoablation for the palliative treatment of indolent subtype of multicentric triple-negative breast cancer. BMJ Case Rep 17(4), 2024. e-Pub 2024. PMID: 38627044.
Loveland-Jones C, Gaughan J, Caudle A, Murphy B, Samiian L, Byrum S, Brill K, Germaine P, Zhang X, Yoon-Flannery K, Carter T, Lopez A, Gruner R, Fantazzio M, Kuerer H. Evaluation of traditional targeted axillary dissection eligibility criteria for node-positive breast cancer after neoadjuvant chemotherapy in a prospective multicenter registry. Eur J Surg Oncol 50(4):108245, 2024. e-Pub 2024. PMID: 38484493.
Piotrowski, MJ, Yi, M, Le-Petross, C, Teshome, M, Kuerer, HM, Lee, J, Hunt, KK, DeSnyder, SM. Optimization of intraoperative lumpectomy specimen labeling. Surgical Oncology Insight 1(1), 2024. e-Pub 2024.
Guhan M, Crane SM, Valerius LS, Cruz D, Smith BD, Woodward WA, Mitchell MP, Valero V, Rauch GM, Krishnamurthy S, Warnecke CL, Kuerer HM, Shaitelman SF. Patient Interest in Exploring Nonsurgical Treatment Approaches for Early-Stage Breast Cancer: A Qualitative Study. Int J Radiat Oncol Biol Phys 118(2):443-454, 2024. e-Pub 2024. PMID: 37802228.
Woodfin AA, Yam C, Teshome M, Kuerer HM, Hunt KK, Meric-Bernstam F, Schaverien M, Barcenas CH, Sun SX. Axillary Nodal Metastases Conversion and Perioperative Complications with Neoadjuvant Pembrolizumab Therapy in Triple-Negative Breast Cancer. Ann Surg Oncol 31(2):974-980, 2024. e-Pub 2024. PMID: 37973647.
Sun SX, Piotrowski MJ, Adesoye T, Mitchell MP, Garber HR, Teshome M, Kuerer HM, Tamirisa N, Singh P. Long-Term Outcomes and Predictors of Response in Breast Cancer Patients with Advanced Nodal Involvement. J Am Coll Surg 238(1):1-9, 2024. e-Pub 2024. PMID: 37870227.
Woodfin AA, Yam C, Teshome M, Kuerer HM, Hunt KK, Meric-Bernstam F, Schaverien M, Barcenas CH, Sun SX. ASO Visual Abstract: Axillary Nodal Metastases Conversion and Perioperative Complications with Neoadjuvant Pembrolizumab Therapy in Triple-Negative Breast Cancer. Ann Surg Oncol. e-Pub 2024. PMID: 38206502.
Farley C, Bassett R, Meric-Bernstam F, Bedrosian I, Caudle A, DeSnyder S, Hunt K, Kuerer H, Singh P, Sun S, Tamirisa N, Teshome M, Hwang RF. To Dissect or Not to Dissect: Can We Predict the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women with Clinically Node-Negative Breast Cancer?. Ann Surg Oncol 30(13):8327-8334, 2023. e-Pub 2023. PMID: 37670121.
Zaveri S, Kuerer HM. ASO Author Reflections: The Importance of a Multidisciplinary Approach to Axillary Management in the Upfront Mastectomy Patient. Ann Surg Oncol 30(12):7131-7132, 2023. e-Pub 2023. PMID: 37535271.
Zaveri S, Everidge S, FitzSullivan E, Hwang R, Smith BD, Lin H, Shen Y, Lucci A, Teshome M, Sun SX, Hunt KK, Kuerer HM. Extremely Low Incidence of Local-Regional Recurrences Observed Among T1-2 N1 (1 or 2 Positive SLNs) Breast Cancer Patients Receiving Upfront Mastectomy Without Completion Axillary Node Dissection. Ann Surg Oncol 30(12):7015-7025, 2023. e-Pub 2023. PMID: 37458948.
Johnson HM, Lin H, Shen Y, Diego EJ, Krishnamurthy S, Yang WT, Smith BD, Valero V, Lucci A, Sun SX, Shaitelman SF, Mitchell MP, Boughey JC, White RL, Rauch GM, Kuerer HM. Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy: A Nonrandomized Clinical Trial. JAMA Netw Open 6(9):e2333933, 2023. e-Pub 2023. PMID: 37707811.
Zaveri S, Everidge S, FitzSullivan E, Hwang R, Smith BD, Lin H, Shen Y, Lucci A, Teshome M, Sun SX, Hunt KK, Kuerer HM. ASO Visual Abstract: Extremely Low Incidence of Local-Regional Recurrences Observed among T1-2N1 (one or two Positive SLNs) Breast Cancer Patients Receiving Upfront Mastectomy without Completion Axillary Node Dissection. Ann Surg Oncol. e-Pub 2023. PMID: 37612547.
Johnson HM, Valero V, Yang WT, Smith BD, Krishnamurthy S, Shen Y, Lin H, Lucci A, Rauch GM, Kuerer HM. Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint. J Am Coll Surg 237(1):101-108, 2023. e-Pub 2023. PMID: 36856291.
Sun SX, Duan Z, Kuerer HM, DeSnyder SM, Cunningham C, Zhao H, Giordano SH. ASO Visual Abstract: Predictors of Emergency Room Visits After Ambulatory Breast Cancer Surgery in the Medicare Population. Ann Surg Oncol 30(3):1699, 2023. e-Pub 2023. PMID: 36622528.
Sun SX, Duan Z, Kuerer HM, DeSnyder SM, Cunningham C, Zhao H, Giordano SH. Predictors of Emergency Room Visits After Ambulatory Breast Cancer Surgery in the Medicare Population. Ann Surg Oncol 30(3):1689-1698, 2023. e-Pub 2023. PMID: 36402898.
Shen Y, Ning J, Lin HY, Shaitelman SF, Kuerer HM, Bedrosian I. Effectiveness Without Efficacy: Cautionary Tale from a Landmark Breast Cancer Randomized Controlled Trial. J Cancer 14(2):193-199, 2023. e-Pub 2023. PMID: 36741254.
Kuerer HM, Smith BD, Krishnamurthy S, Yang WT, Valero V, Shen Y, Lin H, Lucci A, Boughey JC, White RL, Diego EJ, Rauch GM, Trials Group ERC. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol 23(12):1517-1524, 2022. e-Pub 2022. PMID: 36306810.
Cobb AN, Diao K, Teshome M, Lucci A, Ueno NT, Stauder M, Layman RM, Kuerer HM, Woodward WA, Sun SX. ASO Visual Abstract: Long-Term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement. Ann Surg Oncol 29:620-621, 2022. e-Pub 2022. PMID: 36104531.
Kuerer HM. Moving Forward with Omission of Breast Cancer Surgery Following Neoadjuvant Systemic Therapy. Ann Surg Oncol 29(13):7942-7944, 2022. e-Pub 2022. PMID: 36002702.
Cobb AN, Diao K, Teshome M, Lucci A, Ueno NT, Stauder M, Layman RM, Kuerer HM, Woodward WA, Sun SX. Long-term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement. Ann Surg Oncol 29(10):6381-6392, 2022. e-Pub 2022. PMID: 35834145.
Sittenfeld SMC, Zabor EC, Hamilton SN, Kuerer HM, El-Tamer M, Naoum GE, Truong PT, Nichol A, Smith BD, Woodward WA, Moo TA, Powell SN, Shah CS, Taghian AG, Abu-Gheida I, Tendulkar RD. A multi-institutional prediction model to estimate the risk of recurrence and mortality after mastectomy for T1-2N1 breast cancer. Cancer 128(16):3057-3066, 2022. e-Pub 2022. PMID: 35713598.
Sun SX, Suk R, Kuerer HM, Cantor SB, Raber BM, Deshmukh AA. No Treatment Versus Partial Mastectomy Plus Radiation for Ductal Carcinoma In Situ. Ann Surg Oncol 29(1):39-41, 2022. e-Pub 2021. PMID: 34467509.
Kilgore LJ, Murphy BL, Postlewait LM, Liang DH, Bedrosian I, Lucci A, Kuerer HM, Hunt KK, Teshome M. Impact of the early COVID-19 pandemic on Breast Surgical Oncology fellow education. J Surg Oncol 124(7):989-994, 2021. e-Pub 2021. PMID: 34328640.
Rauch GM, Kuerer HM, Jochelson MS. To Look or Not to Look? Yes to Nodal Ultrasound!. J Breast Imaging 3(6):659-665, 2021. e-Pub 2021. PMID: 38424935.
Elmore LC, Kuerer HM, Barcenas CH, Smith BD, Miggins MV, Lucci A, Caudle AS, Meric-Bernstam F, Hunt KK, Teshome M. ASO Visual Abstract: Clinical Course of Breast Cancer Patients with Local Regional Progression During Neoadjuvant Systemic Therapy. Ann Surg Oncol. e-Pub 2021. PMID: 34743278.
Rauch GM, Kuerer HM, Jochelson MS. To look or not to look? yes to nodal ultrasound!. Journal of Breast Imaging 3(6):659-665, 2021. e-Pub 2021.
Elmore LC, Kuerer HM, Barcenas CH, Smith BD, Miggins MV, Lucci A, Caudle AS, Meric-Bernstam F, Hunt KK, Teshome M. Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy. Ann Surg Oncol 28(10):5477-5485, 2021. e-Pub 2021. PMID: 34247335.
Calvillo KZ, Blair SL, Kuerer HM. 22nd Annual Virtual Meeting of the American Society of Breast Surgeons: Science, Innovation, and Practice Changes. Ann Surg Oncol 28(10):5453-5455, 2021. e-Pub 2021. PMID: 34365558.
McCormick B, Winter KA, Woodward W, Kuerer HM, Sneige N, Rakovitch E, Smith BL, Germain I, Hartford AC, O'Rourke MA, Walker EM, Strom EA, Hopkins JO, Pierce LJ, Pu AT, Sumida KNM, Vesprini D, Moughan J, White JR. Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804. J Clin Oncol:JCO2101083. e-Pub 2021. PMID: 34406870.
Postlewait LM, Teshome M, Adesoye T, DeSnyder SM, Lim B, Kuerer HM, Bedrosian I, Sun SX, Woodward WA, Le-Petross HT, Valero V, Ueno NT, Lucci A. Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. Ann Surg Oncol. e-Pub 2021. PMID: 34125346.
Postlewait LM, Teshome M, Adesoye T, DeSnyder SM, Lim B, Kuerer HM, Bedrosian I, Sun SX, Woodward WA, Le-Petross HT, Valero V, Ueno NT, Lucci A. ASO Visual Abstract: Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. Ann Surg Oncol. e-Pub 2021. PMID: 34052918.
Santiago L, Volk RJ, Checka CM, Black D, Lee J, Colen JS, Akay C, Caudle A, Kuerer H, Arribas EM. Acceptability of 3D-printed breast models and their impact on the decisional conflict of breast cancer patients: A feasibility study. J Surg Oncol 123(5):1206-1214, 2021. e-Pub 2021. PMID: 33577715.
Rocco N, Catanuto G, Cinquini M, Audretsch W, Benson J, Criscitiello C, Di Micco R, Kovacs T, Kuerer H, Lozza L, Montagna G, Moschetti I, Nafissi N, O'Connell RL, Oliveri S, Pau L, Scaperrotta G, Thoma A, Winters Z, Nava MB. Should oncoplastic breast conserving surgery be used for the treatment of early stage breast cancer? Using the GRADE approach for development of clinical recommendations. Breast 57:25-35. e-Pub 2021. PMID: 33711697.
Smith BD, Kuerer HM. Same-Day Breast Cancer Surgery and TARGIT-IORT: Better than Selective Omission of Radiotherapy?. Ann Surg Oncol. e-Pub 2021. PMID: 33452605.
Simons JM, Scoggins ME, Kuerer HM, Krishnamurthy S, Yang WT, Sahin AA, Shen Y, Lin H, Bedrosian I, Mittendorf EA, Thompson A, Lane DL, Hunt KK, Caudle AS. Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After Neoadjuvant Chemotherapy for Breast Cancer Patients. Ann Surg Oncol. e-Pub 2021. PMID: 33417121.
Partain N, Postlewait LM, Teshome M, Rosso K, Hall C, Song J, Meas S, DeSnyder SM, Lim B, Valero V, Woodward W, Ueno NT, Kuerer H, Lucci A. The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. Ann Surg Oncol. e-Pub 2021. PMID: 33403525.
Pfob A, Sidey-Gibbons C, Lee HB, Tasoulis MK, Koelbel V, Golatta M, Rauch GM, Smith BD, Valero V, Han W, MacNeill F, Weber WP, Rauch G, Kuerer HM, Heil J. Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy. Eur J Cancer 143:134-146, 2021. e-Pub 2021. PMID: 33307491.
Tasoulis MK, Lee HB, Yang W, Pope R, Krishnamurthy S, Kim SY, Cho N, Teoh V, Rauch GM, Smith BD, Valero V, Mohammed K, Han W, MacNeill F, Kuerer HM. Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer. JAMA Surg 155(12):e204103, 2020. e-Pub 2020. PMID: 33026457.
Schaverien MV, Deigni OA, Adamson KA, Robb GL, Kuerer H, Smith BD, Garvey PB, Hassid VJ, Villa MT, Baumann DP. Complications of Wise-Pattern Compared With Vertical Scar Mastopexy/Breast Reduction in Oncoplastic Breast-Conserving Surgery. Ann Plast Surg 85(6):601-607, 2020. e-Pub 2020. PMID: 32332388.
Singh P, Scoggins ME, Sahin AA, Hwang RF, Kuerer HM, Caudle AS, Mittendorf EA, Thompson AM, Bedrosian I, Teshome M, DeSnyder SM, Meric-Bernstam F, Hunt KK. Effectiveness and Safety of Magseed-localization for Excision of Breast Lesions: A Prospective, Phase IV Trial. Ann Surg Open 1(2), 2020. e-Pub 2020. PMID: 34017965.
Coroneos CJ, Woodward WA, Wong FC, Caudle AS, Shaitelman SF, Kuerer HM, Schaverien MV. Anatomy and physiology of the sentinel lymph nodes of the upper extremity: Implications for axillary reverse mapping in breast cancer. J Surg Oncol. e-Pub 2020. PMID: 33333583.
Kuerer HM, Blair SL. The Virtual Scientific Sessions from the American Society of Breast Surgeons During the COVID-19 Pandemic. Ann Surg Oncol. e-Pub 2020. PMID: 32812104.
Heil J, Pfob A, Kuerer HM. De-escalation towards omission is the tipping point of individualizing breast cancer surgery. Eur J Surg Oncol 46(8):1543-1545, 2020. e-Pub 2020. PMID: 32241595.
Postlewait LM, Teshome M, DeSnyder SM, Lim B, Kuerer HM, Bedrosian I, Woodward WA, Ueno NT, Lucci A. Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery?. Ann Surg Oncol. e-Pub 2020. PMID: 32710271.
Schaverien MV, Kuerer HM, Caudle AS, Smith BD, Hwang RF, Robb GL. Outcomes of Volume Replacement Oncoplastic Breast-Conserving Surgery Using Chest Wall Perforator Flaps: Comparison with Volume Displacement Oncoplastic Surgery and Total Breast Reconstruction. Plast Reconstr Surg 146(1):14-27, 2020. e-Pub 2020. PMID: 32590634.
Park KU, Kyrish K, Yi M, Bedrosian I, Caudle AS, Kuerer HM, Hunt KK, Miggins MV, DeSnyder SM. Opioid Use after Breast-Conserving Surgery: Prospective Evaluation of Risk Factors for High Opioid Use. Ann Surg Oncol 27(3):730-735, 2020. e-Pub 2020. PMID: 31820211.
Chun YS, Mizuno T, Cloyd JM, Ha MJ, Omichi K, Tzeng CD, Aloia TA, Ueno NT, Kuerer HM, Barcenas CH, Vauthey JN. Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes. Eur J Surg Oncol. e-Pub 2020. PMID: 32253074.
Sun SX, Moseley TW, Kuerer HM, Yang WT. Imaging-Based Approach to Axillary Lymph Node Staging and Sentinel Lymph Node Biopsy in Patients With Breast Cancer. AJR Am J Roentgenol 214(2):1-10, 2020. e-Pub 2020. PMID: 31714846.
Park KU, Weiss A, Rosso K, Yi M, Hunt K, Kuerer H, Hanson SE, Candelaria R, Tevis S, Thompson A. Use of Mammographic Measurements to Predict Complications After Nipple-Sparing Mastectomy in BRCA Mutation Carriers. Ann Surg Oncol 27(2):367-372, 2020. e-Pub 2020. PMID: 31399819.
Arthur DW, Winter KA, Kuerer HM, Haffty B, Cuttino L, Todor DA, Anne PR, Anderson P, Woodward WA, McCormick B, Cheston S, Sahijdak WM, Canaday D, Brown DR, Currey A, Fisher CM, Jagsi R, Moughan J, White JR. Effectiveness of Breast-Conserving Surgery and 3-Dimensional Conformal Partial Breast Reirradiation for Recurrence of Breast Cancer in the Ipsilateral Breast: The NRG Oncology/RTOG 1014 Phase 2 Clinical Trial. JAMA Oncol 6(1):75-82, 2020. e-Pub 2020. PMID: 31750868.
Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA, Kuske RR, Ganz PA, Parda DS, Scheier MF, Winter KA, Paik S, Kuerer HM, Vallow LA, Pierce LJ, Mamounas EP, McCormick B, Costantino JP, Bear HD, Germain I, Gustafson G, Grossheim L, Petersen IA, Hudes RS, Curran WJ, Bryant JL, Wolmark N. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet 394(10215):2155-2164, 2019. e-Pub 2019. PMID: 31813636.
Singh P, Kuerer HM. ASO Author Reflections: Neoadjuvant Radiotherapy Followed by Immediate Breast Reconstruction Represents a Novel Therapeutic Sequence for Breast Cancer. Ann Surg Oncol 26(Suppl 3):812-813, 2019. e-Pub 2019. PMID: 31659636.
Sun SX, Kuerer HM. ASO Author Reflections: Selecting Patients for Elimination of Surgery Trials-Predicting Residual Invasive and In Situ Disease in Patients with HER2-Positive Breast Cancer After Neoadjuvant Systemic Therapy. Ann Surg Oncol 26(Suppl 3):804-805, 2019. e-Pub 2019. PMID: 31654165.
Singh P, Hoffman K, Schaverien MV, Krause KJ, Butler C, Smith BD, Kuerer HM. Neoadjuvant Radiotherapy to Facilitate Immediate Breast Reconstruction: A Systematic Review and Current Clinical Trials. Ann Surg Oncol 26(10):3312-3320, 2019. e-Pub 2019. PMID: 31342362.
Holmes D, Kuerer HM. Comprehensive Breast Care for the Future from the American Society of Breast Surgeons. Ann Surg Oncol 26(10):3013-3014, 2019. e-Pub 2019. PMID: 31342380.
Manahan ER, Kuerer HM, Sebastian M, Hughes KS, Boughey JC, Euhus DM, Boolbol SK, Taylor WA. Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons. Ann Surg Oncol 26(10):3025-3031, 2019. e-Pub 2019. PMID: 31342359.
Killelea BK, Modestino AS, Gass J, Kuerer HM, Margenthaler J, Boolbol SK, Dietz JR, Manahan ER. The 2018 Compensation Survey of the American Society of Breast Surgeons. Ann Surg Oncol 26(10):3052-3062, 2019. e-Pub 2019. PMID: 31342382.
Sun S, van la Parra RFD, Rauch GM, Checka C, Tadros AB, Lucci A, Teshome M, Black D, Hwang RF, Smith BD, Krishnamurthy S, Valero V, Yang WT, Kuerer HM. Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy. Ann Surg Oncol 26(10):3071-3079, 2019. e-Pub 2019. PMID: 31342361.
Shin K, Weaver O, Wei W, Caudle AS, Kuerer HM, Yang WT. Sonographic features of benign and malignant axillary nodes post-neoadjuvant chemotherapy. Breast J. e-Pub 2019. PMID: 31448480.
Armer JM, Ballman KV, McCall L, Ostby PL, Zagar E, Kuerer HM, Hunt KK, Boughey JC. Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection. JAMA Surg. e-Pub 2019. PMID: 31314062.
Christopherson K, Lei X, Barcenas C, Buchholz TA, Garg N, Hoffman KE, Kuerer HM, Mittendorf E, Perkins G, Shaitelman SF, Smith GL, Stauder M, Strom EA, Tereffe W, Woodward WA, Smith BD. Outcomes of curative-intent treatment for breast cancer patients presenting with sternal or mediastinal involvement. Int J Radiat Oncol Biol Phys 104(3):574-581, 2019. e-Pub 2019. PMID: 30851348.
Weiss A, Lin H, Babiera GV, Bedrosian I, Shaitelman SF, Shen Y, Kuerer HM, Mittendorf EA, Caudle AS, Hunt KK, Hwang RF. Evolution in practice patterns of axillary management following mastectomy in patients with 1-2 positive sentinel nodes. Breast Cancer Res Treat 176(2):435-444, 2019. e-Pub 2019. PMID: 31025270.
Park KU, Kuerer HM, Rauch GM, Leung JWT, Sahin AA, Wei W, Li Y, Black DM. Digital Breast Tomosynthesis for Intraoperative Margin Assessment during Breast-Conserving Surgery. Ann Surg Oncol 26(6):1720-1728, 2019. e-Pub 2019. PMID: 30877499.
Park KU, Kyrish K, Terrell J, Yi M, Caudle AS, Hunt KK, Kuerer HM, Bedrosian I, Thompson A, DeSnyder SM, Study Group OMODOBSO. Surgeon perception versus reality: Opioid use after breast cancer surgery. J Surg Oncol 119(7):909-915, 2019. e-Pub 2019. PMID: 30737785.
Stecklein SR, Rosso KJ, Nuanjing J, Tadros AB, Weiss A, DeSnyder SM, Kuerer HM, Teshome M, Buchholz TA, Stauder MC, Ueno NT, Lucci A, Woodward WA. Excellent Locoregional Control in Inflammatory Breast Cancer With a Personalized Radiation Therapy Approach. Pract Radiat Oncol. e-Pub 2019. PMID: 31132433.
Tevis SE, Bassett R, Bedrosian I, Barcenas CH, Black DM, Caudle AS, DeSnyder SM, Fitzsullivan E, Hunt KK, Kuerer HM, Lucci A, Meric-Bernstam F, Mittendorf EA, Park K, Teshome M, Thompson AM, Hwang RF. OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients. Ann Surg Oncol 26(3):815-820, 2019. e-Pub 2019. PMID: 30556120.
Caudle AS, Kuerer HM, Krishnamurthy S, Shin K, Hobbs BP, Ma J, Mittendorf EA, Washington AC, DeSnyder SM, Black DM, Hunt KK, Yang WT. Feasibility of fine-needle aspiration for assessing responses to chemotherapy in metastatic nodes marked with clips in breast cancer: A prospective registry study. Cancer 125(3):365-373, 2019. e-Pub 2019. PMID: 30359480.
Tadros AB, Smith BD, Shen Y, Lin H, Krishnamurthy S, Lucci A, Barcenas CH, Hwang RF, Rauch G, Santiago L, Strom EA, DeSnyder SM, Yang WT, Black DM, Albarracin CT, Chavez-MacGregor M, Hunt KK, Kuerer HM. Ductal Carcinoma In Situ and Margins <2?mm: Contemporary Outcomes With Breast Conservation. Ann Surg 269(1):150-157, 2019. e-Pub 2019. PMID: 28742682.
Barron AU, Hoskin TL, Day CN, Hwang ES, Kuerer HM, Boughey JC. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy. JAMA Surg 153(12):1120-1126, 2018. e-Pub 2018. PMID: 30193375.
Kuerer HM. More evidence for further minimisation of breast-cancer surgery. Lancet Oncol, 2018. e-Pub 2018. PMID: 30196032.
Weiss A, Mittendorf EA, DeSnyder SM, Hwang RF, Bea V, Bedrosian I, Hoffman K, Adrade B, Sahin AA, Kuerer HM, Hunt KK, Caudle AS. Expanding Implementation of ACOSOG Z0011 in Surgeon Practice. Clin Breast Cancer 18(4):276-281, 2018. e-Pub 2018. PMID: 29100726.
Ollila DW, Hwang ES, Brenin DR, Kuerer HM, Yao K, Feldman S. The Changing Paradigms for Breast Cancer Surgery: Performing Fewer and Less-Invasive Operations. Ann Surg Oncol, 2018. e-Pub 2018. PMID: 29968033.
Tevis SE, James TA, Kuerer HM, Pusic AL, Yao KA, Merlino J, Dietz J. Patient-Reported Outcomes for Breast Cancer. Ann Surg Oncol, 2018. e-Pub 2018. PMID: 29971671.
Kuerer HM. Increasing Breast Cancer Systemic Therapy Use Before Surgery in the United States: Scaling Down and the Promise of Selective Elimination of Surgery. Ann Surg Oncol, 2018. e-Pub 2018. PMID: 30051370.
Rauch GM, Kuerer HM, Adrada B, Santiago L, Moseley T, Candelaria RP, Arribas E, Sun J, Leung JWT, Krishnamurthy S, Yang WT. Biopsy Feasibility Trial for Breast Cancer Pathologic Complete Response Detection after Neoadjuvant Chemotherapy: Imaging Assessment and Correlation Endpoints. Ann Surg Oncol 25(7):1953-1960, 2018. e-Pub 2018. PMID: 29667115.
DeSnyder SM, Hunt KK, Dong W, Smith BD, Moran MS, Chavez-MacGregor M, Shen Y, Kuerer HM, Lucci A. American Society of Breast Surgeons' Practice Patterns After Publication of the SSO-ASTRO-ASCO DCIS Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation. Ann Surg Oncol, 2018. e-Pub 2018. PMID: 29987598.
van la Parra RFD, Liao K, Smith BD, Yang WT, Leung JWT, Giordano SH, Kuerer HM. Incidence and Outcome of Breast Biopsy Procedures During Follow-up After Treatment for Breast Cancer. JAMA Surg 153(6):559-568, 2018. e-Pub 2018. PMID: 29387884.
Tevis SE, Neuman HB, Mittendorf EA, Kuerer HM, Bedrosian I, DeSnyder SM, Thompson AM, Black DM, Scoggins ME, Sahin AA, Hunt KK, Caudle AS. Multidisciplinary Intraoperative Assessment of Breast Specimens Reduces Number of Positive Margins. Ann Surg Oncol, 2018. e-Pub 2018. PMID: 29947001.
Woodward WA, Ueno NT, Kuerer HM, Lucci A, Shen Y. Reply to 'A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: A large population-based study in the Surveillance, Epidemiology, and End Results database 18'. Breast 39:148-149, 2018. e-Pub 2018. PMID: 29729725.
Elsayegh N, Webster RD, Gutierrez Barrera AM, Lin H, Kuerer HM, Litton JK, Bedrosian I, Arun BK. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer. Cancer Med 7(6):2718-2726, 2018. e-Pub 2018. PMID: 29733510.
Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, Black DM, Santiago L, Hobbs BP, Lucci A Jr, Gilcrease M, Hwang RF, Candelaria RP, Chavez-MacGregor M, Smith BD, Arribas E, Moseley T, Teshome M, Miggins MV, Valero V, Hunt KK, Yang WT. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg 267(5):946-951, 2018. e-Pub 2018. PMID: 28549010.
Nathanson SD, Krag D, Kuerer HM, Newman LA, Brown M, Kerjaschki D, Pereira ER, Padera TP. Breast cancer metastasis through the lympho-vascular system. Clin Exp Metastasis, 2018. e-Pub 2018. PMID: 29796854.
Kuerer HM. Navigating treatment controversies for DCIS in the era of genomic profiling and active surveillance trials. Eur J Surg Oncol 44(4):386-387, 2018. e-Pub 2018. PMID: 29398321.
van la Parra RFD, Tadros AB, Checka CM, Rauch GM, Lucci A, Smith BD, Krishnamurthy S, Valero V, Yang WT, Kuerer HM. Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer. Br J Surg, 2018. e-Pub 2018. PMID: 29465744.
DeSnyder SM, Mittendorf EA, Le-Petross C, Krishnamurthy S, Whitman GJ, Ueno NT, Woodward WA, Kuerer HM, Akay CL, Babiera GV, Yang W, Lucci A. Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer. Clin Breast Cancer 18(1):e73-e77, 2018. e-Pub 2018. PMID: 28755879.
Clifton K, Gutierrez-Barrera A, Ma J, Bassett R, Litton J, Kuerer H, Moulder S, Albarracin C, Hortobagyi G, Arun B. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Res Treat, 2018. e-Pub 2018. PMID: 29470805.
Akay CL, Albarracin C, Torstenson T, Bassett R, Mittendorf EA, Yi M, Kuerer HM, Babiera GV, Bedrosian I, Hunt KK, Hwang RF. Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer. Breast J 24(1):28-34, 2018. e-Pub 2018. PMID: 28608612.
Kuerer HM, Cordeiro PG, Mutter RW. Optimizing Breast Cancer Adjuvant Radiation and Integration of Breast and Reconstructive Surgery. Am Soc Clin Oncol Educ Book 37:93-105, 2017. e-Pub 2017. PMID: 28561684.
Kuerer HM, Krishnamurthy S, Rauch GM, Yang WT, Smith BD, Valero V. Optimal Selection of Breast Cancer Patients for Elimination of Surgery Following Neoadjuvant Systemic Therapy. Ann Surg, 2017. e-Pub 2017. PMID: 29064904.
Arthur DW, Winter KA, Kuerer HM, Haffty BG, Cuttino LW, Todor DA, Simone NL, Hayes SB, Woodward WA, McCormick B, Cohen RJ, Sahijdak WM, Canaday DJ, Brown DR, Currey AD, Fisher CM, Jagsi R, White J. NRG Oncology-Radiation Therapy Oncology Group Study 1014: 1-Year Toxicity Report From a Phase 2 Study of Repeat Breast-Preserving Surgery and 3-Dimensional Conformal Partial-Breast Reirradiation for In-Breast Recurrence. Int J Radiat Oncol Biol Phys 98(5):1028-1035, 2017. e-Pub 2017. PMID: 28721885.
Kuerer HM, MTFD VP, Rea DW, Basik M, De Los Santos J, Heil J. Nonoperative management for invasive breast cancer after neoadjuvant systemic therapy: Conceptual basis and fundamental international feasibility clinical trials. Ann Surg Oncol, 2017. e-Pub 2017. PMID: 28766204.
Kuerer, HM, Smith, BD, Chavez-MacGregor M, Albarracin C, Barcenas CH, Santiago L, Edgerton ME, Rauch GM, Giordano SH, Sahin A, Krishnamurthy S, Woodward W, Tripathy D, Yang WT, Hunt KK. DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. Journal of Cancer, 2017. e-Pub 2017.
Rosso KJ, Tadros AB, Weiss A, Warneke CL, DeSnyder S, Kuerer H, Ueno NT, Stecklein SR, Woodward WA, Lucci A. Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery. Ann Surg Oncol, 2017. e-Pub 2017. PMID: 28766220.
Caudle AS, Bedrosian I, Milton DR, DeSnyder SM, Kuerer HM, Hunt KK, Mittendorf EA. Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members. Ann Surg Oncol, 2017. e-Pub 2017. PMID: 28766207.
Ayoub Z, Strom EA, Ovalle V, Perkins GH, Woodward WA, Tereffe W, Smith BD, Shaitelman SF, Stauder MC, Hoffman KE, DeSnyder SM, Garvey PB, Clemens MW, Barcenas CH, Kuerer HM, Kronowitz S. A 10-Year Experience with Mastectomy and Tissue Expander Placement to Facilitate Subsequent Radiation and Reconstruction. Ann Surg Oncol, 2017. e-Pub 2017. PMID: 28766219.
Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, Black DM, Lucci A, Caudle AS, DeSnyder SM, Teshome M, Barcenas CH, Miggins M, Adrada BE, Moseley T, Hwang RF, Hunt KK, Kuerer HM. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surg 152(7):665-670, 2017. e-Pub 2017. PMID: 28423171.
Fayanju OM, Hall CS, Bauldry JB, Karhade M, Valad LM, Kuerer HM, DeSnyder SM, Barcenas CH, Lucci A. Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer. Am J Surg, 2017. e-Pub 2017. PMID: 28720217.
Ong WL, Schouwenburg MG, van Bommel ACM, Stowell C, Allison KH, Benn KE, Browne JP, Cooter RD, Delaney GP, Duhoux FP, Ganz PA, Hancock P, Jagsi R, Knaul FM, Knip AM, Koppert LB, Kuerer HM, McLaughin S, Mureau MAM, Partridge AH, Reid DP, Sheeran L, Smith TJ, Stoutjesdijk MJ, MJTFD VP, Wengström Y, Yip CH, Saunders C. A Standard Set of Value-Based Patient-Centered Outcomes for Breast Cancer: The International Consortium for Health Outcomes Measurement (ICHOM) Initiative. JAMA Oncol 3(5):677-685, 2017. e-Pub 2017. PMID: 28033439.
Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, Black DM, Santiago L, Hobbs BP, Lucci A, Gilcrease M, Hwang RF, Candelaria RP, Chavez-MacGregor M, Smith BD, Arribas E, Moseley T, Teshome M, Miggins MV, Valero V, Hunt KK, Yang WT. A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy. Annals of Surgery, 2017. e-Pub 2017.
Teshome M, Kuerer HM. Breast conserving surgery and locoregional control after neoadjuvant chemotherapy. European Journal of Surgical Oncology, 2017. e-Pub 2017.
Candelaria RP, Bassett RL, Symmans WF, Ramineni M, Moulder SL, Kuerer HM, Thompson AM, Yang WT. Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype. Oncologist 22(4):394-401, 2017. e-Pub 2017. PMID: 28314842.
Sandberg LJ, Clemens MW, Symmans WF, Valero V, Caudle AS, Smith B, Kuerer HM, Hsu L, Kronowitz SJ. Molecular Profiling Using Breast Cancer Subtype to Plan for Breast Reconstruction. Plast Reconstr Surg 139(3):586e-596e, 2017. e-Pub 2017. PMID: 28234813.
Lin HY, Bedrosian I, Babiera GV, Shaitelman SF, Kuerer HM, Woodward WA, Ueno NT, Shen Y. Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer. Cancer, 2017. e-Pub 2017. PMID: 28295213.
Mitchell KB, Lin H, Shen Y, Colfry A, Kuerer H, Shaitelman SF, Babiera GV, Bedrosian I. DCIS and axillary nodal evaluation: compliance with national guidelines. BMC Surg 17(1):12, 2017. e-Pub 2017. PMID: 28173790.
Krishnamurthy S, Bevers T, Kuerer HM, Smith B, Yang WT. Paradigm Shifts in Breast Care Delivery: Impact of Imaging in a Multidisciplinary Environment. AJR Am J Roentgenol 208(2):248-255, 2017. e-Pub 2017. PMID: 27929664.
Candelaria RP, Huang ML, Adrada BE, Bassett R, Hunt KK, Kuerer HM, Smith BD, Chavez-MacGregor M, Yang WT. Incremental Cancer Detection of Locoregional Restaging with Diagnostic Mammography Combined with Whole-Breast and Regional Nodal Ultrasound in Women with Newly Diagnosed Breast Cancer. Acad Radiol 24(2):191-199, 2017. e-Pub 2017. PMID: 27955877.
Rauch GM, Adrada BE, Kuerer HM, van la Parra RF, Leung JW, Yang WT. Multimodality Imaging for Evaluating Response to Neoadjuvant Chemotherapy in Breast Cancer. AJR Am J Roentgenol:1-10. e-Pub 2016. PMID: 27809573.
Sandberg LJ, Clemens MW, Symmans WF, Valero V, Caudle AS, Smith B, Kuerer HM, Hsu L, Kronowitz SJ. Molecular profiling using breast cancer subtype to plan for breast reconstruction. Plast Reconstr Surg. e-Pub 2016. PMID: 27893626.
Manders JB, Kuerer HM, Smith BD, McCluskey C, Farrar WB, Frazier TG, Li L, Leonard CE, Carter DL, Chawla S, Medeiros LE, Guenther JM, Castellini LE, Buchholz DJ, Mamounas EP, Wapnir IL, Horst KC, Chagpar A, Evans SB, Riker AI, Vali FS, Solin LJ, Jablon L, Recht A, Sharma R, Lu R, Sing AP, Hwang ES, White J, investigators S, participants S. Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ. Ann Surg Oncol. e-Pub 2016. PMID: 27704370.
FitzSullivan E, Bassett RL, Kuerer HM, Mittendorf EA, Yi M, Hunt KK, Babiera GV, Caudle AS, Black DM, Bedrosian I, Reyna C, Teshome M, Meric-Bernstam F, Hwang R. Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy. Ann Surg Oncol. e-Pub 2016. PMID: 27822630.
Kuerer HM, van la Parra RF. Breast Cancer Clinical Trials: Past Half Century Moving Forward Advancing Patient Outcomes. Ann Surg Oncol 23(10):3145-52, 2016. e-Pub 2016. PMID: 27364503.
Vila J, Mittendorf EA, Farante G, Bassett RL, Veronesi P, Galimberti V, Peradze N, Stauder MC, Chavez-MacGregor M, Litton JF, Huo L, Kuerer HM, Hunt KK, Caudle AS. Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer. Ann Surg Oncol 23(11):3501-9, 2016. e-Pub 2016. PMID: 27216742.
Shin K, Caudle AS, Kuerer HM, Santiago L, Candelaria RP, Dogan B, Leung J, Krishnamurthy S, Yang W. Radiologic Mapping for Targeted Axillary Dissection: Needle Biopsy to Excision. AJR Am J Roentgenol:1-8. e-Pub 2016. PMID: 27726422.
Carter SA, Lyons GR, Kuerer HM, Bassett RL, Oates S, Thompson A, Caudle AS, Mittendorf EA, Bedrosian I, Lucci A, DeSnyder SM, Babiera G, Yi M, Baumann DP, Clemens MW, Garvey PB, Hunt KK, Hwang RF. Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer: Single-Institution Analysis of Breast Conservation with Oncoplastic Reconstruction. Ann Surg Oncol 23(10):3190-8, 2016. e-Pub 2016. PMID: 27406093.
Dobbs JL, Shin D, Krishnamurthy S, Kuerer H, Yang W, Richards-Kortum R. Confocal fluorescence microscopy to evaluate changes in adipocytes in the tumor microenvironment associated with invasive ductal carcinoma and ductal carcinoma in situ. Int J Cancer 139(5):1140-9, 2016. e-Pub 2016. PMID: 27116366.
He H, Plaxco JS, Wei W, Huo L, Candelaria RP, Kuerer HM, Yang WT. Incremental Cancer Detection Using Breast Ultrasonography Versus Breast Magnetic Resonance Imaging in the Evaluation of Newly Diagnosed Breast Cancer Patients. Br J Radiol 89(1065):20160401, 2016. e-Pub 2016. PMID: 27384241.
Kuerer HM. Proceed With Caution: Concerns Related to Routine Internal Mammary Lymph Node Radiation for Node-Positive Breast Cancer. J Clin Oncol 34(22):2671, 2016. e-Pub 2016. PMID: 27217458.
Fayanju OM, Mayo TL, Spinks TE, Lee S, Barcenas CH, Smith BD, Giordano SH, Hwang RF, Ehlers RA, Selber JC, Walters R, Tripathy D, Hunt KK, Buchholz TA, Feeley TW, Kuerer HM. Value-Based Breast Cancer Care: A Multidisciplinary Approach for Defining Patient-Centered Outcomes. Ann Surg Oncol 23(8):2385-90, 2016. e-Pub 2016. PMID: 26979306.
Loveland-Jones C, Lin H, Shen Y, Bedrosian I, Shaitelman S, Kuerer H, Woodward W, Ueno N, Valero V, Babiera G. Disparities in the Use of Postmastectomy Radiation Therapy for Inflammatory Breast Cancer. Int J Radiat Oncol Biol Phys 95(4):1218-25, 2016. e-Pub 2016. PMID: 27209502.
Hall CS, Karhade MG, Bowman Bauldry JB, Valad LM, Kuerer HM, DeSnyder SM, Lucci A. Prognostic Value of Circulating Tumor Cells Identified Before Surgical Resection in Nonmetastatic Breast Cancer Patients. J Am Coll Surg 223(1):20-9, 2016. e-Pub 2016. PMID: 27049782.
Teshome M, Kuerer HM. Training of breast surgical oncologists. Chin Clin Oncol 5(3):43, 2016. e-Pub 2016. PMID: 27197510.
Kuerer HM, Yang WT, Krishnamurthy S. Comment on 'Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques'. Br J Cancer 114(10):e3, 2016. e-Pub 2016. PMID: 27092783.
Ovalle V, Strom EA, Godby J, Shaitelman SF, Stauder MC, Amos RA, Kuerer HM, Woodward WA, Hoffman KE. Proton Partial-Breast Irradiation for Early-Stage Cancer: Is It Really So Costly?. Int J Radiat Oncol Biol Phys 95(1):49-51, 2016. e-Pub 2016. PMID: 27084625.
Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, DeSnyder SM, Hwang RF, Adrada BE, Shaitelman SF, Chavez-MacGregor M, Smith BD, Candelaria RP, Babiera GV, Dogan BE, Santiago L, Hunt KK, Kuerer HM. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol 34(10):1072-8, 2016. e-Pub 2016. PMID: 26811528.
Mougalian SS, Hernandez M, Lei X, Lynch S, Kuerer HM, Symmans WF, Theriault RL, Fornage BD, Hsu L, Buchholz TA, Sahin AA, Hunt KK, Yang WT, Hortobagyi GN, Valero V. Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncol 2(4):1-9, 2016. e-Pub 2016. PMID: 26720612.
van la Parra RF, Kuerer HM. Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials. Breast Cancer Res 18(1):28, 2016. e-Pub 2016. PMID: 26951131.
Swisher SK, Vila J, Tucker SL, Bedrosian I, Shaitelman SF, Litton JK, Smith BD, Caudle AS, Kuerer HM, Mittendorf EA. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy. Ann Surg Oncol 23(3):749-56, 2016. e-Pub 2016. PMID: 26511263.
Kronowitz SJ, Mandujano CC, Liu J, Kuerer HM, Smith B, Garvey P, Jagsi R, Hsu L, Hanson S, Valero V. Lipofilling of the Breast Does Not Increase the Risk of Recurrence of Breast Cancer: A Matched Controlled Study. Plast Reconstr Surg 137(2):385-93, 2016. e-Pub 2016. PMID: 26818270.
Rauch GM, Hobbs BP, Kuerer HM, Scoggins ME, Benveniste AP, Park YM, Caudle AS, Fox PS, Smith BD, Adrada BE, Krishnamurthy S, Yang WT. Microcalcifications in 1657 Patients with Pure Ductal Carcinoma in Situ of the Breast: Correlation with Clinical, Histopathologic, Biologic Features, and Local Recurrence. Ann Surg Oncol 23(2):482-9, 2016. e-Pub 2016. PMID: 26416712.
Parker PA, Peterson SK, Bedrosian I, Crosby MA, Shen Y, Black DM, Babiera G, Kuerer HM, Ying J, Dong W, Cantor SB, Brewster AM. Prospective study of surgical decision-making processes for contralateral prophylactic mastectomy in women with breast cancer. Ann Surg 263(1):178-83, 2016. e-Pub 2016. PMID: 25822675.
Elsayegh N, Barrera AM, Muse KI, Lin H, Kuerer HM, Helm M, Litton JK, Arun BK. Evaluation of BRCAPRO Risk Assessment Model in Patients with Ductal Carcinoma In situ Who Underwent Clinical BRCA Genetic Testing. Front Genet 7:71, 2016. e-Pub 2016. PMID: 27200080.
Kuerer HM. MD Anderson Cancer Center Feasibility Trial for Eliminating Breast Cancer Surgery in Exceptional Reponders. American Journal of Hematology / Oncology 12(5):5-7, 2016. e-Pub 2016.
Francis AM, Haugen CE, Grimes LM, Crow JR, Yi M, Mittendorf EA, Bedrosian I, Caudle AS, Babiera GV, Krishnamurthy S, Kuerer HM, Hunt KK. Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ?. Ann Surg Oncol 22(13):4270-9, 2015. e-Pub 2015. PMID: 25905585.
Hall CS, Karhade M, Laubacher BA, Kuerer HM, Krishnamurthy S, DeSnyder S, Anderson AE, Valero V, Ueno NT, Li Y, Su X, Lucci A. Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. J Natl Cancer Inst 107(11), 2015. e-Pub 2015. PMID: 26374427.
Mitchell KB, Kuerer H. Ductal Carcinoma In Situ: Treatment Update and Current Trends. Curr Oncol Rep 17(11):48, 2015. e-Pub 2015. PMID: 26373411.
Dietz JR, Partridge AH, Gemignani ML, Javid SH, Kuerer HM. Breast Cancer Management Updates: Young and Older, Pregnant, or Male. Ann Surg Oncol 22(10):3219-24, 2015. e-Pub 2015. PMID: 26265366.
Holmes D, Colfry A, Czerniecki B, Dickson-Witmer D, Francisco Espinel C, Feldman E, Gallagher K, Greenup R, Herrmann V, Kuerer H, Malik M, Manahan E, O'Neill J, Patel M, Sebastian M, Wheeler A, Kass R. Performance and Practice Guideline for the Use of Neoadjuvant Systemic Therapy in the Management of Breast Cancer. Ann Surg Oncol 22(10):3184-90, 2015. e-Pub 2015. PMID: 26224406.
Lautner M, Lin H, Shen Y, Parker C, Kuerer H, Shaitelman S, Babiera G, Bedrosian I. Disparities in the Use of Breast-Conserving Therapy Among Patients With Early-Stage Breast Cancer. JAMA Surg 150(8):778-86, 2015. e-Pub 2015. PMID: 26083835.
Hall C, Karhade M, Laubacher B, Anderson A, Kuerer H, DeSynder S, Lucci A. Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer. Ann Surg Oncol. e-Pub 2015. PMID: 25968619.
Scoggins ME, Fox PS, Kuerer HM, Rauch GM, Benveniste AP, Park YM, Lari SA, Krishnamurthy S, Yang WT. Correlation between sonographic findings and clinicopathologic and biologic features of pure ductal carcinoma in situ in 691 patients. AJR Am J Roentgenol 204(4):887-88, 2015. e-Pub 2015. PMID: 25794082.
McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, Sneige N, Moughan J, Shah A, Germain I, Hartford AC, Rashtian A, Walker EM, Yuen A, Strom EA, Wilcox JL, Vallow LA, Small W, Pu AT, Kerlin K, White J. RTOG 9804: A prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol 33(7):709-15, 2015. e-Pub 2015. PMID: 25605856.
Ramirez MF, Ai D, Bauer M, Vauthey JN, Gottumukkala V, Kee S, Shon D, Truty M, Kuerer HM, Kurz A, Hernandez M, Cata JP. Innate immune function after breast, lung, and colorectal cancer surgery. J Surg Res 194(1):185-93, 2015. e-Pub 2015. PMID: 25475022.
Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Flippo-Morton TS, Kuerer HM, Bowling M, Hunt KK, in Oncology AFCT. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg 261(3):547-52, 2015. e-Pub 2015. PMID: 25664534.
Caudle AS, Yang WT, Mittendorf EA, Black DM, Hwang R, Hobbs B, Hunt KK, Krishnamurthy S, Kuerer HM. Selective Surgical Localization of Axillary Lymph Nodes Containing Metastases in Patients With Breast Cancer: A Prospective Feasibility Trial. JAMA Surg 150(2):137-43, 2015. e-Pub 2015. PMID: 25517573.
Dobbs JL, Mueller JL, Krishnamurthy S, Shin D, Kuerer H, Yang W, Ramanujam N, Richards-Kortum R. Micro-anatomical quantitative optical imaging: toward automated assessment of breast tissues. Breast Cancer Res 17:105, 2015. e-Pub 2015. PMID: 26290094.
Caudle AS, Kuerer HM. Targeting and limiting surgery for patients with node-positive breast cancer. BMC Med 13(1):149, 2015. e-Pub 2015. PMID: 26109042.
Elsayegh N, Profato J, Barrera AM, Lin H, Kuerer HM, Ardic C, Litton JK, Tripathy D, Arun BK. Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative. J Cancer 6(7):610-5, 2015. e-Pub 2015. PMID: 26078790.
Kuerer HM. Ductal carcinoma in situ: treatment or active surveillance?. Expert Rev Anticancer Ther 15(7):777-85, 2015. e-Pub 2015. PMID: 25938920.
Caudle AS, Kuerer HM, Le-Petross HT, Yang W, Yi M, Bedrosian I, Krishnamurthy S, Fornage BD, Hunt KK, Mittendorf EA. Predicting the Extent of Nodal Disease in Early-Stage Breast Cancer. Ann Surg Oncol 21(11):3440-7, 2014. e-Pub 2014. PMID: 24859939.
Elsayegh N, Kuerer HM, Lin H, Gutierrez Barrera AM, Jackson M, Muse KI, Litton JK, Albarracin C, Afrough A, Hortobagyi GN, Arun BK. Predictors that Influence Contralateral Prophylactic Mastectomy Election Among Women with Ductal Carcinoma In Situ Who Were Evaluated for BRCA Genetic Testing. Ann Surg Oncol 21(11):3466-72, 2014. e-Pub 2014. PMID: 24796968.
Zhou JH, Rosen D, Andreou A, Brouquet A, Abbott D, Loyer E, Gonzalez-Angulo AM, Kopetz S, Meric-Bernstam F, Kuerer H, Abdalla E, Vauthey JN, Sahin AA, Maru DM. Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer. Ann Diagn Pathol 18(5):266-70, 2014. e-Pub 2014. PMID: 25205085.
Haffty BG, Kuerer HM, Powell S. Sorting out othe survival impact of radiation therapy in early-stage invasive breast cancer. Ann Surg Oncol 21(10):3204-8, 2014. e-Pub 2014. PMID: 25092165.
Karhade M, Hall C, Mishra P, Anderson A, Kuerer H, Bedrosian I, Krishnamurthy S, Lucci A. Circulating tumor cells in non-metastatic triple-negative breast cancer. Breast Cancer Res Treat 147(2):325-33, 2014. e-Pub 2014. PMID: 25164970.
Haynes AB, Bloom ES, Bedrosian I, Kuerer HM, Hwang RF, Munsell MF, Chemaly RF, Graviss LS, Caudle AS, Hunt KK, Tereffe W, Shaitelman SF, Babiera GV. Timing of Infectious Complications Following Breast-Conserving Therapy with Catheter-Based Accelerated Partial Breast Irradiation. Ann Surg Oncol 21(8):2512-6, 2014. e-Pub 2014. PMID: 24736987.
Mittendorf EA, Caudle AS, Yang W, Krishnamurthy S, Shaitelman S, Chavez-MacGregor M, Woodward WA, Bedrosian I, Kuerer HM, Hunt KK. Implementation of the American College of Surgeons Oncology Group Z1071 Trial Data in Clinical Practice: Is There a Way Forward for Sentinel Lymph Node Dissection in Clinically Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?. Ann Surg Oncol 21(8):2468-73, 2014. e-Pub 2014. PMID: 24841348.
Black DM, Jiang J, Kuerer HM, Buchholz TA, Smith BD. Racial disparities in adoption of axillary sentinel lymph node biopsy and lymphedema risk in women with breast cancer. JAMA Surg 149(8):788-96, 2014. e-Pub 2014. PMID: 25073831.
Woodward WA, Sneige N, Winter K, Kuerer HM, Hudis C, Rakovitch E, Smith BL, Pierce LJ, Germano I, Pu AT, Walker EM, Grisell DL, White JR, McCormick B, Oncology Group FTRT. Web based pathology assessment in RTOG 98-04. J Clin Pathol. e-Pub 2014. PMID: 24989024.
Caudle AS, Kuerer HM. Breast conservation therapy after neoadjuvant chemotherapy: Optimization of a multimodality approach. J Surg Oncol 110(1):32-6, 2014. e-Pub 2014. PMID: 24623334.
Caudle AS, Cupp JA, Kuerer HM. Management of axillary disease. Surg Oncol Clin N Am 23(3):473-86, 2014. e-Pub 2014. PMID: 24882346.
McBride A, Allen P, Woodward W, Kim M, Kuerer HM, Drinka EK, Sahin A, Strom EA, Buzdar A, Valero V, Hortobagyi GN, Hunt KK, Buchholz TA. Locoregional Recurrence Risk for Patients With T1,2 Breast Cancer With 1-3 Positive Lymph Nodes Treated With Mastectomy and Systemic Treatment. Int J Radiat Oncol Biol Phys 89(2):392-8, 2014. e-Pub 2014. PMID: 24721590.
Akay CL, Ueno NT, Chisholm GB, Hortobagyi GN, Woodward WA, Alvarez RH, Bedrosian I, Kuerer HM, Hunt KK, Huo L, Babiera GV. Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer 120(9):1319-28, 2014. e-Pub 2014. PMID: 24510381.
Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Buzdar AU, Symmans WF, Crow JR, Bender M, Shah RR, Hortobagyi GN, Hunt KK. Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann Oncol, 2014. e-Pub 2014. PMID: 24562447.
FitzSullivan E, Lari SA, Smith B, Caudle AS, Krishnamurthy S, Lucci A, Mittendorf EA, Babiera GV, Black DM, Wagner JL, Bedrosian I, Woodward W, Gainer SM, Hwang R, Meric-Bernstam F, Hunt KK, Kuerer HM. Incidence and consequence of close margins in patients with ductal carcinoma in situ treated with mastectomy: Is further therapy warranted?. Ann Surg Oncol 20(13):4103-12, 2013. e-Pub 2013. PMID: 23975313.
Weksberg DC, Allen PK, Hoffman KE, Litton JK, Strom EA, Shah RR, Kuerer HM, Hunt KK, Buchholz TA, Mittendorf EA. Outcomes and Predictive Factors for Salvage Therapy After Local-Regional Recurrence Following Neoadjuvant Chemotherapy and Breast Conserving Therapy. Ann Surg Oncol 20(11):3430-7, 2013. e-Pub 2013. PMID: 23720073.
Dobbs JL, Ding H, Benveniste AP, Kuerer HM, Krishnamurthy S, Yang W, Richards-Kortum R. Feasibility of confocal fluorescence microscopy for real-time evaluation of neoplasia in fresh human breast tissue. J Biomed Opt 18(10):106016-1 - 10616-10, 2013. e-Pub 2013. PMID: 24165742.
Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Kuerer HM, Bowling M, Flippo-Morton TS, Byrd DR, Ollila DW, Julian TB, McLaughlin SA, McCall L, Symmans WF, Le-Petross HT, Haffty BG, Buchholz TA, Nelson H, Hunt KK, in Oncology AFCT. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310(14):1455-61, 2013. e-Pub 2013. PMID: 24101169.
Gould DJ, Hunt KK, Liu J, Kuerer HM, Crosby MA, Babiera G, Kronowitz SJ. Impact of surgical techniques, biomaterials, and patient variables on rate of nipple necrosis after nipple-sparing mastectomy. Plast Reconstr Surg 132(3):330e-8e, 2013. e-Pub 2013. PMID: 23985644.
Pezzi CM, Kuerer HM, Nelson H. Improving cancer care through quality measures: putting evidence to work with the COC. Bull Am Coll Surg 98(8):62-4, 2013. e-Pub 2013. PMID: 24205578.
Shen MC, Massarweh NN, Lari SA, Vaporciyan AA, Selber JC, Mittendorf EA, Macgregor MC, Smith BD, Kuerer HM. Clinical Course of Breast Cancer Patients with Isolated Sternal and Full-Thickness Chest Wall Recurrences Treated With and Without Radical Surgery. Ann Surg Oncol. e-Pub 2013. PMID: 23959054.
Kim MM, Allen P, Gonzalez-Angulo AM, Woodward WA, Meric-Bernstam F, Buzdar AU, Hunt KK, Kuerer HM, Litton JK, Hortobagyi GN, Buchholz TA, Mittendorf EA. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol 24(8):1999-2004, 2013. e-Pub 2013. PMID: 23562929.
Cadiz F, Kuerer HM, Puga J, Camacho J, Cunill E, Arun B. Establishing a program for individuals at high risk for breast cancer. J Cancer 4(5):433-46, 2013. e-Pub 2013. PMID: 23833688.
Krishnamurthy S, Bischoff F, Ann Mayer J, Wong K, Pham T, Kuerer H, Lodhi A, Bhattacharyya A, Hall C, Lucci A. Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer. Cancer Med 2(2):226-33. e-Pub 2013. PMID: 23634290.
Lang JE, Tereffe W, Mitchell MP, Rao R, Feng L, Meric-Bernstam F, Bedrosian I, Kuerer HM, Hunt KK, Hortobagyi GN, Babiera GV. Primary tumor extirpation in breast cancer patients who present with stage iv disease is associated with improved survival. Ann Surg Oncol 20(6):1893-9, 2013. e-Pub 2013. PMID: 23306905.
Rauch GM, Kuerer HM, Scoggins ME, Fox PS, Benveniste AP, Park YM, Lari SA, Hobbs BP, Adrada BE, Krishnamurthy S, Yang WT. Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status. Breast Cancer Res Treat 139(3):639-47, 2013. e-Pub 2013. PMID: 23774990.
Yi M, Cormier JN, Xing Y, Giordano SH, Chai C, Meric-Bernstam F, Vlastos G, Kuerer HM, Mirza NQ, Buchholz TA, Hunt KK. Other Primary Malignancies in Breast Cancer Patients Treated with Breast Conserving Surgery and Radiation Therapy. Ann Surg Oncol 20(5):1514-21, 2013. e-Pub 2013. PMID: 23224829.
Litton JK, Warneke CL, Hahn KM, Palla SL, Kuerer HM, Perkins GH, Mittendorf EA, Barnett C, Gonzalez-Angulo AM, Hortobágyi GN, Theriault RL. Case Control Study of Women Treated With Chemotherapy for Breast Cancer During Pregnancy as Compared With Nonpregnant Patients With Breast Cancer. Oncologist 18(4):369-76. e-Pub 2013. PMID: 23576478.
Mittendorf EA, Buchholz TA, Tucker SL, Meric-Bernstam F, Kuerer HM, Gonzalez-Angulo AM, Bedrosian I, Babiera GV, Hoffman K, Yi M, Ross MI, Hortobagyi GN, Hunt KK. Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast conserving therapy. Ann Surg 257(2):173-9, 2013. e-Pub 2013. PMID: 23291658.
Yi M, Kuerer HM, Mittendorf EA, Hwang RF, Caudle AS, Bedrosian I, Meric-Bernstam F, Wagner JL, Hunt KK. Impact of the American College of Surgeons Oncology Group Z0011 Criteria Applied to a Contemporary Patient Population. J Am Coll Surg 216(1):105-13, 2013. e-Pub 2013. PMID: 23122536.
Bailes AA, Kuerer HM, Lari SA, Jones LA, Brewster AM. Impact of race and ethnicity on features and outcome of ductal carcinoma in situ of the breast. Cancer 119(1):150-7, 2013. e-Pub 2013. PMID: 22736444.
Alvarado R, Lari SA, Roses RE, Smith BD, Yang W, Mittendorf EA, Arun BK, Lucci A, Babiera GV, Wagner JL, Caudle AS, Meric-Bernstam F, Hwang RF, Bedrosian I, Hunt KK, Kuerer HM. Biology, Treatment, and Outcome in Very Young and Older Women with DCIS. Ann Surg Oncol 19(12):3777-84, 2012. e-Pub 2012. PMID: 22622473.
Caudle AS, Hunt KK, Tucker SL, Hoffman K, Gainer SM, Lucci A, Kuerer HM, Meric-Bernstam F, Shah R, Babiera GV, Sahin AA, Mittendorf EA. American College of Surgeons Oncology Group (ACOSOG) Z0011: Impact on Surgeon Practice Patterns. Ann Surg Oncol 19(10):3144-51, 2012. e-Pub 2012. PMID: 22847123.
Alvarado R, Yi M, Le-Petross H, Gilcrease M, Mittendorf EA, Bedrosian I, Hwang RF, Caudle AS, Babiera GV, Akins JS, Kuerer HM, Hunt KK. The Role for Sentinel Lymph Node Dissection after Neoadjuvant Chemotherapy in Patients who Present with Node-Positive Breast Cancer. Ann Surg Oncol 19(10):3177-84, 2012. e-Pub 2012. PMID: 22772869.
Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, Bedrosian I, Kuerer HM, Krishnamurthy S. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 13(7):688-95, 2012. e-Pub 2012. PMID: 22677156.
Beitsch PD, Wilkinson JB, Vicini FA, Haffty B, Fine R, Whitworth P, Kuerer H, Zannis V, Lyden M. Tumor Bed Control with Balloon-Based Accelerated Partial Breast Irradiation: Incidence of True Recurrences Versus Elsewhere Failures in the American Society of Breast Surgery MammoSite(®) Registry Trial. Ann Surg Oncol. e-Pub 2012. PMID: 22836556.
Kuerer HM, Lari SA, Arun BK, Hu CY, Brewster A, Mittendorf EA, Albarracin CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I, Meric-Bernstam F, Lucci A, Hunt KK. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat 133(3):1131-41, 2012. e-Pub 2012. PMID: 22392043.
Abbott DE, Brouquet A, Mittendorf EA, Andreou A, Meric-Bernstam F, Valero V, Green MC, Kuerer HM, Curley SA, Abdalla EK, Hunt KK, Vauthey JN. Resection of liver metastases from breast cancer: Estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery 151(5):710-6, 2012. e-Pub 2012. PMID: 22285778.
Khan AJ, Arthur D, Vicini F, Beitsch P, Kuerer H, Goyal S, Lyden M, Haffty BG. Six-Year Analysis of Treatment-Related Toxicities in Patients Treated with Accelerated Partial Breast Irradiation on the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial. Ann Surg Oncol 19(5):1477-83, 2012. e-Pub 2012. PMID: 22109731.
Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer 118(9):2385-93, 2012. e-Pub 2012. PMID: 21953213.
Dominici LS, Mittendorf EA, Wang X, Liu J, Kuerer HM, Hunt KK, Brewster A, Babiera GV, Buchholz TA, Meric-Bernstam F, Bedrosian I. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Breast Cancer Res 14(3):R82. e-Pub 2012. PMID: 22621306.
Kuerer HM, Holleman WL. The Health and Well-Being of American Surgery. Ann Surg 255(4):634-6, 2012. e-Pub 2012. PMID: 22367449.
Wagner JL, Fearmonti R, Hunt KK, Hwang RF, Meric-Bernstam F, Kuerer HM, Bedrosian I, Crosby MA, Baumann DP, Ross MI, Feig BW, Krishnamurthy S, Hernandez M, Babiera GV. Prospective Evaluation of the Nipple-Areola Complex Sparing Mastectomy for Risk Reduction and for Early-Stage Breast Cancer. Ann Surg Oncol 19(4):1137-44, 2012. e-Pub 2012. PMID: 21979111.
Bayraktar S, Elsayegh N, Gutierrez Barrera AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton J, Meric-Bernstam F, Hortobagyi GN, Albarracin CT, Arun B. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer 118(6):1515-22, 2012. e-Pub 2012. PMID: 22009639.
Baltzell K, Buehring GC, Krishnamurthy S, Kuerer H, Shen HM, Sison JD. Limited evidence of human papillomavirus on breast tissue using molecular in situ methods. Cancer 118(5):1212-20, 2012. e-Pub 2012. PMID: 21823105.
Gainer SM, Lodhi AK, Bhattacharyya A, Krishnamurthy S, Kuerer HM, Lucci A. Invasive lobular carcinoma predicts micrometastasis in breast cancer. J Surg Res. e-Pub 2012. PMID: 22482764.
Akay CL, Meric-Bernstam F, Hunt KK, Grubbs EG, Bedrosian I, Tucker SL, Kuerer HM, Hoffman KE, Babiera GV, Strom EA, Buchholz TA, Mittendorf EA. Evaluation of the MD Anderson Prognostic Index for Local-Regional Recurrence After Breast Conserving Therapy in Patients Receiving Neoadjuvant Chemotherapy. Ann Surg Oncol 19(3):901-7, 2012. e-Pub 2012. PMID: 21861223.
Yi M, Meric-Bernstam F, Kuerer HM, Mittendorf EA, Bedrosian I, Lucci A, Hwang RF, Crow JR, Luo S, Hunt KK. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol 30(6):600-7, 2012. e-Pub 2012. PMID: 22253459.
Baltzell K, Buehring GC, Krishnamurthy S, Kuerer H, Shen HM, Sison JD. Epstein-Barr virus is seldom found in mammary epithelium of breast cancer tissue using in situ molecular methods. Breast Cancer Res Treat 132(1):267-74, 2012. e-Pub 2012. PMID: 22042367.
Khan AJ, Vicini FA, Beitsch P, Goyal S, Kuerer HM, Keisch M, Quiet C, Zannis V, Keleher A, Snyder H, Gittleman M, Whitworth P, Fine R, Lyden M, Haffty BG. Local Control, Toxicity, and Cosmesis in Women >70 Years Enrolled in the American Society of Breast Surgeons Accelerated Partial Breast Irradiation Registry Trial. Int J Radiat Oncol Biol Phys. e-Pub 2012. PMID: 22361081.
Krishnamurthy S, Bevers T, Kuerer H, Yang WT. Multidisciplinary considerations in the management of high-risk breast lesions. AJR Am J Roentgenol 198(2):W132-40, 2012. e-Pub 2012. PMID: 22268202.
Shah C, Vicini F, Keisch M, Kuerer H, Beitsch P, Haffty B, Lyden M. Outcome after ipsilateral breast tumor recurrence in patients who receive accelerated partial breast irradiation. Cancer. e-Pub 2012. PMID: 22252278.
Mittendorf EA, Hunt KK, Boughey JC, Bassett R, Degnim AC, Harrell R, Yi M, Meric-Bernstam F, Ross MI, Babiera GV, Kuerer HM, Hwang RF. Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg 255(1):109-15, 2012. e-Pub 2012. PMID: 22167004.
Hall C, Krishnamurthy S, Lodhi A, Bhattacharyya A, Anderson A, Kuerer H, Bedrosian I, Singh B, Lucci A. Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer. Cancer 118(2):342-8, 2012. e-Pub 2012. PMID: 21717428.
Roses RE, Kuerer HM. Ductal carcinoma in situ: Clinical trials update and resolving controversies. Curr Cancer Ther Rev 8(3), 2012. e-Pub 2012.
Diehl KM, Green EM, Weinberg A, Frederick WA, Holmes DR, Green B, Morris A, Kuerer HM, Beltran RA, Mendez J, Gines V, Ota DM, Nelson H, Newman LA. Features Associated with Successful Recruitment of Diverse Patients onto Cancer Clinical Trials: Report from the American College of Surgeons Oncology Group. Ann Surg Oncol 18(13):3544-50, 2011. e-Pub 2011. PMID: 21681382.
Yi M, Mittendorf EA, Cormier JN, Buchholz TA, Bilimoria K, Sahin AA, Hortobagyi GN, Gonzalez-Angulo AM, Luo S, Buzdar AU, Crow JR, Kuerer HM, Hunt KK. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current american joint committee on cancer staging system. J Clin Oncol 29(35):4654-61, 2011. e-Pub 2011. PMID: 22084362.
Aburabia M, Roses RE, Kuerer HM, Fine R, Beitsch PD, Goyal S, Haffty B, Lyden M, Vicini FA. Axillary Failure in Patients Treated with MammoSite Accelerated Partial Breast Irradiation. Ann Surg Oncol 18(12):3415-21, 2011. e-Pub 2011. PMID: 21537870.
Van Leeuwen BL, Rosenkranz KM, Lei Feng L, Bedrosian I, Hartmann K, Hunt KK, Kuerer HM, Ross M, Singletary SE, Babiera GV, Surgical Oncology TDO, Center MD. The effect of under-treatment of breast cancer in women 80 years of age and older. Crit Rev Oncol Hematol 79(3):315-320, 2011. e-Pub 2011. PMID: 20655242.
Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, Babiera GV, Hwang RF, Ross MI, Feig BW, Hoffman K, Litton JK, Sahin AA, Yang W, Hortobagyi GN, Buchholz TA, Mittendorf EA. Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: A Practice-Changing Trial. Ann Surg Oncol 18(9):2407-12, 2011. e-Pub 2011. PMID: 21327455.
Wagner JL, Warneke CL, Mittendorf EA, Bedrosian I, Babiera GV, Kuerer HM, Hunt KK, Yang W, Sahin AA, Meric-Bernstam F. Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients. Ann Surg 254(1):119-24, 2011. e-Pub 2011. PMID: 21494124.
Kronowitz SJ, Lam C, Tereffe W, Hunt KK, Kuerer HM, Valero V, Lance S, Robb GL, Feng L, Buchholz TA. A Multidisciplinary Protocol for Planned Skin-Preserving Delayed Breast Reconstruction for Patients with Locally Advanced Breast Cancer Requiring Postmastectomy Radiation Therapy: 3-Year Follow-up. Plast Reconstr Surg 127(6):2154-66, 2011. e-Pub 2011. PMID: 21311392.
Sharma R, Rourke LL, Kronowitz SJ, Oh JL, Lucci A, Litton JK, Robb GL, Babiera GV, Mittendorf EA, Hunt KK, Kuerer HM. Management of local-regional recurrence following immediate breast reconstruction in patients with early breast cancer treated without postmastectomy radiotherapy. Plast Reconstr Surg 127(5):1763-72, 2011. e-Pub 2011. PMID: 21532405.
Yi M, Kronowitz SJ, Meric-Bernstam F, Feig BW, Symmans WF, Lucci A, Ross MI, Babiera GV, Kuerer HM, Hunt KK. Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy. Cancer 117(5):916-24, 2011. e-Pub 2011. PMID: 20945319.
Yi M, Buchholz TA, Meric-Bernstam F, Bedrosian I, Hwang RF, Ross MI, Kuerer HM, Luo S, Gonzalez-Angulo AM, Buzdar AU, Symmans WF, Feig BW, Lucci A, Huang EH, Hunt KK. Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg 253(3):572-9, 2011. e-Pub 2011. PMID: 21209588.
Goyal S, Vicini F, Beitsch PD, Kuerer H, Keisch M, Motwani S, Jeruss JS, Lyden M, Haffty BG. Ductal carcinoma in situ treated with breast-conserving surgery and accelerated partial breast irradiation: comparison of the Mammosite registry trial with intergroup study E5194. Cancer 117(6):1149-55, 2011. e-Pub 2011. PMID: 21381007.
Vicini F, Beitsch P, Quiet C, Gittleman M, Zannis V, Fine R, Whitworth P, Kuerer H, Haffty B, Keisch M, Lyden M. Five-year analysis of treatment efficacy and cosmesis by the American Society of Breast Surgeons Mammosite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 79(3):808-17, 2011. e-Pub 2011. PMID: 20472364.
Balch CM, Shanafelt TD, Sloan J, Satele DV, Kuerer HM. Burnout and Career Satisfaction Among Surgical Oncologists Compared with Other Surgical Specialties. Ann Surg Oncol 18(1):16-25, 2011. e-Pub 2011. PMID: 20953718.
Kuerer HM. Comment on: Rational individualised selection of adjuvant therapy for ductal carcinoma in situ. Lancet Oncol 12(1):2-3, 2011. e-Pub 2011. PMID: 21145285.
Kuerer HM, Buzdar AU, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, Radvanyi L, Meric-Bernstam F, Hunt KK, Symmans WF. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer 117(1):39-47, 2011. e-Pub 2011. PMID: 20740500.
Jeruss JS, Kuerer HM, Beitsch PD, Vicini FA, Keisch M. Update on DCIS Outcomes from the American Society of Breast Surgeons Accelerated Partial Breast Irradiation Registry Trial. Ann Surg Oncol 18(1):65-71, 2011. e-Pub 2011. PMID: 20577822.
Caudle AS, Gonzalez-Angulo AM, Hunt KK, Pusztai L, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Impact of Progression During Neoadjuvant Chemotherapy on Surgical Management of Breast Cancer. Ann Surg Oncol 18(4):932-8, 2011. e-Pub 2011. PMID: 21061075.
Lari SA, Kuerer HM. Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review. J Cancer 2:232-61, 2011. e-Pub 2011. PMID: 21552384.
Roses RE, Arun BK, Lari SA, Mittendorf EA, Lucci A, Hunt KK, Kuerer HM. Ductal Carcinoma-In-Situ of the Breast with Subsequent Distant Metastasis and Death. Ann Surg Oncol 18(10):2873-8, 2011. e-Pub 2011. PMID: 21476105.
Hall C, Krishnamurthy S, Lodhi A, Mosalpuria K, Kuerer HM, Meric-Bernstam F, Bedrosian I, Hunt KK, Lucci A. Disseminated Tumor Cells in Biologic Subtypes of Stage I-III Breast Cancer Patients. Ann Surg Oncol 17(12):3252-8, 2010. e-Pub 2010. PMID: 20559739.
Shinde SS, Forman MR, Kuerer HM, Yan K, Peintinger F, Hunt KK, Hortobagyi GN, Pusztai L, Symmans WF. Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. Cancer 116(21):4933-43, 2010. e-Pub 2010. PMID: 20665494.
Sharma R, Bedrosian I, Lucci A, Hwang RF, Rourke LL, Qiao W, Buchholz TA, Kronowitz SJ, Krishnamurthy S, Babiera GV, Gonzalez-Angulo AM, Meric-Bernstam F, Mittendorf EA, Hunt KK, Kuerer HM. Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol 17(11):2899-908, 2010. e-Pub 2010. PMID: 20443145.
Yi M, Giordano SH, Meric-Bernstam F, Mittendorf EA, Kuerer HM, Hwang RF, Bedrosian I, Rourke L, Hunt KK. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol 17(Suppl 3):343-51, 2010. e-Pub 2010. PMID: 20853057.
Kang T, Yi M, Hunt KK, Mittendorf EA, Babiera GV, Kuerer H, Bedrosian I, Hwang RF, Lucci A, Meric-Bernstam F. Does blue dye contribute to success of sentinel node mapping for breast cancer?. Ann Surg Oncol 17(Suppl 3):280-5, 2010. e-Pub 2010. PMID: 20853047.
Smith BD, Buchholz TA, Kuerer HM. Intraoperative radiotherapy for early breast cancer. Lancet 376(9747):1141; author reply 1143-4, 2010. e-Pub 2010. PMID: 20888981.
Yi M, Hunt KK, Arun BK, Bedrosian I, Barrera AG, Do KA, Kuerer HM, Babiera GV, Mittendorf EA, Ready K, Litton J, Meric-Bernstam F. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila) 3(8):1026-34, 2010. e-Pub 2010. PMID: 20647335.
Dominici LS, Negron Gonzalez VM, Buzdar AU, Lucci A, Mittendorf EA, Le-Petross HT, Babiera GV, Meric-Bernstam F, Hunt KK, Kuerer HM. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer 116(12):2884-9, 2010. e-Pub 2010. PMID: 20564395.
Brown AS, Hunt KK, Shen J, Huo L, Babiera GV, Ross MI, Meric-Bernstam F, Feig BW, Kuerer HM, Boughey JC, Ching CD, Gilcrease MZ. Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment. Cancer 116(12):2878-83, 2010. e-Pub 2010. PMID: 20564394.
Bedrosian I, Babiera GV, Mittendorf EA, Kuerer HM, Pantoja L, Hunt KK, Krishnamurthy S, Meric-Bernstam F. A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer 116(11):2543-8, 2010. e-Pub 2010. PMID: 20336790.
Caudle AS, Gonzalez-Angulo AM, Hunt KK, Liu P, Pusztai L, Symmans WF, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer. J Clin Oncol 28(11):1821-8, 2010. e-Pub 2010. PMID: 20231683.
Dominici LS, Kuerer HM, Babiera G, Hahn KM, Perkins G, Middleton L, Ramirez MM, Yang W, Hortobagyi GN, Theriault RL, Litton JK. Wound Complications from Surgery in Pregnancy-Associated Breast Cancer (PABC). Breast Dis 31(1):1-5, 2010. e-Pub 2010. PMID: 20519803.
Fearmonti RM, Batista LI, Meric-Bernstam F, Bedrosian I, Kuerer HM, Hunt KK, Eva Singletary S, Babiera GV. False Negative Rate of Sentinel Lymph Node Biopsy in Multicentric and Multifocal Breast Cancers May be Higher in Cases with Large Additive Tumor Burden. Breast J 15(6):645-8, 2009. e-Pub 2009. PMID: 19735388.
Boughey JC, Goravanchi F, Parris RN, Kee SS, Kowalski AM, Frenzel JC, Bedrosian I, Meric-Bernstam F, Hunt KK, Ames FC, Kuerer HM, Lucci A. Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. Am J Surg 198(5):720-5, 2009. e-Pub 2009. PMID: 19427625.
Keisch M, Vicini F, Beitsch P, Quiet C, Keleher A, Garcia D, Snider H, Gittleman M, Zannis V, Kuerer H. American Society of Breast Surgeons MammoSite Radiation Therapy System Registry Trial: ductal carcinoma-in-situ subset analysis--4-year data in 194 treated lesions. Am J Surg 198(4):505-7, 2009. e-Pub 2009. PMID: 19800456.
Wagner J, Boughey JC, Garrett B, Babiera G, Kuerer H, Meric-Bernstam F, Singletary E, Hunt KK, Middleton LP, Bedrosian I. Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer. Am J Surg 198(3):387-91, 2009. e-Pub 2009. PMID: 19362281.
Boughey JC, Goravanchi F, Parris RN, Kee SS, Frenzel JC, Hunt KK, Ames FC, Kuerer HM, Lucci A. Improved Postoperative Pain Control using Thoracic Paravertebral Block for Breast Operations. Breast J 15(5):483-8, 2009. e-Pub 2009. PMID: 19624418.
Hunt KK, Yi M, Mittendorf EA, Guerrero C, Babiera GV, Bedrosian I, Hwang RF, Kuerer HM, Ross MI, Meric-Bernstam F. Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy is Accurate and Reduces the Need for Axillary Dissection in Breast Cancer Patients. Ann Surg. e-Pub 2009. PMID: 19730235.
Liedtke C, Hatzis C, Symmans WF, Desmedt C, Haibe-Kains B, Valero V, Kuerer H, Hortobagyi GN, Piccart-Gebhart M, Sotiriou C, Pusztai L. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol 27(19):3185-91, 2009. e-Pub 2009. PMID: 19364972.
Nelson JC, Beitsch PD, Vicini FA, Quiet CA, Garcia D, Snider HC, Gittleman MA, Zannis VJ, Whitworth PW, Fine RE, Keleher AJ, Kuerer HM. Four-year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial. Am J Surg 198(1):83-91, 2009. e-Pub 2009. PMID: 19268900.
Khan AJ, Vicini F, Beitsch P, Haffty B, Quiet C, Keleher A, Garcia D, Snider H, Gittleman M, Zannis V, Kuerer H, Whitacre E, Whitworth P, Fine R. Local control, toxicity, and cosmesis in women younger than 50 enrolled onto the American Society of Breast Surgeons MammoSite Radiation Therapy System registry trial. Ann Surg Oncol 16(6):1612-8, 2009. e-Pub 2009. PMID: 19319606.
Krishnamurthy S, Meric-Bernstam F, Lucci A, Hwang RF, Kuerer HM, Babiera G, Ames FC, Feig BW, Ross MI, Singletary E, Hunt KK, Bedrosian I. A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer. Cancer 115(7):1555-62, 2009. e-Pub 2009. PMID: 19195040.
Yi M, Meric-Bernstam F, Middleton LP, Arun BK, Bedrosian I, Babiera GV, Hwang RF, Kuerer HM, Yang W, Hunt KK. Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer 115(5):962-71, 2009. e-Pub 2009. PMID: 19172584.
Arun B, Vogel KJ, Lopez A, Hernandez M, Atchley D, Broglio KR, Amos CI, Meric-Bernstam F, Kuerer H, Hortobagyi GN, Albarracin CT. High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res (Phila Pa) 2(2):122-7, 2009. e-Pub 2009. PMID: 19174581.
Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, Hylton NM, Middleton LP, Krishnamurthy S, Perkins GH, Babiera G, Edgerton ME, Czerniecki BJ, Arun BK, Hortobagyi GN. Ductal Carcinoma in Situ: State of the Science and Roadmap to Advance the Field. J Clin Oncol 27(2):279-88, 2009. e-Pub 2009. PMID: 19064970.
Rochman S, Mills D, Kim J, Kuerer H, Love S. State of the Science and the Intraductal Approach for Breast Cancer: Proceedings Summary of the Sixth International Symposium on the Intraductal Approach to Breast Cancer Santa Monica, California, 19-21 February 2009. BMC Proceedings 3(Suppl 5):1753-61, 2009. e-Pub 2009.
Kronowitz S, Hunt K, Kuerer H, Strom E, Buchholz T, Ensor J, Koutz C, Robb G. Immediate versus delayed repair of partial mastectomy defects in breast conservation. Breast Cancer Research 11 (Suppl 1)(8):S8, 2009. e-Pub 2009. PMID: 20598180.
Haffty BG, Vicini FA, Beitsch P, Quiet C, Keleher A, Garcia D, Snider H, Gittleman M, Zannis V, Kuerer HM, Whitacre E, Whitworth P, Fine R, Keisch M. Timing of chemotherapy after MammoSite Radiation Therapy System Breast Brachytherapy: Analysis of the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial. Int J Radiat Oncol Biol Phys 72(5):1441-8, 2008. e-Pub 2008. PMID: 18692330.
Peintinger F, Buzdar AU, Kuerer HM, Mejia JA, Hatzis C, Gonzalez-Angulo AM, Pusztai L, Esteva FJ, Dawood SS, Green MC, Hortobagyi GN, Symmans WF. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol 19(12):2020-5, 2008. e-Pub 2008. PMID: 18667396.
Mittendorf EA, Sahin AA, Tucker SL, Meric-Bernstam F, Yi M, Nayeemuddin KM, Babiera GV, Ross MI, Feig BW, Kuerer HM, Hunt KK. Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol 15(12):3369-77, 2008. e-Pub 2008. PMID: 18815841.
Yi M, Meric-Bernstam F, Ross MI, Akins JS, Hwang RF, Lucci A, Kuerer HM, Babiera GV, Gilcrease MZ, Hunt KK. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer?. Cancer 113(1):30-7, 2008. e-Pub 2008. PMID: 18457326.
Yi M, Krishnamurthy S, Kuerer HM, Meric-Bernstam F, Bedrosian I, Ross MI, Ames FC, Lucci A, Hwang RF, Hunt KK. Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg 196(1):81-7, 2008. e-Pub 2008. PMID: 18436181.
Rao R, Kuerer HM, Cristofanilli M, Brigilio K, Shukla S, Rao M, Krishnamurthy S. Breast cancer in the asian indian population of the United States: a call for screening and education. Breast J 14(4):402-3, 2008. e-Pub 2008. PMID: 18540951.
Rao R, Feng L, Kuerer HM, Singletary SE, Bedrosian I, Hunt KK, Ross MI, Hortobagyi GN, Feig BW, Ames FC, Babiera GV. Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol 15(6):1696-1702, 2008. e-Pub 2008. PMID: 18357493.
Badgwell BD, Giordano SH, Duan ZZ, Fang S, Bedrosian I, Kuerer HM, Singletary SE, Hunt KK, Hortobagyi GN, Babiera G. Mammography before diagnosis among women age 80 years and older with breast cancer. J Clin Oncol 26(25):2493-8, 2008. e-Pub 2008. PMID: 18427152.
Peintinger F, Kuerer HM, McGuire SE, Bassett R, Pusztai L, Symmans WF. Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer. Br J Surg 95(4):433-7, 2008. e-Pub 2008. PMID: 18161887.
Vicini F, Beitsch PD, Quiet CA, Keleher AJ, Garcia D, Jr SH, Gittleman MA, Zannis VJ, Kuerer HM, Lyden M. Three-year analysis of treatment efficacy, cosmesis, and toxicity by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI). Cancer 112(4):758-66, 2008. e-Pub 2008. PMID: 18181095.
Kuerer HM, Eberlein TJ, Pollock RE, Huschka M, Baile WF, Morrow M, Michelassi F, Singletary SE, Novotny P, Sloan J, Shanafelt TD. Career satisfaction, practice patterns and burnout among surgical oncologists: report on the quality of life of members of the Society of Surgical Oncology. Ann Surg Oncol 14(11):3043-53, 2007. e-Pub 2007. PMID: 17828575.
Giuliano AE, Boolbol S, Degnim A, Kuerer H, Leitch AM, Morrow M. Society of Surgical Oncology: position statement on prophylactic mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007. Ann Surg Oncol 14(9):2425-7, 2007. e-Pub 2007. PMID: 17597344.
Williams SA, Ehlers RA, Hunt KK, Yi M, Kuerer HM, Singletary SE, Ross MI, Feig BW, Symmans WF, Meric-Bernstam F. Metastases to the breast from nonbreast solid neoplasms: presentation and determinants of survival. Cancer 110(4):731-37, 2007. e-Pub 2007. PMID: 17582626.
Arun B, Valero V, Logan C, Broglio K, Rivera E, Brewster A, Yin G, Green M, Kuerer H, Gong Y, Browne D, Hortobagyi GN, Sneige N. Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials. Clin Cancer Res 13(16):4943-8, 2007. e-Pub 2007. PMID: 17699874.
Peintinger F, Anderson K, Mazouni C, Kuerer HM, Hatzis C, Lin F, Hortobagyi GN, Symmans WF, Pusztai L. Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer. Clin Cancer Res 13(14):4078-82, 2007. e-Pub 2007. PMID: 17634532.
Cabioglu N, Hunt KK, Sahin AA, Kuerer HM, Babiera GV, Singletary SE, Whitman GJ, Ross MI, Ames FC, Feig BW, Buchholz TA, Meric-Bernstam F. Role for intraoperative margin assessment in patients undergoing breast-conserving surgery. Ann Surg Oncol 14(4):1458-71, 2007. e-Pub 2007. PMID: 17260108.
Yen TW, Kuerer HM, Ottesen RA, Rouse L, Niland JC, Edge SB, Theriault RL, Weeks JC. Impact of randomized clinical trial results in the National Comprehensive Cancer Network on the use of tamoxifen after breast surgery for ductal carcinoma in situ. J Clin Oncol 25(2):3251-8, 2007. e-Pub 2007. PMID: 17577019.
Kronowitz SJ, Hunt KK, Kuerer HM, Strom EA, Buchholz TA, Ensor JE, Koutz CA, Robb GL. Practical guidelines for repair of partial mastectomy defects using the breast reduction technique in patients undergoing breast conservation therapy. Plast Reconstr Surg 120(7):1755-68, 2007. e-Pub 2007. PMID: 18090737.
Gonzalez RJ, Buzdar AU, Fraser Symmans W, Yen TW, Broglio KR, Lucci A, Esteva FJ, Yin G, Kuerer HM. Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin). Breast J 13(1):72-5, 2007. e-Pub 2007. PMID: 17214797.
Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Bernstam F, Kuerer HM, Babiera GV, Tereffe W, Liu DD, Hunt KK. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer 110(4):723-30, 2007. e-Pub 2007. PMID: 17587208.
Shen J, Gilcrease MZ, Babiera GV, Ross MI, Meric-Bernstam F, Feig BW, Kuerer HM, Francis A, Ames FC, Hunt KK. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer 109(7):1255-63, 2007. e-Pub 2007. PMID: 17330229.
Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25(28):4414-22, 2007. e-Pub 2007. PMID: 17785706.
McGuire SE, Gonzalez-Angulo AM, Huang EH, Tucker SL, Kau SW, Yu TK, Strom EA, Oh JL, Woodward WA, Tereffe W, Hunt KK, Kuerer HM, Sahin AA, Hortobagyi GN, Buchholz TA. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 68(4):1004-9, 2007. e-Pub 2007. PMID: 17418973.
Mazouni C, Kau SW, Frye D, Andre F, Kuerer HM, Buchholz TA, Symmans WF, Anderson K, Hess KR, Gonzalez-Angulo AM, Hortobagyi GN, Buzdar AU, Pusztai L. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol 18(5):874-80, 2007. e-Pub 2007. PMID: 17293601.
Kuerer HM, Wiechmann LS, Pusztai L. DCIS of the breast: A look towards discovery and advancements in the field. Ann Surg Oncol 14(11):3033-4, 2007. e-Pub 2007. PMID: 17705090.
Boughey JC, Cormier JN, Xing Y, Hunt KK, Meric-Bernstam F, Babiera GV, Ross MI, Kuerer HM, Singletary SE, Bedrosian I. Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomy. Cancer 110(11):2542-50, 2007. e-Pub 2007. PMID: 17932905.
Fearmonti RM, Vicini FA, Pawlik TM, Kuerer HM. Integrating partial breast irradiation into surgical practice and clinical trials. Surg Clin North Am 87(2):485-98, 2007. e-Pub 2007. PMID: 17498539.
Vo T, Xing Y, Meric-Bernstam F, Mirza N, Vlastos G, Symmans WF, Perkins GH, Buchholz TA, Babiera GV, Kuerer HM, Bedrosian I, Akins JS, Hunt KK. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg 194(4):527-31, 2007. e-Pub 2007. PMID: 17826073.
Peintinger F, Kuerer HM, Anderson K, Boughey JC, Meric-Bernstam F, Singletary SE, Hunt KK, Whitman GJ, Stephens T, Buzdar AU, Green MC, Symmans WF. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol 13(11):1443-9, 2006. e-Pub 2006. PMID: 17028770.
Boughey JC, Khakpour N, Meric-Bernstam F, Ross MI, Kuerer HM, Singletary SE, Babiera GV, Arun B, Hunt KK, Bedrosian I. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer 107(7):1440-7, 2006. e-Pub 2006. PMID: 16955504.
Rouzier R, Pusztai L, Garbay JR, Delaloge S, Hunt KK, Hortobagyi GN, Berry D, Kuerer HM. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. Cancer 107(7):1459-66, 2006. e-Pub 2006. PMID: 16948128.
Rosenkranz KM, Bedrosian I, Feng L, Hunt KK, Hartman K, Lucci A, Meric-Bernstam F, Kuerer HM, Singletary ES, Hwang R, Feig B, Ross M, Ames F, Babiera GV. Breast cancer in the very elderly: treatment patterns and complications in a tertiary cancer center. Am J Surg 192(4):541-4, 2006. e-Pub 2006. PMID: 16978971.
Boughey JC, Bedrosian I, Meric-Bernstam F, Ross MI, Kuerer HM, Akins JS, Giordano SH, Babiera GV, Ames FC, Hunt KK. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg 203(4):475-80, 2006. e-Pub 2006. PMID: 17000390.
Vo TN, Meric-Bernstam F, Yi M, Buchholz TA, Ames FC, Kuerer HM, Bedrosian I, Hunt KK. Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. Am J Surg 192(4):552-5, 2006. e-Pub 2006. PMID: 16978974.
Kronowitz SJ, Kuerer HM, Hunt KK, Ross MI, Massey PR, Ensor JE, Robb GL. Impact of sentinel lymph node biopsy on the evolution of breast reconstruction. Plast Reconstr Surg 118(5):1089-99, 2006. e-Pub 2006. PMID: 17016172.
Benitez PR, Streeter O, Vicini F, Mehta V, Quiet C, Kuske R, Hayes MK, Arthur D, Kuerer H, Freedman G, Keisch M, Dipetrillo T, Khan D, Hudes R. Preliminary results and evaluation of MammoSite balloon brachytherapy for partial breast irradiation for pure ductal carcinoma in situ: a phase II clinical study. Am J Surg 192(4):427-33, 2006. e-Pub 2006. PMID: 16978943.
Hahn KM, Johnson PH, Gordon N, Kuerer H, Middleton L, Ramirez M, Yang W, Perkins G, Hortobagyi GN, Theriault RL. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 107(6):1219-26, 2006. e-Pub 2006. PMID: 16894524.
Boughey JC, Peintinger F, Meric-Bernstam F, Perry AC, Hunt KK, Babiera GV, Singletary SE, Bedrosian I, Lucci A, Buzdar AU, Pusztai L, Kuerer HM. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg 244(3):464-70, 2006. e-Pub 2006. PMID: 16926572.
Peintinger F, Symmans WF, Gonzalez-Angulo AM, Boughey JC, Buzdar AU, Yu TK, Hunt KK, Singletary SE, Babiera GV, Lucci A, Meric-Bernstam F, Kuerer HM. The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer 107(6):1248-54, 2006. e-Pub 2006. PMID: 16862596.
Erguvan-Dogan B, Whitman GJ, Nguyen VA, Dryden MJ, Stafford RJ, Hazle J, McAlee KR, Phelps MJ, Ice MF, Kuerer HM, Middleton LP. Specimen radiography in confirmation of MRI-guided needle localization and surgical excision of breast lesions. AJR Am J Roentgenol 187(2):339-44, 2006. e-Pub 2006. PMID: 16861535.
Boughey JC, Ross MI, Babiera GV, Bedrosian I, Feig BW, Hwang RF, Kuerer HM, Hunt KK. Sentinel lymph node surgery in locally recurrent breast cancer. Clin Breast Cancer 7(3):248-53, 2006. e-Pub 2006. PMID: 16942642.
Kawase K, Gayed IW, Hunt KK, Kuerer HM, Akins J, Yi M, Grimes L, Babiera GV, Ross MI, Feig BW, Ames FC, Singletary SE, Buchholz TA, Symmans WF, Meric-Bernstam F. Use of lymphoscintigraphy defines lymphatic drainage patterns before sentinel lymph node biopsy for breast cancer. J Am Coll Surg 203(1):64-72, 2006. e-Pub 2006. PMID: 16798488.
Jeruss JS, Vicini FA, Beitsch PD, Haffty BG, Quiet CA, Zannis VJ, Keleher AJ, Garcia DM, Snider HC, Gittleman MA, Whitacre E, Whitworth PW, Fine RE, Arrambide S, Kuerer HM. Initial outcomes for patients treated on the American Society of Breast Surgeons MammoSite clinical trial for ductal carcinoma-in-situ of the breast. Ann Surg Oncol 13(7):967-76, 2006. e-Pub 2006. PMID: 16788759.
Babiera GV, Rao R, Feng L, Meric-Bernstam F, Kuerer HM, Singletary SE, Hunt KK, Ross MI, Gwyn KM, Feig BW, Ames FC, Hortobagyi GN. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol 13(6):776-82, 2006. e-Pub 2006. PMID: 16614878.
Jeruss JS, Vicini FA, Beitsch PD, Haffty BG, Quiet CA, Zannis VJ, Keleher AJ, Garcia DM, Snider HC, Gittleman MA, Whitacre E, Whitworth PW, Fine RE, Arrambide S, Kuerer HM. Initial Outcomes for Patients Treated on the American Society of Breast Surgeons MammoSite Clinical Trial for Ductal Carcinoma-In-Situ of the Breast. Ann Surg Oncol. e-Pub 2006. PMID: 16703275.
Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 93(5):539-46, 2006. e-Pub 2006. PMID: 16329089.
Khakpour N, Zager JS, Yen T, Stephens T, Kuerer HM, Singletary ES, Ross MI, Hunt KK, Babiera GV. The role of ultrasound in the surgical management of patients diagnosed with ductal carcinoma in situ of the breast. Breast J 12(3):212-5, 2006. e-Pub 2006. PMID: 16684318.
Lambert LA, Ayers GD, Hwang RF, Hunt KK, Ross MI, Kuerer HM, Singletary SE, Babiera GV, Ames FC, Feig B, Lucci A, Krishnamurthy S, Meric-Bernstam F. Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol 13(3):310-20, 2006. e-Pub 2006. PMID: 16463073.
Chagpar AB, Middleton LP, Sahin AA, Dempsey P, Buzdar AU, Mirza AN, Ames FC, Babiera GV, Feig BW, Hunt KK, Kuerer HM, Meric-Bernstam F, Ross MI, Singletary SE. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg 243(2):257-64, 2006. e-Pub 2006. PMID: 16432360.
Adepoju LJ, Symmans WF, Babiera GV, Singletary SE, Arun B, Sneige N, Pusztai L, Buchholz TA, Sahin A, Hunt KK, Meric-Bernstam F, Ross MI, Ames FC, Kuerer HM. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer 106(1):42-50, 2006. e-Pub 2006. PMID: 16333852.
Andtbacka RH, Babiera G, Singletary SE, Hunt KK, Meric-Bernstam F, Feig BW, Ames FC, Ross MI, Dejesus Y, Kuerer HM. Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg 243(1):96-101, 2006. e-Pub 2006. PMID: 16371742.
Kronowitz SJ, Feledy JA, Hunt KK, Kuerer HM, Youssef A, Koutz CA, Robb GL. Determining the optimal approach to breast reconstruction after partial mastectomy. Plast Reconstr Surg 117(1):1-11; discussion 12-4, 2006. e-Pub 2006. PMID: 16404237.
Pawlik TM, Hawke DH, Liu Y, Krishnamurthy S, Fritsche H, Hunt KK, Kuerer HM. Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. BMC Cancer 6:68, 2006. e-Pub 2006. PMID: 16542425.
Albrecht TL, Kuerer HM, Ruckdeschel JC, Mendez J, Harper F. Transdisciplinary studies of surgical oncology trial accrual: a National Institutes of Health/National Cancer Institute Roadmap-Affiliated Project Update. Cancer 107(1):171-4, 2006. e-Pub 2006. PMID: 16721802.
Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, Kau SW, Fornage B, Sahin A, Broglio K, Singletary SE, Valero V. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23(36):9304-11, 2005. e-Pub 2005. PMID: 16361629.
Li J, Zhao J, Yu X, Lange J, Kuerer H, Krishnamurthy S, Schilling E, Khan SA, Sukumar S, Chan DW. Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. Clin Cancer Res 11(23):8312-20, 2005. e-Pub 2005. PMID: 16322290.
Buchholz TA, Garg AK, Chakravarti N, Aggarwal BB, Esteva FJ, Kuerer HM, Singletary SE, Hortobagyi GN, Pusztai L, Cristofanilli M, Sahin AA. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer Res 11(23):8398-402, 2005. e-Pub 2005. PMID: 16322301.
Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rouzier R, Dunmire V, Stec J, Valero V, Sneige N, Albarracin C, Wu Y, Ross JS, Wagner P, Theriault RL, Arun B, Kuerer H, Hess KR, Zhang W, Hortobagyi GN, Pusztai L. A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocr Relat Cancer 12(4):1059-69, 2005. e-Pub 2005. PMID: 16322343.
Coombes KR, Tsavachidis S, Morris JS, Baggerly KA, Hung MC, Kuerer HM. Improved peak detection and quantification of mass spectrometry data acquired from surface-enhanced laser desorption and ionization by denoising spectra with the undecimated discrete wavelet transform. Proteomics 5(16):4107-17, 2005. e-Pub 2005. PMID: 16254928.
Jeruss JS, Kuerer HM. Bone marrow micrometastases in breast cancer. N Engl J Med 353(20):2191; author reply 2191, 2005. e-Pub 2005. PMID: 16291991.
Alpert TE, Kuerer HM, Arthur DW, Lannin DR, Haffty BG. Ipsilateral breast tumor recurrence after breast conservation therapy: outcomes of salvage mastectomy vs. salvage breast-conserving surgery and prognostic factors for salvage breast preservation. Int J Radiat Oncol Biol Phys 63(3):845-51, 2005. e-Pub 2005. PMID: 16199315.
Kuerer HM. If at first or second you don't succeed: mastectomy?. Ann Surg Oncol 12(11):864-5, 2005. e-Pub 2005. PMID: 16177857.
Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, Kau SW, Huang EH, Morandi P, Ocana A, Cristofanilli M, Valero V, Buzdar AU, Hortobagyi GN. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol 23(28):7098-104, 2005. e-Pub 2005. PMID: 16192593.
Khakpour N, Hunt KK, Kuerer HM, Yi M, Meric-Bernstam F, Ross MI, Lucci A. Sentinel lymph node dissection provides axillary control equal to complete axillary node dissection in breast cancer patients with lobular histology and a negative sentinel node. Am J Surg 190(4):598-601, 2005. e-Pub 2005. PMID: 16164930.
Zannis V, Beitsch P, Vicini F, Quiet C, Keleher A, Garcia D, Snider H, Gittleman M, Kuerer H, Whitacre E, Whitworth P, Fine R, Haffty B, Stolier A, Mabie J. Descriptions and outcomes of insertion techniques of a breast brachytherapy balloon catheter in 1403 patients enrolled in the American Society of Breast Surgeons MammoSite breast brachytherapy registry trial. Am J Surg 190(4):530-8, 2005. e-Pub 2005. PMID: 16164915.
Al-Refaie W, Kuerer HM, Khuwaja A, Perry A, Hunt KK, Feig B, Ames F, Ross M, Singletary SE, Meric-Bernstam F, Babiera GV. Determinants of mastectomy in breast conservation therapy candidates. Am J Surg 190(4):602-5, 2005. e-Pub 2005. PMID: 16164931.
Vicini FA, Beitsch PD, Quiet CA, Keleher A, Garcia D, Snider HC, Gittleman MA, Zannis VJ, Kuerer H, Whitacre EB, Whitworth PW, Fine RE, Haffty BG, Arrambide LS. First analysis of patient demographics, technical reproducibility, cosmesis, and early toxicity: results of the American Society of Breast Surgeons MammoSite breast brachytherapy trial. Cancer 104(6):1138-48, 2005. e-Pub 2005. PMID: 16088962.
Raut CP, Hunt KK, Akins JS, Daley MD, Ross MI, Singletary SE, Marshall GD, Jr, Meric-Bernstam F, Babiera G, Feig BW, Ames FC, Kuerer HM. Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: results of a surgical prospective clinical practice protocol. Cancer 104(4):692-9, 2005. e-Pub 2005. PMID: 15981283.
Shen J, Hunt KK, Mirza NQ, Buchholz TA, Babiera GV, Kuerer HM, Bedrosian I, Ross MI, Ames FC, Feig BW, Singletary SE, Cristofanilli M, Meric-Bernstam F. Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence. Cancer 104(3):479-90, 2005. e-Pub 2005. PMID: 15968686.
Buchholz TA, Tu X, Ang KK, Esteva FJ, Kuerer HM, Pusztai L, Cristofanilli M, Singletary SE, Hortobagyi GN, Sahin AA. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer 104(4):676-81, 2005. e-Pub 2005. PMID: 15981280.
Pawlik TM, Kuerer HM. Accelerated Partial Breast Irradiation as an Alternative to Whole-Breast Irradiation in Breast-Conserving Therapy for Early-Stage Breast Cancer. Womens Health (Lond) 1(1):59-71, 2005. e-Pub 2005. PMID: 28291417.
Pawlik TM, Kuerer HM. Accelerated partial breast irradiation as an alternative to whole breast irradiation in breast-conserving therapy for early-stage breast cancer. Womens Health (Lond Engl) 1(1):59-71, 2005. e-Pub 2005. PMID: 19803947.
Cabioglu N, Hunt KK, Buchholz TA, Mirza N, Singletary SE, Kuerer HM, Babiera GV, Ames FC, Sahin AA, Meric-Bernstam F. Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cancer 104(1):20-9, 2005. e-Pub 2005. PMID: 15912514.
Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Hortobagyi GN, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Buchholz TA. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 62(2):351-7, 2005. e-Pub 2005. PMID: 15890574.
Kawase K, Dimaio DJ, Tucker SL, Buchholz TA, Ross MI, Feig BW, Kuerer HM, Meric-Bernstam F, Babiera G, Ames FC, Singletary SE, Hunt KK. Paget's disease of the breast: there is a role for breast-conserving therapy. Ann Surg Oncol 12(5):391-7, 2005. e-Pub 2005. PMID: 15915373.
Shahar KH, Buchholz TA, Delpassand E, Sahin AA, Ross MI, Ames FC, Kuerer HM, Feig BW, Meric-Bernstam F, Babiera GV, Singletary SE, Akins JS, Mirza NQ, Hunt KK. Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma. Cancer 103(7):1323-9, 2005. e-Pub 2005. PMID: 15726547.
Yen TW, Hunt KK, Ross MI, Mirza NQ, Babiera GV, Meric-Bernstam F, Singletary SE, Symmans WF, Giordano SH, Feig BW, Ames FC, Kuerer HM. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg 200(4):516-26, 2005. e-Pub 2005. PMID: 15804465.
Kronowitz SJ, Kuerer HM. Sentinel lymph node biopsy followed by delayed mastectomy and reconstruction. Am J Surg 189(2):251-2, 2005. e-Pub 2005. PMID: 15721002.
Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig BW, Sahin AA, Perkins GH, Babiera G, Hortobagyi GN, Buchholz TA. Breast conservation after neoadjuvant chemotherapy. Cancer 103(4):689-95, 2005. e-Pub 2005. PMID: 15641036.
Babiera GV, Delpassand ES, Breslin TM, Ross MI, Ames FC, Singletary SE, Kuerer HM, Feig BW, Meric-Bernstam F, Hunt KK. Lymphatic drainage patterns on early versus delayed breast lymphoscintigraphy performed after injection of filtered Tc-99m sulfur colloid in breast cancer patients undergoing sentinel lymph node biopsy. Clin Nucl Med 30(1):11-5, 2005. e-Pub 2005. PMID: 15604959.
Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, Pusztai L, Chen JN, Clarke CH, Arun B, Hung MC, Kuerer HM. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat 89(2):149-57, 2005. e-Pub 2005. PMID: 15692757.
Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans WF, Pusztai L. Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer. . Proc Natl Acad Sci USA 102(23):8315-8320, 2005. e-Pub 2005. PMID: 15914550.
Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buchholz TA, Hortobagyi GN. Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes. . J Clin Oncol 23(1):41-8, 2005. e-Pub 2005. PMID: 15625359.
Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Hortobagyi GN, Buchholz TA. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 22(23):4691-9, 2004. e-Pub 2004. PMID: 15570071.
Kuerer HM, Coombes KR, Chen JN, Xiao L, Clarke C, Fritsche H, Krishnamurthy S, Marcy S, Hung MC, Hunt KK. Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer. Surgery 136(5):1061-9, 2004. e-Pub 2004. PMID: 15523402.
Goldflam K, Hunt KK, Gershenwald JE, Singletary SE, Mirza N, Kuerer HM, Babiera GV, Ames FC, Ross MI, Feig BW, Sahin AA, Arun B, Meric-Bernstam F. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer 101(9):1977-86, 2004. e-Pub 2004. PMID: 15389473.
Keleher A, Wendt R, rd, Delpassand E, Stachowiak AM, Kuerer HM. The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99m sulfur colloid. Breast J 10(6):492-5, 2004. e-Pub 2004. PMID: 15569204.
Krishnamurthy S, Zhao L, Hayes K, Glassman AB, Cristofanilli M, Singletary SE, Hunt KK, Kuerer HM, Sneige N. Feasibility and utility of using chromosomal aneusomy to further define the cytologic categories in nipple aspirate fluid specimens: a preliminary study. Cancer 102(5):322-7, 2004. e-Pub 2004. PMID: 15376199.
Tseng JF, Kronowitz SJ, Sun CC, Perry AC, Hunt KK, Babiera GV, Newman LA, Singletary SE, Mirza NQ, Ames FC, Meric-Bernstam F, Ross MI, Feig BW, Robb GL, Kuerer HM. The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer. Cancer 101(7):1514-23, 2004. e-Pub 2004. PMID: 15378473.
Newman LA, Hurd T, Leitch M, Kuerer HM, Diehl K, Lucci A, Giuliano A, Hunt KK, Putnam W, Wells SA. A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group. J Am Coll Surg 199(4):644-51, 2004. e-Pub 2004. PMID: 15454152.
Shen J, Valero V, Buchholz TA, Singletary SE, Ames FC, Ross MI, Cristofanilli M, Babiera GV, Meric-Bernstam F, Feig B, Hunt KK, Kuerer HM. Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol 11(9):854-60, 2004. e-Pub 2004. PMID: 15313733.
Shen J, Hunt KK, Mirza NQ, Krishnamurthy S, Singletary SE, Kuerer HM, Meric-Bernstam F, Feig B, Ross MI, Ames FC, Babiera GV. Intramammary lymph node metastases are an independent predictor of poor outcome in patients with breast carcinoma. Cancer 101(6):1330-7, 2004. e-Pub 2004. PMID: 15316905.
Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, Perkins GH, Schechter NR, Kuerer HM, Buzdar AU, Valero V, Hunt KK, Hortobagyi GN, Sahin AA. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 59(5):1337-42, 2004. e-Pub 2004. PMID: 15275718.
Cabioglu N, Krishnamurthy S, Kuerer HM, Hunt KK, Singletary SE, Meric-Bernstam F, Ross MI, Feig BW, Ames FC, Babiera GV. Feasibility of breast-conserving surgery for patients with breast carcinoma associated with nipple discharge. Cancer 101(3):508-17, 2004. e-Pub 2004. PMID: 15274063.
Daley MD, Norman PH, Leak JA, Nguyen DT, Bui TP, Kowalski AM, Srejic U, Popat K, Arens JF, Gershenwald JE, Hunt KK, Kuerer HM. Adverse events associated with the intraoperative injection of isosulfan blue. J Clin Anesth 16(5):332-41, 2004. e-Pub 2004. PMID: 15374553.
Shahar KH, Hunt KK, Thames HD, Ross MI, Perkins GH, Kuerer HM, Strom EA, McNeese MD, Meric F, Schechter NR, Sahin AA, Middleton LP, Buchholz TA. Factors predictive of having four or more positive axillary lymph nodes in patients with positive sentinel lymph nodes: implications for selection of radiation fields. Int J Radiat Oncol Biol Phys 59(4):1074-9, 2004. e-Pub 2004. PMID: 15234041.
Ko BK, Efferson CL, Kawano K, Kuerer HM, Sahin A, Murray JL, Ioannides CG. Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2+ tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes. Int J Oncol 24(6):1413-8, 2004. e-Pub 2004. PMID: 15138582.
Chagpar A, Evelegh M, Fritsche HA, Jr, Krishnamurthy S, Hunt KK, Kuerer HM. Prospective evaluation of a novel approach for the use of a quantitative galactose oxidase-Schiff reaction in ductal fluid samples from women with breast carcinoma. Cancer 100(12):2549-54, 2004. e-Pub 2004. PMID: 15197795.
Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig BW, Sahin AA, Perkins GH, Schechter NR, Hortobagyi GN, Buchholz TA. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol 22(12):2303-12, 2004. e-Pub 2004. PMID: 15197191.
Garg AK, Strom EA, McNeese MD, Buzdar AU, Hortobagyi GN, Kuerer HM, Perkins GH, Singletary SE, Hunt KK, Sahin A, Schechter N, Valero V, Tucker SL, Buchholz TA. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys 59(1):138-45, 2004. e-Pub 2004. PMID: 15093909.
Kronowitz SJ, Hunt KK, Kuerer HM, Babiera G, McNeese MD, Buchholz TA, Strom EA, Robb GL. Delayed-immediate breast reconstruction. Plast Reconstr Surg 113(6):1617-28, 2004. e-Pub 2004. PMID: 15114121.
Pusztai L, Gregory BW, Baggerly KA, Peng B, Koomen J, Kuerer HM, Esteva FJ, Symmans WF, Wagner P, Hortobagyi GN, Laronga C, Semmes OJ, Wright GL, Jr, Drake RR, Vlahou A. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 100(9):1814-22, 2004. e-Pub 2004. PMID: 15112261.
Fornage BD, Sneige N, Ross MI, Mirza AN, Kuerer HM, Edeiken BS, Ames FC, Newman LA, Babiera GV, Singletary SE. Small (< or = 2-cm) breast cancer treated with US-guided radiofrequency ablation: feasibility study. Radiology 231(1):215-24, 2004. e-Pub 2004. PMID: 14990810.
Yen TW, Hunt KK, Mirza NQ, Thomas ES, Singletary SE, Babiera GV, Meric-Bernstam F, Buchholz TA, Feig BW, Ross MI, Ames FC, Theriault RL, Kuerer HM. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer 100(5):942-9, 2004. e-Pub 2004. PMID: 14983489.
Raut CP, Daley MD, Hunt KK, Akins J, Ross MI, Singletary SE, Marshall GD, Jr, Meric-Bernstam F, Babiera G, Feig BW, Ames FC, Kuerer HM. Anaphylactoid reactions to isosulfan blue dye during breast cancer lymphatic mapping in patients given preoperative prophylaxis. J Clin Oncol 22(3):567-8, 2004. e-Pub 2004. PMID: 14752082.
Pawlik TM, Perry A, Strom EA, Babiera GV, Buchholz TA, Singletary E, Perkins GH, Ross MI, Schecter NR, Meric-Bernstam F, Ames FC, Hunt KK, Kuerer HM. Potential applicability of balloon catheter-based accelerated partial breast irradiation after conservative surgery for breast carcinoma. Cancer 100(3):490-8, 2004. e-Pub 2004. PMID: 14745864.
Chagpar A, Langstein HN, Kronowitz SJ, Singletary SE, Ross MI, Buchholz TA, Hunt KK, Kuerer HM. Treatment and outcome of patients with chest wall recurrence after mastectomy and breast reconstruction. Am J Surg 187(2):164-9, 2004. e-Pub 2004. PMID: 14769300.
Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, Fiterman DJ, Gal-Gombos E, Whitman G, Rouzier R, Green M, Kuerer H, Buzdar AU, Hortobagyi GN, Symmans WF. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. . Cancer 100(7):1365-73, 2004. e-Pub 2004. PMID: 15042669.
Bedrosian I, Bedi D, Kuerer HM, Fornage BD, Harker L, Ross MI, Ames FC, Krishnamurthy S, Edeiken-Monroe BS, Meric F, Feig BW, Akins J, Singletary SE, Mirza NQ, Hunt KK. Impact of clinicopathological factors on sensitivity of axillary ultrasonography in the detection of axillary nodal metastases in patients with breast cancer. Ann Surg Oncol 10(9):1025-30, 2003. e-Pub 2003. PMID: 14597440.
Kuerer HM, Pawlik TM, Strom EA. Intracavitary balloon brachytherapy for breast cancer: surgical considerations. in regard to Keisch M, Vicini F, Kuske RR, et al., IJROBP 2003;55:289-293. Int J Radiat Oncol Biol Phys 57(3):900; author reply 900-2, 2003. e-Pub 2003. PMID: 14529797.
Coombes KR, Fritsche HA, Jr, Clarke C, Chen JN, Baggerly KA, Morris JS, Xiao LC, Hung MC, Kuerer HM. Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. Clin Chem 49(10):1615-23, 2003. e-Pub 2003. PMID: 14500586.
Chagpar A, Yen T, Sahin A, Hunt KK, Whitman GJ, Ames FC, Ross MI, Meric-Bernstam F, Babiera GV, Singletary SE, Kuerer HM. Intraoperative margin assessment reduces reexcision rates in patients with ductal carcinoma in situ treated with breast-conserving surgery. Am J Surg 186(4):371-7, 2003. e-Pub 2003. PMID: 14553853.
Chagpar A, Kuerer HM, Hunt KK, Strom EA, Buchholz TA. Outcome of treatment for breast cancer patients with chest wall recurrence according to initial stage: implications for post-mastectomy radiation therapy. Int J Radiat Oncol Biol Phys 57(1):128-35, 2003. e-Pub 2003. PMID: 12909225.
Chagpar A, Meric-Bernstam F, Hunt KK, Ross MI, Cristofanilli M, Singletary SE, Buchholz TA, Ames FC, Marcy S, Babiera GV, Feig BW, Hortobagyi GN, Kuerer HM. Chest wall recurrence after mastectomy does not always portend a dismal outcome. Ann Surg Oncol 10(6):628-34, 2003. e-Pub 2003. PMID: 12839847.
Zhang F, Yang Y, Smith T, Kau SW, McConathy JM, Esteva FJ, Kuerer HM, Symmans WF, Buzdar AU, Hortobagyi GN, Pusztai L. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 97(7):1758-65, 2003. e-Pub 2003. PMID: 12655533.
Krishnamurthy S, Sneige N, Thompson PA, Marcy SM, Singletary SE, Cristofanilli M, Hunt KK, Kuerer HM. Nipple aspirate fluid cytology in breast carcinoma. Cancer 99(2):97-104, 2003. e-Pub 2003. PMID: 12704689.
Hwang RF, Krishnamurthy S, Hunt KK, Mirza N, Ames FC, Feig B, Kuerer HM, Singletary SE, Babiera G, Meric F, Akins JS, Neely J, Ross MI. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol 10(3):248-54, 2003. e-Pub 2003. PMID: 12679309.
Lipa JE, Youssef AA, Kuerer HM, Robb GL, Chang DW. Breast reconstruction in older women: advantages of autogenous tissue. Plast Reconstr Surg 111(3):1110-21, 2003. e-Pub 2003. PMID: 12621181.
Cabioglu N, Hunt KK, Singletary SE, Stephens TW, Marcy S, Meric F, Ross MI, Babiera GV, Ames FC, Kuerer HM. Surgical decision making and factors determining a diagnosis of breast carcinoma in women presenting with nipple discharge. J Am Coll Surg 196(3):354-64, 2003. e-Pub 2003. PMID: 12648684.
Wu CT, Morita ET, Treseler PA, Esserman LJ, Hwang ES, Kuerer HM, Santos CL, Leong SP. Failure to harvest sentinel lymph nodes identified by preoperative lymphoscintigraphy in breast cancer patients. Breast J 9(2):86-90, 2003. e-Pub 2003. PMID: 12603380.
Meric F, Mirza NQ, Vlastos G, Buchholz TA, Kuerer HM, Babiera GV, Singletary SE, Ross MI, Ames FC, Feig BW, Krishnamurthy S, Perkins GH, McNeese MD, Strom EA, Valero V, Hunt KK. Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer 97(4):926-33, 2003. e-Pub 2003. PMID: 12569592.
Kuerer HM, Thompson PA, Krishnamurthy S, Fritsche HA, Marcy SM, Babiera GV, Singletary SE, Cristofanilli M, Sneige N, Hunt KK. High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer. Clin Cancer Res 9(2):601-5, 2003. e-Pub 2003. PMID: 12576424.
Diaz LK, Hunt K, Ames F, Meric F, Kuerer H, Babiera G, Ross M, Singletary E, Middleton LP, Symmans WF, Krishnamurthy S, Sahin A, Sneige N, Gilcrease MZ. Histologic localization of sentinel lymph node metastases in breast cancer. . Am J Surg Pathol 27(3):385-9, 2003. e-Pub 2003. PMID: 12604895.
Albo D, Ames FC, Hunt KK, Ross MI, Singletary SE, Kuerer HM. Evaluation of lymph node status in male breast cancer patients: a role for sentinel lymph node biopsy. Breast Cancer Res Treat 77(1):9-14, 2003. e-Pub 2003. PMID: 12602900.
Kuerer HM, Goldknopf IL, Fritsche H, Krishnamurthy S, Sheta EA, Hunt KK. Identification of distinct protein expression patterns in bilateral matched pair breast ductal fluid specimens from women with unilateral invasive breast carcinoma. High-throughput biomarker discovery. Cancer 95(11):2276-82, 2002. e-Pub 2002. PMID: 12436432.
Buchholz TA, Stivers DN, Stec J, Ayers M, Clark E, Bolt A, Sahin AA, Symmans WF, Hess KR, Kuerer HM, Valero V, Hortobagyi GN, Pusztai L. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J 8(6):461-8, 2002. e-Pub 2002. PMID: 12500855.
Vlastos G, Mirza NQ, Meric F, Hunt KK, Mirza AN, Newman LA, Ames FC, Kuerer HM, Ross MI, Feig B, Babiera G, Buchholz TA, Hortobagyi GN, Singletary SE. Breast-conservation therapy in early-stage breast cancer patients with a positive family history. Ann Surg Oncol 9(9):912-9, 2002. e-Pub 2002. PMID: 12417515.
Silva EG, Mistry D, Li D, Kuerer HM, Atkinson EN, Lopez AN, Shannon R, Hortobagyi GN. Elevated luteinizing hormone in serum, breast cancer tissue, and normal breast tissue from breast cancer patients. Breast Cancer Res Treat 76(2):125-30, 2002. e-Pub 2002. PMID: 12452449.
Huang E, Buchholz TA, Meric F, Krishnamurthy S, Mirza NQ, Ames FC, Feig BW, Kuerer HM, Ross MI, Singletary SE, McNeese MD, Strom EA, Hunt KK. Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. Cancer 95(10):2059-67, 2002. e-Pub 2002. PMID: 12412158.
Krishnamurthy S, Sneige N, Ordonez NG, Hunt KK, Kuerer HM. Characterization of foam cells in nipple aspirate fluid. Diagn Cytopathol 27(5):261-4; discussion 265, 2002. e-Pub 2002. PMID: 12411988.
Buchholz TA, Kronowitz SJ, Kuerer HM. Immediate breast reconstruction after skin-sparing mastectomy for the treatment of advanced breast cancer: radiation oncology considerations. Ann Surg Oncol 9(8):820-1, 2002. e-Pub 2002. PMID: 12374667.
Solorzano CC, Middleton LP, Hunt KK, Mirza N, Meric F, Kuerer HM, Ross MI, Ames FC, Feig BW, Pollock RE, Singletary SE, Babiera G. Treatment and outcome of patients with intracystic papillary carcinoma of the breast. Am J Surg 184(4):364-8, 2002. e-Pub 2002. PMID: 12383904.
Krishnamurthy S, Sneige N, Bedi DG, Edieken BS, Fornage BD, Kuerer HM, Singletary SE, Hunt KK. Role of ultrasound-guided fine-needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma. Cancer 95(5):982-8, 2002. e-Pub 2002. PMID: 12209680.
Dackiw AP, Kuerer HM, Clark OH. Current national health insurance policies for thyroid cancer prophylactic surgery in the United States. World J Surg 26(8):903-6, 2002. e-Pub 2002. PMID: 12045864.
Huang E, McNeese MD, Strom EA, Perkins GH, Katz A, Hortobagyi GN, Valero V, Kuerer HM, Singletary SE, Hunt KK, Buzdar AU, Buchholz TA. Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. Int J Radiat Oncol Biol Phys 53(5):1225-33, 2002. e-Pub 2002. PMID: 12128124.
Meric F, Buchholz TA, Mirza NQ, Vlastos G, Ames FC, Ross MI, Pollock RE, Singletary SE, Feig BW, Kuerer HM, Newman LA, Perkins GH, Strom EA, McNeese MD, Hortobagyi GN, Hunt KK. Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol 9(6):543-9, 2002. e-Pub 2002. PMID: 12095969.
Buchholz TA, Katz A, Strom EA, McNeese MD, Perkins GH, Hortobagyi GN, Thames HD, Kuerer HM, Singletary SE, Sahin AA, Hunt KK, Buzdar AU, Valero V, Sneige N, Tucker SL. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 53(4):880-8, 2002. e-Pub 2002. PMID: 12095553.
Kuerer HM, Krishnamurthy S, Kronowitz SJ. Important technical considerations for skin-sparing mastectomy with sentinel lymph node dissection. Arch Surg 137(6):747, 2002. e-Pub 2002. PMID: 12049553.
Wang J, Buchholz TA, Middleton LP, Allred DC, Tucker SL, Kuerer HM, Esteva FJ, Hortobagyi GN, Sahin AA. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer 94(12):3107-14, 2002. e-Pub 2002. PMID: 12115341.
Kuerer HM, Peoples GE, Sahin AA, Murray JL, Singletary SE, Castilleja A, Hunt KK, Gershenson DM, Ioannides CG. Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast. J Interferon Cytokine Res 22(5):583-92, 2002. e-Pub 2002. PMID: 12060497.
Kronowitz SJ, Chang DW, Robb GL, Hunt KK, Ames FC, Ross MI, Singletary SE, Symmans WF, Kroll SS, Kuerer HM. Implications of axillary sentinel lymph node biopsy in immediate autologous breast reconstruction. Plast Reconstr Surg 109(6):1888-96, 2002. e-Pub 2002. PMID: 11994589.
Mirza NQ, Vlastos G, Meric F, Buchholz TA, Esnaola N, Singletary SE, Kuerer HM, Newman LA, Ames FC, Ross MI, Feig BW, Pollock RE, McNeese M, Strom E, Hunt KK. Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy. Ann Surg Oncol 9(3):256-65, 2002. e-Pub 2002. PMID: 11923132.
Newman LA, Buzdar AU, Singletary SE, Kuerer HM, Buchholz T, Ames FC, Ross MI, Hunt KK. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol 9(3):228-34, 2002. e-Pub 2002. PMID: 11923128.
Meric F, Bernstam EV, Mirza NQ, Hunt KK, Ames FC, Ross MI, Kuerer HM, Pollock RE, Musen MA, Singletary SE. Breast cancer on the World Wide Web: cross sectional survey of quality of information and popularity of websites. Bmj 324(7337):577-81, 2002. e-Pub 2002. PMID: 11884322.
Kuerer HM, Beahm EK, Swisher SG, Ross MI. Surgery for inoperable breast cancer. Am J Surg 183(2):160-1, 2002. e-Pub 2002. PMID: 11918881.
Kuerer HM, Gwyn K, Ames FC, Theriault RL. Conservative surgery and chemotherapy for breast carcinoma during pregnancy. Surgery 131(1):108-10, 2002. e-Pub 2002. PMID: 11812971.
Chagpar AB, Singletary SE, Kuerer HM. Percutaneous ablation of breast tumors: towards an era of surgery without scalpels. . Women’s Oncology Review 2:395-402, 2002. e-Pub 2002.
Krishnamurthy S, Kuerer HM. Foam cells in nipple aspiration fluid. Cytopathology 13(1):64, 2002. e-Pub 2002. PMID: 11985570.
Buchholz TA, Tucker SL, Masullo L, Kuerer HM, Erwin J, Salas J, Frye D, Strom EA, McNeese MD, Perkins G, Katz A, Singletary SE, Hunt KK, Buzdar AU, Hortobagyi GN. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol 20(1):17-23, 2002. e-Pub 2002. PMID: 11773149.
Kuerer HM, Singletary SE, Buzdar AU, Ames FC, Valero V, Buchholz TA, Ross MI, Pusztai L, Hortobagyi GN, Hunt KK. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg 182(6):601-8, 2001. e-Pub 2001. PMID: 11839324.
Solorzano CC, Ross MI, Delpassand E, Mirza N, Akins JS, Kuerer HM, Meric F, Ames FC, Newman L, Feig B, Singletary SE, Hunt KK. Utility of breast sentinel lymph node biopsy using day-before-surgery injection of high-dose 99mTc-labeled sulfur colloid. Ann Surg Oncol 8(10):821-7, 2001. e-Pub 2001. PMID: 11776497.
Dooley WC, Ljung BM, Veronesi U, Cazzaniga M, Elledge RM, O'Shaughnessy JA, Kuerer HM, Hung DT, Khan SA, Phillips RF, Ganz PA, Euhus DM, Esserman LJ, Haffty BG, King BL, Kelley MC, Anderson MM, Schmit PJ, Clark RR, Kass FC, Anderson BO, Troyan SL, Arias RD, Quiring JN, Love SM, Page DL, King EB. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst 93(21):1624-32, 2001. e-Pub 2001. PMID: 11698566.
Albo D, Wayne JD, Hunt KK, Rahlfs TF, Singletary SE, Ames FC, Feig BW, Ross MI, Kuerer HM. Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am J Surg 182(4):393-8, 2001. e-Pub 2001. PMID: 11720678.
Vlastos G, Mirza NQ, Meric F, Hunt KK, Kuerer HM, Ames FC, Ross MI, Buchholz TA, Hortobagyi GN, Singletary SE. Breast conservation therapy as a treatment option for the elderly. The M. D. Anderson experience. Cancer 92(5):1092-100, 2001. e-Pub 2001. PMID: 11571720.
Buchholz TA, Hill BS, Tucker SL, Frye DK, Kuerer HM, Buzdar AU, McNeese MD, Singletary SE, Ueno NT, Pusztai L, Valero V, Hortobagyi GN. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J 7(5):413-20, 2001. e-Pub 2001. PMID: 11693900.
Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. . Ann Surg Oncol 8(6):549-559, 2001. e-Pub 2001. PMID: 11456056.
Vlastos G, Jean ME, Mirza AN, Mirza NQ, Kuerer HM, Ames FC, Hunt KK, Ross MI, Buchholz TA, Buzdar AU, Singletary SE. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol 8(5):425-31, 2001. e-Pub 2001. PMID: 11407517.
Kuerer HM, Hunt KK, Singletary SE, Ames FC. Unusual aspects of breast cancer: Blue hives during lymphatic mapping for breast cancer. J Clin Oncol 19(9):2573-4, 2001. e-Pub 2001. PMID: 11331339.
Newman LA, Kuerer HM, Fornage B, Mirza N, Hunt KK, Ross MI, Ames FC, Buzdar AU, Singletary SE. Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer. Am J Surg 181(4):313-8, 2001. e-Pub 2001. PMID: 11438265.
Newman LA, Kuerer HM, McNeese MD, Hunt KK, Gurtner GC, Vlastos GS, Robb G, Singletary SE. Reduction mammoplasty improves breast conservation therapy in patients with macromastia. Am J Surg 181(3):215-20, 2001. e-Pub 2001. PMID: 11376574.
Kuerer HM, Wilson MW, Bowersox JC. Innominate vein stenosis mimicking locally advanced breast cancer in a dialysis patient. Breast J 7(2):128, 2001. e-Pub 2001. PMID: 11328322.
Kuerer HM, Wayne JD, Ross MI. Anaphylaxis during breast cancer lymphatic mapping. Surgery 129(1):119-20, 2001. e-Pub 2001. PMID: 11150045.
Breslin TM, Cohen L, Sahin A, Fleming JB, Kuerer HM, Newman LA, Delpassand ES, House R, Ames FC, Feig BW, Ross MI, Singletary SE, Buzdar AU, Hortobagyi GN, Hunt KK. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 18(20):3480-6, 2000. e-Pub 2000. PMID: 11032588.
Mirza NQ, Vlastos G, Meric F, Sahin AA, Singletary SE, Newman LA, Kuerer HM, Ames FC, Ross MI, Feig BW, Pollock RE, Buchholz TA, McNeese MD, Strom EA, Hortobagyi GN, Hunt KK. Ductal carcinoma-in-situ: long-term results of breast-conserving therapy. Ann Surg Oncol 7(9):656-64, 2000. e-Pub 2000. PMID: 11034242.
Newman LA, Hunt KK, Buchholz T, Kuerer HM, Vlastos G, Mirza N, Ames FC, Ross MI, Singletary SE. Presentation, management and outcome of axillary recurrence from breast cancer. Am J Surg 180(4):252-6, 2000. e-Pub 2000. PMID: 11113430.
Cohen LF, Breslin TM, Kuerer HM, Ross MI, Hunt KK, Sahin AA. Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy. Am J Surg Pathol 24(9):1266-72, 2000. e-Pub 2000. PMID: 10976701.
Newman LA, Kuerer HM, Hunt KK, Ames FC, Ross MI, Feig BW, Hortobagyi GN, Buzdar AU, Singletary SE. Response to induction chemotherapy in black and white patients with locally advanced breast cancer. Breast J 6(4):242-6, 2000. e-Pub 2000. PMID: 11348372.
Kuerer HM, Hwang ES, Anthony JP, Dudley RA, Crawford B, Aubry WM, Esserman LJ. Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery. Ann Surg Oncol 7(5):325-32, 2000. e-Pub 2000. PMID: 10864338.
Divino CM, Kuerer HM, Tartter PI. Drains prevent seromas following lumpectomy with axillary dissection. Breast J 6(1):31-3, 2000. e-Pub 2000. PMID: 11348332.
Newman LA, Kuerer HM, Hunt KK, Ames FC, Ross MI, Theriault R, Fry N, Kroll SS, Robb GL, Singletary SE. Feasibility of immediate breast reconstruction for locally advanced breast cancer. Ann Surg Oncol 6(7):671-5, 1999. e-Pub 1999. PMID: 10560853.
Kuerer HM, Sahin AA, Hunt KK, Newman LA, Breslin TM, Ames FC, Ross MI, Buzdar AU, Hortobagyi GN, Singletary SE. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 230(1):72-8, 1999. e-Pub 1999. PMID: 10400039.
Kuerer HM, Hwang ES, Esserman LJ. Prophylactic mastectomy in women with a high risk of breast cancer. N Engl J Med 340(23):1838; author reply 1839, 1999. e-Pub 1999. PMID: 10366321.
Newman LA, Kuerer HM, Hunt KK, Singh G, Ames FC, Feig BW, Ross MI, Taylor S, Singletary SE. Local recurrence and survival among black women with early-stage breast cancer treated with breast-conservation therapy or mastectomy. Ann Surg Oncol 6(3):241-8, 1999. e-Pub 1999. PMID: 10340882.
Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17(2):460-9, 1999. e-Pub 1999. PMID: 10080586.
Kuerer HM, Newman LA, Buzdar AU, Hunt KK, Dhingra K, Buchholz TA, Binkley SM, Ames FC, Feig BW, Ross MI, Hortobagyi GN, Singletary SE. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 176(6):502-9, 1998. e-Pub 1998. PMID: 9926779.
Kuerer HM, Newman LA, Fornage BD, Dhingra K, Hunt KK, Buzdar AU, Ames FC, Ross MI, Feig BW, Hortobagyi GN, Singletary SE. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. Ann Surg Oncol 5(8):673-80, 1998. e-Pub 1998. PMID: 9869512.
Newman LA, Kuerer HM, Hunt KK, Kroll SS, Ames FC, Ross MI, Feig BW, Singletary SE. Presentation, treatment, and outcome of local recurrence after skin-sparing mastectomy and immediate breast reconstruction. Ann Surg Oncol 5(7):620-6, 1998. e-Pub 1998. PMID: 9831111.
Kuerer HM, Newman LA, Buzdar AU, Dhingra K, Hunt KK, Buchholz TA, Binkley SM, Strom EA, Ames FC, Ross MI, Feig BW, McNeese MD, Hortobagyi GN, Singletary SE. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am 4(4):230-6, 1998. e-Pub 1998. PMID: 9689981.
Kuerer HM, Cunningham JD, Bleiweiss IJ, Doucette J, Divino CM, Brower ST, Tartter PI. Conservative surgical treatment of breast carcinoma associated with pregnancy. The Breast Journal 4:171-176, 1998. e-Pub 1998.
Kuerer HM, Bleiweiss IJ, Weiss MF. Bilateral Paget’s disease of the male breast. . The Breast Journal 4:123-25, 1998. e-Pub 1998.
Kuerer HM, Curtiss S, Zisman SR, Burrows WM, Kim U, Hollier LH. Traumatic thoracic aortic transection: Diagnosis, management, and survival. . Surgical Rounds 21:362-367, 1998. e-Pub 1998.
Kuerer HM, Shim H, Pertsemlidis D, Unger P. Functioning pancreatic acinar cell carcinoma: immunohistochemical and ultrastructural analyses. Am J Clin Oncol 20(1):101-7, 1997. e-Pub 1997. PMID: 9020300.
Kuerer HM, Forman D, Divino CM, Wasserman EJ, Brower ST, Cunningham JD. Cholecystocholedochal fistula associated with Mirizzi syndrome: presentation, diagnosis, and surgical management. . Contemp Surg 49:131, 1996. e-Pub 1996.
Oropello JM, Leibowitz A, Kuerer HM, Benjamin E. Delayed pneumothorax after subclavian vein catheterization. J Intensive Care Med:10:261, 1995. e-Pub 1995.
Pollack AH, Kuerer HM. Steatocystoma multiplex: appearance at mammography. Radiology 180(3):836-8, 1991. e-Pub 1991. PMID: 1871303.
Shih LY, Kuerer HM, Chen TH, Desposito F. Strain difference in galactokinase level and susceptibility to the teratogenic effect of dietary galactose in mice: I. Teratogenic and embryopathic effect. Teratology 38(2):175-9, 1988. e-Pub 1988. PMID: 3175951.

Invited Articles

Kuerer HM, Hunt KK. Limiting Axillary Surgery for Patients with Initial Biopsy-Proven Axillary Metastases After Preoperative Chemotherapy: To Clip or Not to Clip?. Ann Surg Oncol 23(11):3432-4, 2016. e-Pub 2016. PMID: 27469119.
Suarez J, Arthur D, Woodward W, Kuerer HM. Breast preservation in patients with local recurrence after breast conserving therapy. Curr Breast Cancer Rep, Springer, 2008. e-Pub 2008.
Rouzier R, Kuerer HM, Pusztai L. Prediction of chemosensitivity of breast tumors treated with primary chemotherapy using clinical nomograms. American Journal of Hematology/Oncology 6(3):155-8, 2007. e-Pub 2007.
Kuerer HM. Breast Cancer Axillary Surgery: Before, After, or None at All?. Ann Surg Oncol, 2006. e-Pub 2006. PMID: 16791445.
Gonzalez RJ, Kuerer HM. Trastuzumab (herceptin) for ductal carcinoma in situ of the breast. Breast Disease Quarterly 17(2):122, 2006. e-Pub 2006.
Kuerer HM. Con: Sentinel Lymph Node Biopsy for DCIS. The Breast Surgeon is not a Barber. Ann Surg Oncol 14(3):1007-8, 2006. e-Pub 2006. PMID: 17009142.
Pawlik TM, Kuerer HM. The evolving role of proteomics in the early detection of breast cancer. Int J Fertil Womens Med 50(5 Pt. 1):212-6, 2005. e-Pub 2005. PMID: 16468471.
Kuerer HM. Advancing the standard of breast cancer care: The neoadjuvant approach for testing promising novel systemic agents. Am J Oncol Rev 3(4):203-6, 2004. e-Pub 2004.
Yen TWF, Kuerer HM. Use of tamoxifen after surgery for ductal carcinoma in situ. Breast Diseases 15(3):227-31, 2004. e-Pub 2004.
Yen TWF, Kuerer HM. Tamoxifen use following surgery for ductal carcinoma in situ. Am J Oncol Rev 3(7):392-8, 2004. e-Pub 2004.
Kronowitz SJ, Kuerer HM, Robb GL. Implications of sentinel lymph node biopsy in the setting of immediate breast reconstruction. Breast Diseases 15(3):234-7, 2004. e-Pub 2004.
Chagpar A, Kuerer HM. Long-term survival of patients with supraclavicular metastases at diagnosis of breast cancer. Women's Oncology Review 3:174-5, 2003. e-Pub 2003.
Meric-Bernstam F, Mirza NQ, Vlastos G, Buchholz TA, Kuerer HM, Babiera GV, Singletary SE, Ross MI, Ames FC, Feig BW, Krishnamurthy S, Perkins GH, McNeese MD, Strom EA, Valero V, Hunt KK. Impact of positive surgical margins and ipsilateral breast tumor recurrence on disease-specific survival after breast-conserving therapy. Am J of Oncol Rev 2(8):428-33, 2003. e-Pub 2003.
Goldknopf IL, Park HR, Kuerer HM. Merging diagnostics with therapeutics through proteomics, an example of breast cancer. IVD Technology 9(1):39-43, 2003. e-Pub 2003.
Kuerer HM. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer: Is there really anything new in breast cancer treatment?. Am J of Oncol Rev 2(1):45-7, 2003. e-Pub 2003.
Buchholz TA, Tucker SL, Katz A, McNeese MD, Strom EA, Perkins GH, Buzdar AU, Kuerer HM, Hunt KK, Singletary SE, Sahin AA, Thames HD, Meric F, Masullo L, Hortobagyi GN. Factors predictive for local-regional recurrence after neoadjuvant chemotherapy and mastectomy: Implications for radiation treatments. Am J of Oncol Rev 1(1):13-16, 2002. e-Pub 2002.
Kuerer HM, Hunt KK. The rationale for integration of lymphatic mapping and sentinel node biopsy in the management of breast cancer after neoadjuvant chemotherapy. Seminars in Breast Disease 5(2):80-7, 2002. e-Pub 2002.
Kuerer HM, Singletary SE. Integration of neoadjuvant chemotherapy and surgery in the treatment of patients with breast carcinoma. Breast Disease an International Journal 12(1):69-81, 2001. e-Pub 2001. PMID: 15687608.
Kuerer HM, Wolverton DE, Sickles EA. Current recommendations and interpretation of screening and diagnostic mammography. Primary care & cancer 9:18-27, 1999. e-Pub 1999.

Review Articles

Tasoulis MK, Lee HB, Kuerer HM. Omission of Breast Surgery in Exceptional Responders. Clin Breast Cancer 24(4):310-318, 2024. e-Pub 2024. PMID: 38365541.
Tasoulis MK, Heil J, Kuerer HM. De-escalating Surgery Among Patients with HER2?+?and Triple Negative Breast Cancer. Curr Breast Cancer Rep 14(4):1-7, 2022. e-Pub 2022. PMID: 35915668.
Dubsky P, Pinker K, Cardoso F, Montagna G, Ritter M, Denkert C, Rubio IT, de Azambuja E, Curigliano G, Gentilini O, Gnant M, Günthert A, Hauser N, Heil J, Knauer M, Knotek-Roggenbauerc M, Knox S, Kovacs T, Kuerer HM, Loibl S, Mannhart M, Meattini I, Penault-Llorca F, Radosevic-Robin N, Sager P, Španic T, Steyerova P, Tausch C, MTFDV P, Weber WP, Cardoso MJ, Poortmans P. Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. Lancet Oncol 22(1):e18-e28, 2021. e-Pub 2021. PMID: 33387500.
Heil J, Kuerer HM, Pfob A, Rauch G, Sinn HP, Golatta M, Liefers GJ, Vrancken Peeters MJ. Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges. Ann Oncol 31(1):61-71, 2020. e-Pub 2020. PMID: 31912797.
Teshome M, Kuerer HM. Breast conserving surgery and locoregional control after neoadjuvant chemotherapy. Eur J Surg Oncol 43(5):865-874, 2017. e-Pub 2017. PMID: 28284519.
Kuerer HM, Smith BD, Chavez-MacGregor M, Albarracin C, Barcenas CH, Santiago L, Edgerton ME, Rauch GM, Giordano SH, Sahin A, Krishnamurthy S, Woodward W, Tripathy D, Yang WT, Hunt KK. DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. J Cancer 8(14):2653-2662, 2017. e-Pub 2017. PMID: 28928852.
Kronowitz SJ, Kuerer HM, Buchholz TA, Valero V, Hunt KK. A management algorithm and practical oncoplastic surgical techniques for repairing partial mastectomy defects. Plast Reconstr Surg 122(6):1631-47, 2008. e-Pub 2008. PMID: 19050516.
Kuerer HM, Breslin T, Shanafelt TD, Baile WF, Crawford W, Balch CM. Road map for maintaining career satisfaction and balance in surgical oncology. J Am Coll Surg 207(3):435-42, 2008. e-Pub 2008. PMID: 18722950.
Weichmann L, Kuerer HM. The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer 112(10):2130-42, 2008. e-Pub 2008. PMID: 18383519.
Boughey JC, Gonzalez RJ, Bonner E, Kuerer HM. Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. Oncologist 12(11):1276-87, 2007. e-Pub 2007. PMID: 18055847.
Lang JE, Kuerer HM. Breast ductal secretions: clinical features, potential uses, and possible applications. Cancer Control 14(4):350-9, 2007. e-Pub 2007. PMID: 17914335.
Kronowitz SJ, Kuerer HM. Advances and surgical decision-making for breast reconstruction. Cancer 107(5):893-907, 2006. e-Pub 2006. PMID: 16862569.
Silverstein MJ, Lagios MD, Recht A, Allred DC, Harms SE, Holland R, Holmes DR, Hughes LL, Jackman RJ, Julian TB, Kuerer HM, Mabry HC, McCready DR, McMasters KM, Page DL, Parker SH, Pass HA, Pegram M, Rubin E, Stavros AT, Tripathy D, Vicini F, Whitworth PW. Image-detected breast cancer: state of the art diagnosis and treatment. J Am Coll Surg 201(4):586-97, 2005. e-Pub 2005. PMID: 16183499.
Chagpar A, Middleton LP, Sahin AA, Meric-Bernstam F, Kuerer HM, Feig BW, Ross MI, Ames FC, Singletary SE, Buchholz TA, Valero V, Hunt KK. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer 103(8):1581-6, 2005. e-Pub 2005. PMID: 15747375.
Buchholz TA, Kuerer HM, Strom EA. Is partial breast irradiation a step forward or backward?. Semin Radiat Oncol 15(2):69-75, 2005. e-Pub 2005. PMID: 15809931.
Kuerer HM, Newman LA. Lymphatic mapping and sentinel lymph node biopsy for breast cancer: developments and resolving controversies. J Clin Oncol 23(8):1698-705, 2005. e-Pub 2005. PMID: 15755978.
Newman LA, Kuerer HM. Advances in breast conservation therapy. J Clin Oncol 23(8):1685-97, 2005. e-Pub 2005. PMID: 15755977.
Radhakrishnan R, Donato ML, Prieto VG, Mays SR, Raad, II, Kuerer HM. Invasive cutaneous fungal infections requiring radical resection in cancer patients undergoing chemotherapy. J Surg Oncol 88(1):21-26, 2004. e-Pub 2004. PMID: 15384060.
Xing Y, Cormier JN, Kuerer HM, Hunt KK. Sentinel lymph node biopsy following neoadjuvant chemotherapy: review of the literature and recommendations for use in patient management. Asian J Surg 27(4):262-7, 2004. e-Pub 2004. PMID: 15564176.
Pawlik TM, Buchholz TA, Kuerer HM. The biologic rationale for and emerging role of accelerated partial breast irradiation for breast cancer. J Am Coll Surg 199(3):479-92, 2004. e-Pub 2004. PMID: 15325619.
Kuerer HM, Arthur DW, Haffty BG. Repeat breast-conserving surgery for in-breast local breast carcinoma recurrence: the potential role of partial breast irradiation. Cancer 100(11):2269-80, 2004. e-Pub 2004. PMID: 15160329.
Kuerer HM, Julian TB, Strom EA, Lyerly HK, Giuliano AE, Mamounas EP, Vicini FA. Accelerated partial breast irradiation after conservative surgery for breast cancer. Ann Surg 239(3):338-51, 2004. e-Pub 2004. PMID: 15075650.
Singletary SE, Dowlatshahi K, Dooley W, Hollenbeck ST, Kern K, Kuerer H, Newman LA, Simmons R, Whitworth P. Minimally invasive operation for breast cancer. . Curr Probl Surg 41(4):394-447, 2004. e-Pub 2004. PMID: 15114298.
Ko BK, Kawano K, Murray JL, Disis ML, Efferson CL, Kuerer HM, Peoples GE, Ioannides CG. Clinical studies of vaccines targeting breast cancer. Clin Cancer Res 9(9):3222-34, 2003. e-Pub 2003. PMID: 12960107.
Singletary SE, Fornage BD, Sneige N, Ross MI, Simmons R, Giuliano A, Hansen N, Kuerer HM, Newman LA, Ames FC, Babiera G, Meric F, Hunt KK, Edeiken B, Mirza AN. Radiofrequency ablation of early-stage invasive breast tumors: an overview. Cancer J 8(2):177-80, 2002. e-Pub 2002. PMID: 11999950.
O'Shaughnessy JA, Ljung BM, Dooley WC, Chang J, Kuerer HM, Hung DT, Grant MD, Khan SA, Phillips RF, Duvall K, Euhus DM, King BL, Anderson BO, Troyan SL, Kim J, Veronesi U, Cazzaniga M. Ductal lavage and the clinical management of women at high risk for breast carcinoma: a commentary. Cancer 94(2):292-8, 2002. e-Pub 2002. PMID: 11900214.
Keleher AJ, Theriault RL, Gwyn KM, Hunt KK, Stelling CB, Singletary SE, Ames FC, Buchholz TA, Sahin AA, Kuerer HM. Multidisciplinary management of breast cancer concurrent with pregnancy. J Am Coll Surg 194(1):54-64, 2002. e-Pub 2002. PMID: 11800340.
Kuerer HM, Buzdar AU, Singletary SE. Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast. J Surg Oncol 77(2):139-47, 2001. e-Pub 2001. PMID: 11398169.
Newman LA, Kuerer HM, Hunt KK, Vlastos G, Ames FC, Ross MI, Singletary SE. Educational review: Role of the surgeon in hereditary breast cancer. Ann Surg Oncol 8(4):368-78, 2001. e-Pub 2001. PMID: 11352312.
Mirza AN, Fornage BD, Sneige N, Kuerer HM, Newman LA, Ames FC, Singletary SE. Radiofrequency ablation of solid tumors: Overview and preliminary results in the treatment of T1 breast tumors. Cancer J 7(2):95-102, 2001. e-Pub 2001. PMID: 11324771.
Newman LA, Kuerer HM, Hunt KK, Vlastos G, Ames FC, Ross MI, Singletary SE. Prophylactic mastectomy. J Am Coll Surg 191(3):322-30, 2000. e-Pub 2000. PMID: 10989906.
Kuerer HM, Hunt KK, Newman LA, Ross MI, Ames FC, Singletary SE. Neoadjuvant chemotherapy in women with invasive breast carcinoma: conceptual basis and fundamental surgical issues. J Am Coll Surg 190(3):350-63, 2000. e-Pub 2000. PMID: 10703863.
Newman LA, Kuerer HM, Harper T, Hunt KK, Laronga C, Breslin T, Singletary SE. Special considerations in breast cancer risk and survival. J Surg Oncol 71(4):250-60, 1999. e-Pub 1999. PMID: 10440767.
Kuerer HM, Cunningham JD, Brower ST, Tartter PI. Breast carcinoma associated with pregnancy and lactation. Surg Oncol 6(2):93-8, 1997. e-Pub 1997. PMID: 9436655.
Michl J, Qiu QY, Kuerer HM. Homing receptors and addressins. Curr Opin Immunol 3(3):373-82, 1991. e-Pub 1991. PMID: 1910617.

Professional Educational Materials

Cupp JA, Kuerer HM. Ductal carcinoma in situ. Surgical Council on Resident Education (SCORE), General Surgery Resident Curriculum Portal. Surgical Council on Resident Education (SCORE), 2014.
Kuerer HM, Robb G. Video Clip: Immediate partial breast reconstruction (Reduction Mammoplasty Technique), mammographic needle-localized segmental mastectomy, sentinel lymph node dissection. In: Kuerer's Breast Surgical Oncology. McGraw-Hill Professionals, 2010.
Kuerer HM. Video Clip: Axillary lymph node dissection. In: Kuerer's Breast Surgical Oncology. McGraw-Hill Professionals, 2010.

Editorials

Akhtar A, Menen RS, Hm K. Commentary on: Survival benefit of breast surgery for low grade ductal carcinoma in situ. A population based cohort study. Breast Diseases: A Year Book Quarterly, 2015.
Kuerer HM. Commentary on: Oncologic safety for breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer. Breast Diseases: A Year Book Quarterly, 2013.
Kuerer HM. Commentary on: Preoperative axillary ultrasound in breast cancer: safely avoiding frozen section of sentinel lymph nodes in breast-conserving surgery. Breast Diseases: A Year Book Quarterly, 2013.
Kuerer HM. Commentary on: Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: A study based on NSABP Protocol B-24. Breast Diseases: A Year Book Quarterly 2012 23:345-346, 2013.
Allen LR, Kuerer HM. Commentary on: Stage migration after introduction of sentinel lymph node dissection in breast cancer treatment in Denmark: a nationwide study. Breast Diseases: A Year Book Quarterly 23:69, 2012.
Suarez J, Kuerer HM. Commentary on: Influence of margin status on outcomes in lobular carcinoma: Experience of the European Institute of Oncology. Breast Diseases: A Year Book Quarterly 22:388-389, 2012.
Cadiz F, Kuerer HM. Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trials. Breast Diseases: A Year Book Quarterly 23:163-164, 2012.
Kuerer HM. Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Breast Disease: A Year Book Quarterly, 2011.
Kuerer HM. Determinants of breast conservation rates: reasons for mastectomy at a comprehensive cancer center. Breast Diseases: A Year Book Quarterly 20:179, 2009.
Kuerer HM. Axillary-conserving surgery is facilitated by neoadjuvant chemotherapy of breast cancer. Breast Diseases, 2009.
Kuerer HM. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Breast Diseases 19(2), 2008.
Kuerer HM. The significance of surgical margins for patients with atypical ductal hyperplasia. Breast Diseases, 2007.
Bonner EJ, Kuerer HM. Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer. Breast Diseases 17(2):156, 2006.
Kuerer HM. Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carries and other women at high inherited breast cancer risk. Breast Disease 16(4):330-1, 2006.
Kuerer HM. Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy. Breast Diseases 17(1):76, 2006.
Kuerer HM. Salvage treatment for local or local-regional recurrence after initial breast conservation treatment with radiation for ductal carcinoma in situ. Breast Diseases 17(2):157, 2006.
Kuerer HM. Thomsen-Friedenreich and Tn Antigens in nipple fluid: Carbohydrate biomarkers for breast cancer detection. Breast Diseases 17(2):156, 2006.
Kuerer HM. Postlumpectomy insertion of the MammoSite Brachytherapy device using the scar entry technique: Initial experience and technical considerations. Breast Diseases 17(1):86, 2006.
Kuerer HM. Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: An interim analyses of a prospective multi-institutional cohort study. Breast Diseases 15(4):442, 2005.
Kuerer HM. A prospective analysis of the effect of blue-dye volume on sentinel lymph node mapping success and incidence of allergic reaction in patients with breast cancer. Breast Diseases 15(4):445-6, 2005.
Kuerer HM. Nipple aspirate fluid cytology and the Gail model for breast cancer risk assessment in a screening population. Breast Diseases 16(3):249-50, 2005.
Kuerer HM. Mastectomy and concomitant sentinel lymph node biopsy for invasive breast cancer. Breast Diseases 16(3):260-1, 2005.
Kuerer HM. Variation in estradiol, estradiol precursors, and estrogen-related products in nipple aspirate fluid from normal premenopausal women. Breast Diseases 16(1):29, 2005.
Mendez JE, Kuerer HM. Fertility preservation in breast cancer patients: A positive controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. Women's Oncology Review 5(3):177, 2005.
Kuerer HM. Partial breast irradiation in breast-conserving therapy by way of interstitial brachytherapy. Breast Diseases 16(2):179-80, 2005.
Kuerer HM. Breast cancer in patients with prior augmentation: presentation, stage, and lymphatic mapping. Breast Diseases 16(3):266, 2005.
Kuerer HM. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Breast Diseases 15(4):419, 2005.
Kuerer HM. If at first or second you don't succeed: Mastectomy?. Ann Surg Oncol 12(11):864-5, 2005.
Kuerer HM. Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease. Breast Diseases 15(2):166, 2004.
Kuerer HM. Association of kallikrein expression in nipple aspirate fluid with breast cancer risk. Breast Diseases 15(3):286, 2004.
Kuerer HM. Full-dose intraoperative radiotherapy with electrons during breast-conserving surgery. Breast Diseases 15(2):183-4, 2004.
Kuerer HM. Intraoperative radiation therapy for breast cancer: Technical notes. Breast Diseases: A Year Book Quarterly 14(4):406-407, 2004.
Kuerer HM. Ductal lavage in patient undergoing mastectomy for mammary carcinoma: a correlative study. Breast Diseases 15(2):169, 2004.
Kuerer HM. Detection of chromosomal instability in paired breast surgery and ductal lavage specimens by interphase fluorescence in situ hybridization. Breast Diseases 14(4):367, 2004.
Kuerer HM. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project B-27. Breast Diseases 15(3):315-6, 2004.
Kuerer HM. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Breast Diseases 14(4):434, 2004.
Kuerer HM. Failure to harvest sentinel lymph nodes identified by preoperative lymphoscintigraphy in breast cancer patients. Breast Diseases 14(4):415-6, 2004.
Kuerer HM, Kronowitz ST. Irradiation after immediate tissue expander/implant breast reconstruction: Outcomes, complications, aesthetic results, and satisfaction among 156 patients. The Women's Oncology Review 4(4):231-3, 2004.
Ehlers RA, Kuerer HM. Factitious oxygen desaturation after isosulfan blue injection. Breast Diseases 15(2):182, 2004.
Kuerer HM. Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer?. Breast Diseases 15(3):290, 2004.
Kuerer HM. Effect of massage technique on sentinel lymph node mapping for cancer of the breast. Breast Diseases 14(4):418, 2004.
Kuerer HM. Microsatellite changes in nipple aspirate fluid and breast tissue from women with breast carcinoma or its precursors. Breast Diseases 15(1):46, 2004.
Shen J, Kuerer HM. Pilot trial of cryoprobe-assisted breast conserving surgery for small ultrasound-visible cancers. Women's Oncology Review 4(1):61-2, 2004.
Kuerer HM. High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer. Breast Diseases 14(3):300-1, 2003.
Kuerer HM. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. Breast Diseases 14(2):177-8, 2003.
Kuerer HM. Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy. Breast Diseases 14(2):188, 2003.
Kuerer HM. Completion axillary lymph node dissection minimizes to likelihood of false negatives for patients with invasive breast carcinoma and cytokeratin positive only sentinel lymph nodes. Breast Diseases 14(2):190-1, 2003.
Kronowitz SJ, Kuerer HM. Sentinel lymph node biopsy followed by delayed mastectomy and reconstruction. Breast Diseases 14(3):314-5, 2003.
Kuerer HM. Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer. Breast Diseases 14(1):56, 2003.
Vaidya S, Kuerer HM. Detection treatment and outcome of isolated supraclavicular recurrence in 42 patients with invasive breast carcinoma. The Women's Oncology Review 3:309-10, 2003.
Kuerer HM. Evaluation of axillary status in breast cancer: CT-based determination of sentinel lymph node size. Breast Diseases 14(3):317-8, 2003.
Kuerer HM. Does aggressive local therapy improve survival in metastatic breast cancer?. Women's Oncology Review 3(1):105-6, 2003.
Kuerer HM. Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer. Breast Diseases 14(2):195, 2003.
Kuerer HM. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. Breast Diseases 13(4):387-8, 2002.
Kuerer HM. Genetic counseling impacts decision for prophylactic surgery for patients perceived to be at high risk for breast cancer. Breast Diseases 13(1):72, 2002.
Kuerer HM. Biomarkers assays in nipple aspirate fluid. Breast Diseases 13(3):244, 2002.
Kuerer HM. Early results of an endoscope-assisted subcutaneous mastectomy and reconstruction for breast cancer. Breast Diseases 13(3):277, 2002.
Ahmad A, Kuerer HM, Buchholz TA. Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. Women's Oncology Review 2(1):39-95, 2002.
Kuerer HM. Gamma probe and ultrasonography-guided fine-needle aspiration biopsy of sentinel lymph nodes in breast cancer. Breast Diseases 12(4):438, 2002.
Kuerer HM. Anaphylaxis after peritumoral injection of sulphan blue 1% for identification of sentinel node in lymphatic mapping of the breast. Breast Diseases 13(3):253, 2002.
Kuerer HM. Papillary lesions of the breast: evaluation with stereotactic directional vacuum-assisted biopsy. Breast Diseases 13(2):158, 2002.
Kuerer HM. Nipple aspirate cytology and pathologic parameters predict residual cancer and nodal involvement after excisional breast biopsy. Breast Diseases 13(3):245, 2002.
Kuerer HM. Skin-sparing mastectomy with sentinel lymph node dissection: less is more. Breast Diseases 13(2):185, 2002.
Kuerer HM. Locally advanced breast cancer: Is surgery necessary?. Breast Diseases 12(4):412-3, 2002.
Kuerer HM. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?. Breast Diseases 13(1):65, 2002.
Kuerer HM. Does surgery modify growth kinetics of breast cancer micrometastases?. Breast Diseases 13(2):170-1, 2002.
Kuerer HM. Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Breast Diseases 13(2):164, 2002.
Kuerer HM. ERBB2 overexpression in breast carcinoma: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy. Breast Diseases 11:440, 2001.
Kuerer HM. Primary axillary radiotherapy as axillary treatment in breast-conserving therapy for patients with breast carcinoma and clinically negative axillary lymph nodes. Breast Diseases 11:415-6, 2001.
Kuerer HM. A simple intraductal aspiration method for cytodiagnosis in nipple discharge. Breast Diseases 12(2):177, 2001.
Kuerer HM. Preoperative paclitaxel and radiotherapy for locally advanced breast cancer: Surgical aspects. Breast Diseases 11(4):417, 2001.
Kuerer HM. Positron emission tomography with fluorine-18 fluorodeoxyglucose to evaluate response to early breast carcinoma treated with stereotaxic interstitial laser therapy. Breast Diseases 11(4):417-8, 2001.
Kuerer HM. A simple approach to nipple discharge. Breast Diseases 12(2):196-7, 2001.
Kuerer HM. Mammaglobin, a potential marker of breast cancer nodal metastasis. Breast Diseases 12(2):178, 2001.
Kuerer HM. Do surgical oncologists achieve lower rates of locoregional recurrence in node positive breast cancer treated with mastectomy alone?. J Surg Oncol 78:8-9, 2001.
Kuerer HM. Primary axillary radiotherapy as axillary treatment in breast-conserving therapy for patients with breast carcinoma and clinically negative axillary lymph nodes. Breast Diseases 11(4):415-6, 2001.
Kuerer HM. The relationship of HMOs, health insurance, and delivery systems to breast cancer outcomes. Breast Diseases 12(1):127, 2001.
Kuerer HM. Axillary lymph node involvement in stage II breast cancer: treatment implications. Breast Diseases 11:85-6, 2000.
Kuerer HM. Radiofrequency ablation of breast cancer. Breast Diseases 11:183, 2000.
Kuerer HM. Detection of Epstein-Barr Virus in Invasive Breast Cancer. Breast Diseases 11:23-4, 2000.
Kuerer HM. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. Breast Diseases 11:135, 2000.
Kuerer HM. Detection and significance of occult axillary metastatic disease in breast cancer patients. Breast Diseases 11:68-70, 2000.
Kuerer HM. Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with TI breast cancers. Breast Disease 11:174-5, 2000.
Kuerer HM. A cost effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes. Breast Diseases 11:71-2, 2000.
Kuerer HM. Differences in breast cancer treatment and survival between older and younger women. Breast Diseases 11:30, 2000.
Kuerer HM. Reoperation for locally recurrent breast cancer in patients previously treated with conservative surgery. Breast Diseases 10:110, 1999.
Kuerer HM. Complications of axillary lymph node dissection for carcinoma of the breast. Breast Diseases 10:195-6, 1999.
Kuerer HM. Neoadjuvant chemotherapy in young breast cancer patients: correlation between response and relapse?. Breast Diseases 10:496-8, 1999.
Kuerer HM. Dormancy of mammary carcinoma after mastectomy. Breast Diseases 10:273, 1999.
Kuerer HM. The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. Breast Diseases 10:311-12, 1999.
Kuerer HM. Medical and psychosocial effects of early discharge after surgery for breast cancer: randomized trial. Breast Diseases 9:389-90, 1999.
Kuerer HM. Preoperative chemotherapy and radiotherapy in breast cancer. Breast Diseases 10:114, 1999.
Kuerer HM. Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. Abstracts in Hematology & Oncology 2:5-6, 1999.
Kuerer HM. Long-term follow-up of a randomized trial on adjuvant chemotherapy and hormonal therapy in locally advanced breast cancer. Breast Diseases 9:420, 1999.
Kuerer HM. Unilateral male breast masses: cancer risk and their evaluation and management. Breast Diseases 10:275, 1999.
Kuerer HM. Postoperative suction drainage of the axilla: for how long? Prospective randomized trial. Breast Diseases 10:316, 1999.
Kuerer HM. A multivariate analysis of tumor biological factors predicting response to cytotoxic treatment in advanced breast cancer. Breast Diseases 10:184, 1999.

Abstracts

Cobb A, Lucci A, Kuerer H, Teshome M, Woodward W, Ueno N, Stauder M, Layman R, Sun S. Long-term outcomes in inflammatory breast cancer patients with supraclavicular nodal involvement. The American Society of Breast Surgeons, 23rd Annual Meeting. e-Pub 2022.
Ganz PA, Cecchini RS, White JR, Vicini F, Julian TB, Arthur DW, Rabinovitch R, Kuske RR, Parda DS, Scheier M, Winter KA, Paik S, Kuerer HM, Vallow L, Pierce LJ, Mamounas EP, Costantino JP, McCormick B, Curran Jr WJ, Wolmark N. Patient-reported Outcomes (PROs) in NRG Oncology/NSABP B-39/RTOG 0413: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) v Partial Breast Irradiation (PBI) in Stage 0, I, or II Breast Cancer. 2019 ASCO Annual Meeting, Chicago, IL, 2019. e-Pub 2019.
Sun SX, Kuerer HM. Patient selection for non-operative management of HER2+ invasive breast cancer after neoadjuvant systemic therapy. The American Society of Breast Surgeons, 20th Annual Meeting, 2019. e-Pub 2019.
Simons JM, Nurudeen S, Yi M, Kuerer HM, Caudle AS, DeSnyder SM, Mittendorf EA, Bedrosian I, Hunt KK. Long-term survival following sentinel lymph node biopsy in clinically node negative breast cancer patients treated with primary surgery or neoadjuvant chemotherapy. The American Society of Breast Surgeons, 20th Annual Meeting, 2019. e-Pub 2019.
Simons J, Scoggins M, Kuerer HM, Sahin A, Snell A, Bedrosian I, Lee J, Hunt K, Caudle A. Prospective clinical trial of nonradioactive magnetic nodal seed localization to facilitate targeted axillary dissection. The American Society of Breast Surgeons, 20th Annual Meeting, 2019. e-Pub 2019.
Park KU, Kyrish K, Yi M, Bedrosian I, Caudle A, Kuerer HM, Hunt K, Miggins M, DeSnyder S. Opioid Use After Breast Conserving Surgery: Identifying Risk Factors For High Opioid Use. The American Society of Breast Surgeons, 20th Annual Meeting, 2019. e-Pub 2019.
Singh P, Scoggins M, Sahin A, Hwang R, Kuerer H, Caudle A, Mittendorf E, Thompson A, Bedrosian I, Teshome M, DeSnyder S, Meric-Bernstam F, Hunt K. Effectiveness and safety of magseed-localization for surgical excision of breast lesions. Society of Surgical Oncology, 2019. e-Pub 2019.
Raber B, Bedrosian I, Kuerer HM, Holmes K, Sun S, Teshome M. National Trends in Access to Inclusive LGBT Patient-Centered Oncology Care. Society of Surgical Oncology, 2019. e-Pub 2019.
Sun SX, Suk R, Kuerer HM, Cantor SB, Raber BM, Deshmukh AA. Cost-effectiveness analysis of active surveillance compared to partial mastectomy plus radiation for ductal carcinoma in situ: Is non-operative management a viable option?. Society of Surgical Oncology, 2019. e-Pub 2019.
Vicini FA, Cecchini RS, White JR, Julian TB, Arthur DW, Rabinovitch RA, Kuske RR, Kuerer HM, Vallow LA, Pierce LJ, Mamounas EP, Costantino JP, Bear HD, Germain I, Gustafson G, Grossheim L, Peterson IA, Hudes RS, Curran WJ, Wolmark N. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. San Antonio Breast Cancer Symposium, San Antonio, Texas, 2018. e-Pub 2018.
McCormick B, Winter KA, Kuerer HM, Sneige N, Rakovitch E, Smith BL, Germain I, Hartford AC, O’Rourke MA, Walker EM, Strom EA, Atkins JN, Pierce LJ, Pu AT, Sumida KN, Vesprini D, Moughan J, White JR. RTOG 9804 Abstract 2018. American Society for Radiation Oncology (ASTRO), San Antonio TX, 2018. e-Pub 2018.
Stecklein SR, Rosso KJ, Tadros AB, Weiss A, Warneke CL, DeSnyder S, Kuerer HK, Ueno NT, Lucci A, Woodward WA. Excellent Locoregional Control in Inflammatory Breast Cancer with a Personalized Radiotherapy Approach. American Society for Radiation Oncology (ASTRO), San Antonio TX, 2018. e-Pub 2018.
Li L, Rockwood K, Abarracin C, Sahin A, Hunt K, Kuerer HM, Krishnamurthy S. Role of Intraoperative Evaluation in Avoiding Positive margins in Patients Undergoing Breast Conservation Surgery for a Diagnosis of Ductal Carcinoma In Situ. USCAP's 2018 Annual Meeting, 2018. e-Pub 2018.
Gan Q, Caudle A, Kuerer HM, Krishnamurthy S. Current Role of Intraoperative Frozen Section Evaluation of Axillary Sentinel Lymph Nodes in Patients with Early-Stage Breast Cancer Undergoing Mastectomy. USCAP's 2018 Annual Meeting, 2018. e-Pub 2018.
Moon HJ, Caudle AS, Kuerer HM, Beatriz A, Candelaria R, Santiago L, Krsihnamurthy S, Wei W, Yang WT. Targeted Axillary Dissection: Challenges with Axillary Lymph Node Clip Placement, Clip Identification, and Clip Retrieval post Neoadjuvant Therapy. Radiological Society of North America, 103rd Annual Meeting. Chicago, IL, 2017. e-Pub 2017.
Christopherson K, Barcenas CH, Perkins GH, Shaitelman SF, Woodward W, Lei X, Buchholz TA, Hoffman K, Kuerer HM, Smith GL, Stauder MC, Strom EA, Tereffe W, Smith B. Outcomes of curative-intent treatment for breast cancer patients presenting with sternal or mediastinal involvement. American Society for Radiation Oncology Annual Meeting. San Diego, CA, 2017. e-Pub 2017.
Tadros A, Kuerer HM. Margins < 2 mm for patients with cuctal carcinoma in situ and contraindication for breast conservation with radiotherapy. ASCO 2017 Annual Meeting, Chicago IL, 2017. e-Pub 2017.
Weiss A, Mittendorf E, DeSnyder S, Hwang R, Bedrosian I, Hoffman K, Adrada B, Bea V, Sahin A, Kuerer H, Hunt K, Caudle A. ACOSOG Z0011: Impact After 5 Years. American Society of Breast Surgeons, Annutal 18th Meeting. 04/2017. Las Vegas, NV, 2017. e-Pub 2017.
Black D, Niu J, Bea V, Refinetti A, Teshome M, Hunt K, Kuerer H, Giordano S. Continued disparities in breast cancer stage at diagnosis and survival by race and socioeconomic status. American Society of Breast Surgeons, Annutal 18th Meeting. 04/2017. Las Vegas, NV, 2017. e-Pub 2017.
Rosso KJ, Tadros AB, Weiss A, Warneke C, DeSnyder S, Kuerer H, Ueno NT, Stecklein SR, Woodward WA, Lucci A. Improved locoregional control in a contemporary cohort of nonmetastatic inflammatory breast cancer patients undergoing surgery. American Society of Breast Surgeons 18th Annual Meeting. 04/2017, Las Vegas, NV, 2017. e-Pub 2017.
Hwang R, Jiang J, Carter S, Shih T, Oates S, Butler C, Kuerer H, Babiera G, Mittendorf E, Lucci A, Caudle A, Bedrosian I, Thompson A, DeSnyder S, Baumann D, Clemens M, Garvey P, Schaverien M, Buchholz T, Giordano S, Hunt K, Smith B. Cost and complication burden of oncoplastic breast conservation compared to other treatment options in women with breast cancer. American Society of Breast Surgeons, Annutal 18th Meeting. 04/2017. Las Vegas, NV, 2017. e-Pub 2017.
Ayoub Z, Strom EA, Ovalle V, Perkins GH, Woodward WA, Tereffe W, Smith BD, Shaitelman SF, Stauder MC, Hoffman KE, DeSnyder SM, Garvey PB, Clemens MW, Barcenas CH, Kuerer HM, Kronowitz S. Radiotherapy after skin-sparing mastectomy and placement of a tissue expander: Effectiveness of a coordinated, multidisciplinary approach. American Radium Society 99th Annual Meeting. 05/2017. Colorado Spring, CO, 2017. e-Pub 2017.
Ayoub Z, Strom E, Ovalle V, Perkins G, Woodward W, Tereffe W, Smith B, Shaitelman S, Stauder M, Hoffman K, DeSnyder S, Garvey P, Clemens M, Barcenas C, Kuerer H, Kronowitz S. A ten-year experience with mastectomy and tissue expander placement to facilitate subsequent radiation and reconstruction. American Society of Breast Surgeons, Annutal 18th Meeting. 04/2017. Las Vegas, NV, 2017. e-Pub 2017.
Weiss A, Kuerer HM, Yang WT, Krishnamurthy S, DeSnyder SM, Black DM, Babiera GV, Teshome M, Hunt KK, Caudle AS. Potential for Targeted Axillary Dissection in Patients Who Do Not Receive Neoadjuvant Chemotherapy. American Society of Breast Surgeons 18th Annual Meeting. 04/ 2017, Las Vegas, NV, 2017. e-Pub 2017.
Elsayegh N, Gutierez Barrera AM, Kuerer HM, Hernandez ND, Litton JK, Arun BK. CPM rate among individuals with breast cencer who underwent multiplex gene testing for hereditary cancer: Single institution experience. San Antonio Breast Cancer Symposium, San Antonio, Texas, 2016. e-Pub 2016.
Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, Santiago L, Lucci A, Hobbs BP, Gilcrease M, Hwang R, Candelaria RP, Chavez Mac-Gregor M, Arribas E, Moseley T, Teshome M, Miggins MV, Smith BD, Valero V, Hunt KK, Yang WT. Feasibility trial for identification of patients for eliminating breast cancer surgery following neoadjuvant systemic therapy. San Antonio Breast Cancer Symposium, San Antonio, Texas, 2016. e-Pub 2016.
Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, Santiago L, Lucci A, Hobbs BP, Gilcrease M, Hwang R, Candelaria RP, Chavez MacGregor A, Arribas E, Moseley T, Teshome M, Miggins MV, Smith BD, Valero V, Hunt KK, Yang WT. Feasibility trial for identification of patients for eliminating breast cancer surgery following neoadjuvant systemic therapy. Cancer Research, 2016. e-Pub 2016.
Fayanju O, Kuerer HM. Body Mass Index, Pathologic Complete Response, and Circulating Tumor Cells after Neoadjuvant Chemotherapy for Breast Cancer. American Society of Breast Surgeons 17th Annual Meeting. 04/2016, Dallas, TX, 2016. e-Pub 2016.
Carter SA, Lyons GR, Bassett RL, Babiera G, Bedrosian I, Hunt KK, DeSnyder SM, Kuerer HM, Caudle AS, Black S, Ross, MI, Teshome M, Thompson A, Yi M, Oates S, Garvey PB, Baumann D, Hwang R. An Analysis of 5651 Surgeries for Patients with Breast Cancer: the Emerging Trend for Breast Conservation and Oncoplastic Reconstruction with Oncologic and Post-Operative Outcomes. American Society of Breast Surgeons 17th Annual Meeting. 04/2016, Dallas, TX, 2016. e-Pub 2016.
Omofoye T, Candelaria RP, Wei W, Dogan BE, Nguyen X, Yang WT, Kuerer HM. Development of an ultrasound (US) Lexicon to improve detection of axillary lymph node (AXLN) metastasis in patients with primary breast cancer. SBI/ACR Breast Imaging Symposium. 04/2016, Austin, TX, 2016. e-Pub 2016.
Yi M, Mittendorf EA, Black S, Kuerer HM, Bedrosian I, Babiera G, Caudle AS, DeSnyder SM, Hunt KK. Sentinel Lymph Node Dissection in Patients with Multicentric Invasive Breast Cancer. Society of Surgical Oncology Annual Cancer Symposium. 03/2016, Boston, MA, 2016. e-Pub 2016.
Manders J, Kuerer HM, Smith BD, McClusky C, Farrar W, Fraizer TG, Li L, Leonard CE, Carter DL, Chalwa S, Medeiros LE, Guenther JM, Castellini LE, Buchholz DJ, Mamounas EP, Wapnir IL, Horst KC, Chagar A, Evans SB, Riker AI, Vali FS, Solin LJ, Jablon L, Recht A, Sharma R, Lu R, Sing AP, White J. The 12-gene DCIS Score assay: Impact on radiation treatment (XRT) recommendations. San Antonio, TX. San Antonio Breast Cancer Symposium, 2015. e-Pub 2015.
Omofoye T, Candelaria RP, Wei W, Dogan BE, Nguyen X, Yang WT, Kuerer HM. Development of an Ultrasound (US) Lexicon to improve detection of Axillary Lymph node (AXLN) metastasis in patients with primary breast cancer. 101st Scientific Assembly and Annual Meeting. Chicago,IL, 2015. e-Pub 2015.
Shin K, Caudle AS, Kuerer HM, Wei W, Yang WT. Sonographic features of benign and malignant axillary nodes post neoadjuvant chemotherapy. 101st Scientific Assembly and Annual Meeting (RSNA). Chicago, IL, 2015. e-Pub 2015.
Vila J, Bassett Jr RL, Mittendorf EA, Bedrosian I, Shaitelman SF, Stauder MC, Chavez-MacGregor M, Litton JK, Yang WT, Huo L, Kuerer HM, Hunt KK, Caudle AS. A nomogram to predict axillary response to neoadjuvant chemotherapy in clinically node positive breast patients. ASCO Annual Meeting, 05/15, Chicago, IL, 2015. e-Pub 2015.
Ovalle V, Strom EA, Godby J, Shaitelman SF, Kuerer HM, Woodward WA, Hoffman KE. Proton accelerated partial breast irradiation for early stage breast cancer: A not-so-costly alternative. Particle Therapy Cooperative Group (PTCOG) – North America 2014 Inaugural Meeting, 10/14, Houston, TX, 2015. e-Pub 2015.
Lucci A, Hall C, Kuerer H, Anderson A, Karhade M, Laubacher B, Krishnamurthy S. Circulating and disseminated tumor cells in non-metastatic breast cancer. 49th Congress of the European Society for Surgical Research, 2015. e-Pub 2015.
Parker C, Shen Y, Lin H, Lautner M, Kuerer H, Shaitelman S, Babiera G, Bedrosian I. Impact of hormone receptor status and surgical therapy on overall survival for early stage breast cancer. 2014 ASCO Breast Cancer Sympopsium, 09/14, San Francisco, CA, 2015. e-Pub 2015.
Sauder CAM, Stauder M, Hunt KK, Lucci A, Mittendorf EA, Whitman G, Kuerer HM, Caudle AS. Outcomes with contralateral axillary nodal metastases in breast cancer. Society of Surgical Oncology Annual Cancer Symposium, 03/15, Houston, TX, 2015. e-Pub 2015.
Caudle AS, Yang W, Krishnamurthy S, Hobbs BP, Mittendorf EA, Black D, Hwang R, Hunt KK, Kuerer HM. Targeted axillary dissection (TAD for node positive breast cancer: A feasibility trial for selective resection of axillary lymph node metastases. Society of Surgical Oncology Annual Cancer Symposium, 03/15, Houston, TX, 2015. e-Pub 2015.
Elsayegh N, Gutierrez Barrera AM, Profato JL, Lin H, Arun BK, Litton J, Kuerer HM. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ without a BRCA mutation. 2014 ASCO Breast Cancer Symposium, 09/14, San Francisco, CA, 2015. e-Pub 2015.
Black DM, Wagner J, Mittendorf E, Hwang R, DeSnyder S, Ames F, Yoburn T, Wipf N, Gollihar S, Meric-Bernstam F, Dogan BE, Dryden M, Wang YT, Rohren E, Gilcrease M, Kuerer HM, Hunt KK, Caudle AS. Radioactive seed localization for breast conserving surgery: A single institution experience. Society of Surgical Oncology Annual Cancer Symposium, 03/15, Houston, TX, 2015. e-Pub 2015.
Caudle AS, Yang W, Mittendorf EA, Black DM, Gilcrease M, Bedrosian I, Hobbs BP, Candelaria RP, Babiera GV, Dogan BE, Santiago L, Hunt KK, Krishnamurthy S, Kuerer HM. Improving assessment for residual nodal disease after neoadjuvant chemotherapy with image-guided surgery and pathology evaluations. 2014 ASCO Breast Cancer Symposium, 09/14, San Francisco, CA, 2015. e-Pub 2015.
Miggins MV, Krishnamurthy S, Kuerer HM, Hwang R. Clinicopathologic analysis of encapsulated papillary carcinomas of the breast confirms a favorable prognosis. American Society of Breast Surgeons 16th Annual Meeting, 04/15, Orlando, FL, 2015. e-Pub 2015.
Arthur DW, Winter KA, Kuerer HM, Haffty BG, Cuttino LW, et al. NRG Oncology/RTOG 1014: A Phase II study of repeat breast preserving surgery and 3D-conformal partial breast re-irradiation (PBrI) for local recurrence of breast carcinoma. ASTRO Annual Meeting, 10/15, San Antonio, TX, 2015. e-Pub 2015.
Colfry J, Linn H, Shen Y, Kuerer H, Shaitelman S, Babiera G, Bedrosian I. Axillary management in DCIS patients within the National Cancer Database. American Society of Breast Surgeons 16th Annual Meeting, 04/15, Orlando, FL, 2015. e-Pub 2015.
Yi M, Mittendorf EA, Yang W, Arun BK, Babiera GV, Kuerer HM, Crow JR, Lange G, Shah RR, Hunt KK. Factors associated with increasing mastectomy rates in early stage breast cancer patients: Report from a single institution and population-based database. 126th Annual Meeting of the Southern Surgical Association, 11/14, Palm Beach, FL, 2015. e-Pub 2015.
Loveland-Jones C, Shaitelman S, Lin H, Shen Y, Bedrosian I, Kuerer H, Babiera G. Disparities in the use of post-mastectomy radiation therapy for inflammatory breast cancer. Society of Surgical Oncology Annual Cancer Symposium, 03/15, Houston, TX, 2015. e-Pub 2015.
Omofoye T, Candelaria RP, Wei W, Dogan BE, Nguyen X, Yang WT, Kuerer HM. Development of an ultrasound (US) Lexicon to improve detection of axillary lymph node (AXLN) metastasis in patients with primary breast cancer. RSNA 2015. Chicago IL, 2015. e-Pub 2015.
Hall C, Kuerer K, Karhade M, Anderson A, Laubacher B, Gainer S, Lucci A. Circulating tumor cells after neoadjuvant therapy in non-metastatic triple negative breast cancer. Society of Surgical Oncology Annual Cancer Symposium, 03/15, Houston, TX, 2015. e-Pub 2015.
Plaxo J, He H, Huo L, Wei W, Candelaria RP, Yang WT, Kuerer HM. Incremental cancer detection utilizing breast ultrasound versus breast MRI in the evaluation of newly diagnosed breast cancer patients. RSNA 2015, 2015. e-Pub 2015.
Rauch GM, Hobbs B, Kuerer HM, Scoggins ME, Benveniste A, Yang WT. Mammographic features of microcalcifation and survival in patients with pure ductal carcinoma in situ of the breast: population based retrospective cohort study. 100th RSNA Scientific Assembly and Annual Meeting, 11/14, Chicago, IL, 2015. e-Pub 2015.
Caudle A, Yang W, Krishnamurthy S, Hobbs B, Mittendorf E, Black D, Hwang R, Hunt K, Kuerer H. New targeted surgery to selectively remove breast cancer nodal metastases. 49th Congress of the European Society for Surgical Research, 2014. e-Pub 2014.
Goravanchi F, Rigby D, Rebello E, Lange G, Kowalski A, Kee S, Lucci A, Caudle A, Baumann D, French K, Kuerer H. Outpatient breast surgery is safe: Recent experience with 10836 patients at M. D. Anderson Cancer Center. 49th International Congress of European Society for Surgical Research (ESSR), 2014. e-Pub 2014.
Caudle AS, Yang W, Krishnamurthy S, Hobbs BP, Mittendorf EA, Black D, Hwang R, Hunt KK Kuerer HM. Targeted axillary dissection (TAD) for node positive breast cancer: A feasibility trial for selective resection of axillary lymph node metastases. 67th Annual SSO Cancer Symposium, Phoenix, AZ, 2014. e-Pub 2014.
Cadiz F, Margarit S, Kuerer HM, Raimilla P, Puga J, j C, Carvajal C, Arun B. Implementation of a program for individuals at high risk for breast cancer at Clinica Alemana, Santiago, Chile, initial experience. Senologic International Society 2014, 2014. e-Pub 2014.
Rauch GM, Hobbs B, Kuerer HM, Scoggins ME, Lari S, Yang WT. Microcalcifications in 1,658 patients with pure ductal carcinoma in situ of the breast: imaging findings with clinical, histopathologic and biologic correlation. 99th RSNA Scientific Assembly and Annual Meeting, Chicago, IL, 2013. e-Pub 2013.
Lautner M, Parker C, Lin H, Shen Y, Kuerer HM, Shaitelman S, Babiera G, Bedrosian I. National trends in mastectomy rates from 1998 to 2010. 67th Annual SSO Cancer Symposium, Phoenix, AZ, 2013. e-Pub 2013.
Elsayegh N, Gutierrez-Barrera AM, Baum G, Muse KI, Kuerer H, Litton JK, Arun BK. Factors associated with prophylactic mastectomy among BRCA positive patients with no personal history of breast cancer. San Antonio Breast Cancer Symposium, San Antonio, TX, 2013. e-Pub 2013.
Shen MC, Bloom E, Shaitelman SF, Wei C, Haynes AB, Mittendorf EA, Kuerer HM, Bedrosian I, Hwang RF, Hunt KK, Tereffe W, Strom E, Babiera GV. Comparison of infectious complications between breast conserving therapy with catheter-based accelerated partial irradiation and whole breast irradiation. San Antonio Breast Cancer Symposium, San Antonio, TX, 2013. e-Pub 2013.
FitzSullivan E, Kuerer HM, Bassett RL, Mittendorf EA, Yi M, Hunt K, Babiera G, Caudle AS, Black DM, Bedrosian I, Meric-Bernstam F, Hwang RF. Outcomes of sentinel lymph node-positive breast cancer patients treated with mastectomy without axillary therapy. ASCO Breast Cancer Symposium, San Francisco, CA, 2013. e-Pub 2013.
Francis AM, Grimes LM, Yi M, Mittendorf EA, Bedrosian I, Caudle A, Meric-Bernstam F, Babiera G, Krishnamurthy S, Kuerer HM, Hunt K. Utility of sentinel lymph node dissection (SLND) in ductal carcinoma in situ (DCIS). Society of Surgical Oncology 66th Annual Breast Cancer Symposium, National Harbor, MD, 2013. e-Pub 2013.
Caudle AS, Kuerer HM, Le-Petross HT, Yang W, Bedrosian I, Krishnamurthy, Lucci A, Hunt KK, Mittendorf EA. Predicting the extent of nodal disease in early breast cancer. ASCO Breast Cancer Symposium, San Francisco, CA, 2013. e-Pub 2013.
Caudle AS, Le-Petross HT, Kuerer HM, Lari S, Hunt KK, Alvarez R, Krishnamurthy S, Yang WT. Nodal ultrasound reliability varies with molecular subtypes in breast cancer after neoadjuvant chemotherapy. ARRS Annual Meeting, Washington, DC, 2013. e-Pub 2013.
Kalambo MN, Fox P, Kuerer HM, Krishnamurthy S, Lari S, Yang WT. Pure ductal carcinoma in situ: Imaging, clinical and pathologic features of recurrence. 99th RSNA Scientific Assembly and Annual Meeting, Chicago, IL, 2013. e-Pub 2013.
FitzSullivan, Lari SA, Smith B, Caudle A, Krishnamurthy S, Lucci A, Mittendorf E, Babiera G, Black D, Wagner J, Bedrosian I, Woodward W, Gainer S, Hwang R, Meric-Bernstam F, Hunt K, Kuerer HM. Incidence and consequence of close margins for DCIS treated with mastectomy. 66th Society of Surgical Oncology Annual Cancer Symposium, National Harbor, MD, 2013. e-Pub 2013.
Dallas NA, Bedrosian I, Allen LR, Bloom ES, Sf S, Mittendorf EA, Woodward W, Tereffe W, Kuerer HM, Hunt K, Alvarado R, Babiera G. Factors associated with non-receipt of accelerated partial breast irradiation (APBI) in early-stage breast cancer. Society of Surgical Oncology 66th Annual Cancer Symposium, 2013. e-Pub 2013.
Scoggins ME, Rauch GM, Fox PS, Benveniste A, Kuerer HM, Yang WT. Sonographic findings in 691 pure ductal carcinoma lesions with histopathologic and biologic correlation. 99th RSNA Scientific Assembly and Annual Meeting, Chicago, IL, 2013. e-Pub 2013.
Haynes AB, Bloom ES, Bedrosian I, Kuerer HM, Hwang RF, Caudle AS, Hunt KK, Tereffe W, Shaitelman SF, Babiera GV. Timing of infectious complications following breast conserving therapy using catheter-based accelerated partial breast irradiation. San Antonio Breast Cancer Symposium 2012, 2012. e-Pub 2012.
McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, Sneige N, Shah A, Germain I, Hartford AC, Rashtian A, Walker EM, Yuen A, Strom EA, Wilcox JL, Vallow LA, Small Jr W, Pu AT, Kerlin K, White JR. RTOG: 9804: A prospective randomized trial for "Good Risk" ductal carcinoma in situ (DCIS), comparing radiation (RT) to observation (OBS). 2012 ASCO Annual Meeting, Chicago, IL, 2012. e-Pub 2012.
Dallas NA, Min Y, Hunt K, Shah RR, Kuerer HM, Litton JK, Wu Y, Caudle AS, Meric-Bernstam F, Sahin AA, Mittendorf EA. Evaluation of the stage IB designation of the 7th edition of the AJCC staging system. 2012 ASCO Annual Meeting, Chicago, IL, 2012. e-Pub 2012.
Alvarado R, Lari S, Roses RE, Smith BD, Yang W, Mittendorf EA, Arun BK, Lucci A, Babiera GV, Wagner JL, Caudle AS, Meric-Bernstam F, Hwang R, Bedrosian I, Hunt KK, Kuerer HM. Biology, treatment, and outcome in very young and older women with DCIS. Society of Surgical Oncology 65th Annual Cancer Symposium, Orlando, FL, 2012. e-Pub 2012.
Black DM, Jiang J, Kuerer HM, Buchholz TA, Smith BD. Differences in the utilization of axillary sentinel lymph node biopsy among black and white patients with negative breast cancer from 2002-2007. San Antonio Breast Cancer Symposium, 2012. e-Pub 2012.
Dobbs J, Benveniste AP, Kuerer HM, Krishnamurthy S, Yang WT. Imaging of human breast tissue with confocal fluorescence microscopy. Radiological Society of North America 98th Scientific Assembly and Annual Meeting, Chicago, IL, 2012. e-Pub 2012.
Weksberg DC, Allen PK, Hoffman KE, Strom EA, Shah R, Kuerer HM, Hunt KK, Buchholz TA, Mittendorf EA. Outcomes and predictive factors for salvage therapy after locoregional recurrence treated initially with neoadjuvant chemotherapy and breast conserving therapy. 2012 ASTRO 54th Annual Meeting, Boston, MA, 2012. e-Pub 2012.
Allen LR, Gadgil P, Mittendorf EA, Bassett Jr RL, Hunt KK, Meric-Bernstam F, Babiera G, Kuerer HM, Bedrosian I, Lucci Jr A, Hwang R, Yi M, Ross MI. Nomogram to predict sentinel lymph node involvement in clinically node negative breast cancer patients receiving neoadjuvant chemotherapy. 2012 ASCO Breast Cancer Symposium, San Francisco, CA, 2012. e-Pub 2012.
Yi M, Mittendorf EA, Hwang RF, Babiera GV, Kuerer HM, Crow JR, Lange G, Shah RR, Hunt KK. Are mastectomy rates really increasing? Experiences from a single institution and a population-based data base. 2012 ASCO Annual Meeting, Chicago, IL, 2012. e-Pub 2012.
McCormick B, Moughan J, Hudis C, Kuerer HM, Rakovitch E, Smith BL, Sneige N, Shah A, German I, White JR. RTOG 9804: Low risk breast ductal carcinoma in situ (DCIS): Results from the RTOG Phase III 9804 Trial. 2012 ASTRO 54th Annual Meeting, Boston, MA, 2012. e-Pub 2012.
Rauch GM, Kuerer HM, Benveniste AP, Scoggins ME, Fox PS, Park YM, Lari SA, Hobbs BP, Krishnamurthy S, Yang W. Ductal carcinoma in situ: correlation of estrogen hormone receptor expression on clinicopathological and imaging features. Radiological Society of North American 98th Scientific Assembly and Annual Meeting, 2012, Chicago, IL, 2012. e-Pub 2012.
Akay C, Ueno NT, Chisholm GB, Hortobagyi GN, Woodward WA, Alvarez RH, Lucci JR A, Bedrosian I, Kuerer HM, Hunt KK, Huo L, Babiera G. Primary tumor resection to improve survival and local disease control in stage IV inflammatory breast cancer. 2012 ASCO Annual Meeting, Chicago, IL, 2012. e-Pub 2012.
Elsayegh N, Gutierrez-Barrera AM, Muse KI, Lin HY, Turco D, Litton JK, Kuerer H, Arun BK. Predictors of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ (DCIS) who underwent evaluation for BRCA genetic testing. 2012 ASCO Annual Meeting, Chicago, IL, 2012. e-Pub 2012.
Gainer SM, Krishnamurthy S, Bhattacharyya A, Lodhi A, Hall CS, Bedrosian I, Kuerer HM, Lucci Jr A. Use of disseminated tumor cells to predict outcome in patients with stage I-III breast cancer. ASCO Breast Cancer Symposium, San Francisco, CA, 2012. e-Pub 2012.
Krishnamurthy S, Bishoff FZ, Mayer JA, Kuerer HM, Lodhi A, Bhattacharyya A, Hall CS, Wong K, Pham T, Pircher TJ, Lucci Jr A. Detection of discordant HER2 status by FISH in circulating tumor cells and disseminated tumor cells in early stage breast cancer using a microfluidic-based cell enrichment and extraction platform (OncoCEE TM). 2012 ASCO Annual Meeting, Chicago, IL, 2012. e-Pub 2012.
Roses RE, Kuerer HM, Albarracin CT, Lari SA, Arun BK. Phenotype of pure DCIS in BRCA mutation carriers. Society of Surgical Oncology 65th Annual Cancer Symposium, Orlando, FL, 2012. e-Pub 2012.
Gainer SM, Lodhi AK, Bhattacharyya A, Hall CS, Krishnamurthy S, Kuerer HM, Lucci A. Invasive lobular carcinoma predicts micrometastatic disease in stage I-III breast cancer. 7th Annual Academic Surgical Congress, Las Vegas, NV, 2012. e-Pub 2012.
Allen LR, Babiera G, Tereffe W, Kuerer HM, Bedrosian I, Bloom E, Shaitelman S, Alvarado R. Factors associated with non-receipt of acceleration partial breast irradiation (APBI). San Antonio Breast Cancer Symposium, 2012. e-Pub 2012.
Allen LR, Gadgil PV, Bassett R, Hunt KK, Mittendorf EA, Yi M, Babiera G, Kuerer HM, Ross MI, Bedrosian I, Meric-Bernstam F, Hwang RF. Nomogram to predict sentinel lymph node involvement in patients with clinically node-negative breast cancer receiving neoadjuvant chemotherapy. J Clin Onc 30((suppl 27: abstr 150)), 2012. e-Pub 2012.
Goravanchi F, Kowalski A, Kee S, Lucci A, Gottumukkala V, Robb G, Berger J, Kuerer H. Outpatient breast surgery is safe: Recent experience with 2,872 patients at M. D. Anderson Cancer Center. 16th World Congress of the SIS and the 29th National Congress of the Spanish Society of Senology and Breast Disease, 2011. e-Pub 2011.
Mittendorf EA, Buchholz TA, Tucker SL, Meric-Bernstam F, Kuerer HM, Gonzalez-Angulo AM, Bedrosian I, Babiera G, Yi M, Ross MI, Hortobagyi GN, Hunt K. Impact of chemotherapy timing on local regional failures in breast cancer patients undergoing breast conserving therapy. ASCO 2011 Breast Cancer Symposium, San Francisco, CA Abstract #86506, 2011. e-Pub 2011.
Yi M, Mittendorf EA, Buchholz TA, Sahin AA, Kuerer HM, Luo S, Bilimoria KY, Crow J, Cormier NJ, Gonzalez-Angulo AM, Buzdar A, Hortobagyi GN, Hunt K. Novel staging system for disease-specific survival in breast cancer patients treated with surgery as the first intervention: Time to modify current AJCC staging. ASCO 2011 Breast Cancer Symposium, San Francisco, CA, 2011. e-Pub 2011.
Hall C, Krishnamurthy S, Lodhi A, Bhattacharyya, Anderson A, Kuerer HM, Bedrosian I, Lucci A. Bone marrow stromal-derived growth factor-1 and interluekin-8 levels are increased in stage I-III breast cancer patients with disseminated tumor cells. American Society of Oncology 47th Annual Meeting, Chicago, IL, 2011. e-Pub 2011.
Veerapong J, Boughey J, Mittendorf E, Harrell R, Bassett R, Ross M, Yi M, Meric-Bernstam F, Babiera G, Kuerer H, Lucci A, Bedrosian I, Brodt J, Jakub J, Hunt K, Hwang R. A validated risk assessment of sentinel lymph node involvement in breast cancer patients. Society of Surgical Oncology 64th Annual Cancer Symposium 2011, 2011. e-Pub 2011.
Kowalski A, Goravanchi F, Kuerer H, Milbourne A, Parris R, Kee S, Gottumukkala V, Adalsteinsson S. Outpatient breast surgery in early pregnancy-breast cancer patients is optimized using paravertebral block (pvb) anesthesia. 16th World Congress of the SIS and the 29th National Congress of the Spanish Society of Senology and Breast Diseases, 2011. e-Pub 2011.
Kronowitz SJ, Tereffe W, Hunt K, Kuerer HM, Valero V, Robb GL, Feng L, Buchholz TA. A multidisciplinary protocol for planned skin-preserving delayed breast reconstruction for patients with locally advanced breast cancer requiring postmastectomy radiation therapy: 3-year follow-up. American Society of Clinical Oncology 47th Annual Meeting, Chicago, IL, 2011. e-Pub 2011.
Arthur DW, Vicini FA, Beitsch PD, Kuerer H, Haffty BG, Keisch M, Lyden M. Six-year analysis of treatment related toxicities by the American Society of Breast Surgeons MammoSite breast brachytherapy registry trial in patients treated with accelerated partial breast irradiation. ASTRO (American Society of Therapeutic Radiation and Oncology) 53rd Annual Meeting, Miami Beach, FL, 2011. e-Pub 2011.
Elsayegh N, Bayraktar S, Gutierrez-Barrera AM, Lin H, Kuerer HM, Muse KI, Ready K, Litton JK, Meric-Bernstam F, Hortobagyi GN, Arun B. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with DCIS. American Society of Clinical Oncology 47th Annual Meeting, Chicago, IL, 2011. e-Pub 2011.
Krishnamurthy S, Bischoff FZ, Mayer JA, Wong K, Mikolajczyk S, Pham T, Kuerer HM, Lodhi A Bhattacharyya A, Hall C, Lucci Jr A. Detection of HER2 status of circulating tumor cells and disseminated tumor cells using a microfluidic platform (cell enrichment and extraction technology, CEE). American Society of Clinical Oncology 47th Annual Meeting, Chicago, IL, 2011. e-Pub 2011.
Yi M, Meric-Bernstam F, Kuerer HM, Hwang RF, Bedrosian I, Mittendorf EA, Rourke L, Hunt KK. Role of completion axillary lymph node dissection for sentinel node-positive breast cancer patients. American Society of Breast Surgeons, Las Vegas, NV, 2010. e-Pub 2010.
Sharma R, Rourke LL, Kronowitz SJ, Oh JL, Lucci A, Litton JK, Meric-Bernstam F, Robb GL, Babiera GV, Mittendorf EA, Hunt KK, Kuerer HM. Incidence and management of local-regional recurrence (LRR) following immediate breast reconstruction in patients with 0 and 1 to 3 positive lymph nodes treated without post-mastectomy radiation therapy (PMRT). American Society of Breast Surgeons 11th Annual Meeting, Las Vegas, NV, 2010. e-Pub 2010.
Kang T, Yi M, Hunt KK, Babiera GV, Kuerer H, Bedrosian I, Mittendorf EA, Hwang RF, Lucci A, Meric-Bernstam F. Does blue dye contribute to the success of sentinel node mapping for breast cancer?. American Society of Breast Surgeons 11th Annual Meeting, Las Vegas, NV, 2010. e-Pub 2010.
Jeruss JS, Kuerer HM, Beitsch PD, Vicini F, Keisch M. Update on DCIS outcomes from the American Society of Breast Surgeons MammoSite Clinical Trial Registry. The Society of Surgical Oncology 63rd Annual Cancer Symposium, St. Louis, MO, 2010. e-Pub 2010.
Sharma R, Bedrosian I, Lucci A, Hwang RF, Rourke LL, Buchholz TA, Qiao W, Meric-Bernstam F, Gonzalez-Angulo AM, Kronowitz SJ, Babiera GV, Mittendorf EA, Krishnamurthy S, Hunt KK, Kuerer HM. Present day local-regional recurrence rates (LRR) in patients with T1 and T2 breast cancer (BC) with 0 and 1 to 3 lymph node (LN) metastases following mastectomy without radiation. The Society of Surgical Oncology 63rd Annual Cancer Symposium, St. Louis, MO, 2010. e-Pub 2010.
Kuerer HM. Reconstruction and radiotherapy: The MD Anderson Approach. The Royal Australasian College of Surgeons, Perth '10 Annual Scientific Congress, Perth, Australia. ANZ J Surg BS22:80, 2010. e-Pub 2010.
Kuerer HM. The role of preoperative systemic therapy in breast cancer management. The Royal Australasian College of Surgeons, Perth '10 Annual Scientific Congress, Perth, Australia. ANZ J Surg BS23:80, 2010. e-Pub 2010.
Kuerer HM. DCIS: State of science, current controversies and planned clinical trials. The Royal Australasian College of Surgeons, Perth '10 Annual Scientific Congress, Perth, Australia. ANZ J Surg BS24:80, 2010. e-Pub 2010.
Kuerer HM. Satisfaction and balance in surgical oncology. The Royal Australasian College of Surgeons, Perth, Australia. ANZ J Surg BS25:80, 2010. e-Pub 2010.
Gainer S, Lodhi A, Krishnamurthy S, Jackson S, Hall C, Andreopoulou E, Singh B, Bedrosian I, Meric-Bernstam F, Kuerer H, Hunt K, Cristofanilli M, Lucci A. Predictors of persistent micrometastatic disease after neoadjuvant chemotherapy. 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 2009. e-Pub 2009.
Dominici LS, Negron-Gonzalez V, Buzdar AU, Lucci A, Mittendorf EA, Le-Petross H, Babiera G, Meric-Bernstam F, Hunt KK, Kuerer HM. Eradication of axillary lymph node metastases occurs in 74% of patients receiving trastuzumab-based neoadjuvant systemic therapy for HER2 positive breast cancer. 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 2009. e-Pub 2009.
Goyal S, Vicini F, Beitsch PD, Keisch M, Kuerer HM, Lyden M, Haffty BG. Low risk ductal carcinoma in situ (DCIS) treated with breast conserving surgery & accelerated partial breast irradiation (APBI): comparison of the Mammosite Registry Trial with Intergroup Study E5194. 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 2009. e-Pub 2009.
Streeter OE, Benitez PR, Vicini FA, Mehta VK, Quiet CA, Kuske RR, Hayes MK, Arthur DW, Kuerer HM, Strom EA, Freedman GM, Keisch ME, DiPetrillo TA, Khan DC, Hudes RS, Groshen SG, Silverstein MJ. 3-year follow-up on the partial breast irradiation trial for DCIS using the MammoSite brachytherapy balloon catheter. 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 2009. e-Pub 2009.
Krishnamurthy S, Tang S, Wang X, Lucci A, Kuerer HM, Babiera G, Bedrosian I, Hunt KK, Meric-Bernstam F. Utility of one step nucleic acid amplification (OSNA) assay for comprehensive examination of axillary lymph nodes in breast cancer. 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 2009. e-Pub 2009.
Kronowitz SJ, Lam C, Lance S, Tereffe W, Hunt KK, Kuerer HM, Valero V, Robb GL, Buchholz T. A multidisciplinary protocol for skin preserving delayed breast reconstruction after postmastectomy radiation therapy for patients with locally advanced breast cancer: 6 year follow up. American Association of Plastic Surgeons Annual Meeting, Toronto, Canada, 2009. e-Pub 2009.
Dominici LS, Mittendorf EA, Liu J, Kuerer HM, Hunt KK, Brewster A, Babiera G, Meric-Bernstam F, Yu TK, Bedrosian I. Implications of constructed biologic subtype and its relationship to locoregional recurrent following mastectomy. American Society of Clinical Oncology, San Francisco, CA, 2009. e-Pub 2009.
Bedrosian I, Babiera GV, Mittendorf EA, Kuerer HM, Pantoja L, Hunt KK, Krishnamurthy S, Meric-Bernstam F. A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. American College of Surgeons 95th Annual Clinical Congress, Chicago, IL, 2009. e-Pub 2009.
Wagner JL, Warneke C, Bedrosian I, Mittendorf E, Babiera G, Kuerer H, Hunt K, Yang W, Sahin A, Meric-Bernstam F. Modest delays in primary surgical treatment are not associated with significant progression of tumor size in breast cancer patients. American Society of Clinic Oncology, Orlando, FL, 2009. e-Pub 2009.
Kowalski AM, Kuerer HM, Milbourne A, Goravanchi F, Parris R, Adalsteinsson ST. Paravertebral block for breast cancer surgery: A case series report. SOAP (Society of Obstetrical Anesthesia & Perinatology) 41st Annual Meeting, Washington, DC, 2009. e-Pub 2009.
Caudle AS, Gonzalez-Angulo AM, Hunt KK, Liu P, Pusztai L, Symmans WF, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. American Society of Clinical Oncology, Orlando, FL, 2009. e-Pub 2009.
Dominici LS, Kuerer HM, Babiera G, Hahn KM, Perkings G, Middleton L, Ramirez MM, Yang W, Hortobagyi GN, Theriault RL, Litton JK. Wound applications from surgery in pregnancy-associated breast cancer (PABC). The American Society of Breast Surgeons, San Diego, CA, 2009. e-Pub 2009.
Hunt KK, Yi M, Mittendorf EA, Guerrero C, Babiera GV, Bedrosian I, Hwang RF, Kuerer HM, Ross, MI, Meric-Bernstam F. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer. American Surgical Association, Indian Wells, CA, 2009. e-Pub 2009.
Wagner JL, Boughey JC, Babiera GV, Kuerer HM, Meric-Bernstam F, Singletary SE, Hunt KK, Middleton LP, Bedrosian I. Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer. American Society of Clinical Oncology Breast Cancer Symposium, Washington, DC, 2008. e-Pub 2008.
Min Y, Buchholz TA, Meric-Bernstam F, Bedrosian I, Hwang R, Ross MI, Kuerer H, Feig B, Lucci A, Hunt KK. Ipsilateral Breast Tumor Relapse after Breast Conservation Therapy. American Society of Clinical Oncology Breast Cancer Symposium, Washington, DC, 2008. e-Pub 2008.
Shinde SS, Forman M, Kuerer HM, Yan K, Pusztai L, Hunt KK, Symmans WF. Triple negative breast cancer phenotype is independently associated with increased parity and shorter breastfeeding duration. American Society of Clinical Oncology Breast Cancer Symposium, Washington, DC, 2008. e-Pub 2008.
Beitsch PD, Vicini F, Haffty B, Kuerer HM, Zannis V, Whitworth P, Fine R. Recurrence and Survival in the American Society of Breast Surgeons (ASBS) MammoSite RTS Registry Trial. American Society for Therapeutic Radiology and Oncology, Boston, MA, 2008. e-Pub 2008.
Symmans WF, Hatzis C, Liedtke C, Desmedt C, Valero V, Kuerer HM, Hortobagyi GN, Piccart-Gebhart M, Pusztai L, Sotiriou C. Genomic Grade Index (GGI) predicts pathologic response to preoperative chemotherapy in breast cancer. American Society of Clinical Oncology, Chicago, IL, 2008. e-Pub 2008.
Hubbard R, Peintinger F, Liedtke C, Hatzis C, Kuerer HM, Valero V, Buzdar A, Hortobagyi GN, Pusztai L, Symmans WF. Residual cancer burden after neoadjuvant taxane-anthracycline chemotherapy is independently prognostic in every subset of breast cancer. American Society of Clinical Oncology, Chicago, IL, 2008. e-Pub 2008.
Nelson J, Beitsch P, Vicini F, Quiet C, Garcia D, Snider H, Gittleman M, Zannis V, Whitworth P, Fine R, Kuerer HM. Four year Clinical Update from the American Society of Brest Surgeons MammoSite Brachytherapy Trial. American Society of Breast Surgeons, New York, NY, 2008. e-Pub 2008.
Yi M, Meric-Bernstam F, Middleton LP, Arun BK, Bedrosian I, Babiera G, Hwang RF, Feig BW, Kuerer HM, Lucci A, Ross MI, Hunt KK. Predictors of Contralateral Breast Cancer in Patients with Unilateral Breast Cancer. American Society of Breast Surgeons, New York, NY, 2008. e-Pub 2008.
Lang JE, Tereffe W, Rao R, Feng L, Meric-Bernstam F, Bedrosian I, Kuerer HM, Singletary E, Hunt KK, Hortobagyi G, Babiera GV. Response to Neoadjuvant Chemotherapy (NC) Prior to Resection of the Primary Tumor in Stage IV Breast Cancer May Help Select for Improved Survival. American Society of Breast Surgeons, New York, NY, 2008. e-Pub 2008.
Boughey JC, Goravanchi F, Parris RN, Kee SS, Frenzel JC, Kowalski A, Hunt KK, Ames FC, Kuerer HM, Lucci A. A Prospective Randomized Trial of Paravertebral Block for Breast Surgery. American Society of Breast Surgeons, New York, NY, 2008. e-Pub 2008.
Boughey JC, Goravanchi F, Parris RN, Kee SS, Frenzel JC, Hunt KK, Ames F, Kuerer HM. Improved post-operative pain management of Breast Oncologic Surgeries with Paravertebral Block. American Society of Regional Anesthesia and Pain Medicine, Boca Raton, FL, 2007. e-Pub 2007.
Fearmonti RM, Batista LI, Meric-Bernstam F, Hunt KK, Bedrosian I, Kuerer HM, Singletary SE, Babiera GV. Margin width correlates with residual disease at re-excision for ductal carcinoma in situ (DCIS) of the breast. American Society of Clinical Oncology, Chicago, IL, 2007. e-Pub 2007.
Beitsch PD, Vicini F, Quiet C, Whitacre E, Snider H, Gittleman M, Zannis V, Kuerer HM, Whitworth P, Fine R. Complications and efficacy of mammosite radiation therapy system (RTS) accelerated partial breast irradiation (APBI) at three-years. American Society of Clinical Oncology, Chicago, IL, 2007. e-Pub 2007.
Boughey JC, Garrett B, Harker L, Middleton L, Babiera G, Meric-Bernstam F, Kuerer HM, Lucci A, Hunt KK, Bedrosian I. Neoadjuvant chemotherapy in invasive lobular carcinoma does not improve rates of breast conservation. American Society of Clinical Oncology, Chicago, IL, 2007. e-Pub 2007.
Fearmonti RM, Batista LI, Meric-Bernstam F, Bedrosian I, Kuerer HM, Singletary SE, Hunt KK, Warneke C, Babiera GV. Association of margin width residual disease for ductal carcinoma in situ (DCIS) of the breast. American Society of Clinical Oncology, Chicago, IL, 2007. e-Pub 2007.
Lang JE, Rao R, Feng L, Meric-Bernstam F, Bedrosian I, Kuerer HM, Singletary SE, Hunt KK, Hortobagyi GN, Babiera GV. Impact on overall survival of primary tumor extirpation in breast cancer patients who present with stage IV disease. American Society of Clinical Oncology, Chicago, IL, 2007. e-Pub 2007.
Mittendorf EA, Sahin A, Tucker SL, Meric-Bernstam F, Yi M, Ames FC, Ross MI, Feig BW, Kuerer HM, Hunt KK. Lymphovascular Invasion and Lobular Histology are strong predictors of detecting isolated tumor cells in sentinel lymph nodes from early stage breast cancer patients. American Society of Clinical Oncology, Chicago, IL, 2007. e-Pub 2007.
Lang J, Rao R, Feng L, Meric-Bernstam F, Bedrosian I, Kuerer HM, Singletary E, Hunt K, Hortobagyi G, Babiera G. An update of the MD Anderson Cancer Center experience: effect of primary tumor extirpation in breast cancer patients who present with Stage IV disease and an intact primary tumor. American Society of Clinical Oncology, Chicago, IL, 2007. e-Pub 2007.
Yi M, Krishnamurthy S, Kuerer HM, Meric-Bernstam F, Bedrosian I, Ross MI, Ames FC, Lucci A, Hunt KK. The Significance of Primary Tumor Characteristics in Predicting Positive Sentinel Lymph Nodes in Ductal Carcinoma in situ or Microinvasive Breast Cancer. American Society of Breast Surgeons, Phoenix, AZ, 2007. e-Pub 2007.
Beitsch PD, Vicini F, Quiet C, Whitacre E, Snider H, Gittleman M, Zannis V, Kuerer HM, Whitworth P, Fine R. Complications and efficacy of MammoSite Radiation Therapy (RTS) accelerated partial breast irradiation (APBI) at three-years. American Society of Clinical Oncology, Chicago, IL, 2007. e-Pub 2007.
Boughey JC, Goravanchi F, Hunt KK, Frenzel J, Kee S, Parris R, Kuerer HM, Ames FC, Lucci A. Paravertebral block in breast surgery: initial experience. American Society of Breast Surgeons, Phoenix, AZ, 2007. e-Pub 2007.
Vo T, Xing Y, Meric-Bernstam F, Symmans FW, Buchholz TA, Ames FC, Kuerer HM, Bedrosian I, Hunt KK. Long-term outcomes for mucinous, medullary, and tubular carcinomas treated with breast conservation therapy. American Society of Breast Surgeons, Phoenix, AZ, 2007. e-Pub 2007.
Robioux A, Buyse M, Buzdar A, Geyer CE, Pajon E, DiNunno L, Fehrenbacher L, Kuerer HM, Liles D, Paik S, Mamounas EP, Wolmark N. Neoadjuvant Chemotherapy with Sequential Weekly Nanoparticle Albumin-Bound Paclitaxel (ABI-007, Abraxene ®) followed by 5-Fluoroaracil, Epirubicin and Cyclophosphamide (FEC) in Locally Advanced Breast Cancer (LABC): A Phase II Trial of the NSABP Foundation Research Group. San Antonio Breast Cancer Conference, San Antonio, TX, 2006. e-Pub 2006.
Peintinger F, Anderson K, Mazouni C, Kuerer HM, Symmans WF, Pusztai L. Correlation between residual cancer volume and MDACC genomic response predictor score in breast cancer patients treated with preoperative chemotherapy. San Antonio Breast Cancer Conference, San Antonio, TX, 2006. e-Pub 2006.
Haffty BG, Vicini FA, Beitsch P, Quiet C, Keleher A, Garcia D, Snider H, Gittleman M, Zannis V, Kuerer HM, Whitacre E, Whitworth P, Fine R, Keisch M. Timing of chemotherapy following MammoSite breast brachytherapy: Analysis of the American Society of Breast Surgeons (ASBS) MammoSite breast brachytherapy registry trial. San Antonio Breast Cancer Conference, San Antonio, TX, 2006. e-Pub 2006.
Streeter O, Benitez P, Vicini F, Vivek M, Quiet C, Kuske R, Hayes M, Arthur D, Kuerer HM, Strom E, Freedman G, Keisch M, DiPetrillo T, Khan D, Hudes R. Partial breast irradiation for ductal carcinoma in situ using MammoSite brachytherapy. San Antonio Breast Cancer Conference, San Antonio, TX, 2006. e-Pub 2006.
Yen TW, Kuerer HM, Otteson RA, Rouse L, Niland JC, Edge SB, Theriault RL, Weeks JC. Impact of randomized clinical trial results on the use of tamoxifen (TAM) following breast surgery for ductal carcinoma in situ (DCIS) in the National Comprehensive Cancer Network (NCCN). San Antonio Breast Cancer Symposium, San Antonio, TX, 2006. e-Pub 2006.
Symmans WF, Peitinger F, Hatzis C, Rajan R, Kuerer HM, Valero V, Assad L, Hennessy B, Green M, Buzdar A, Singletary E, Hortobagyi GN, Pusztai L. A New Measurement Of Residual Cancer Burden To Predict Survival After Neoadjuvant Chemotherapy. American Society of Clinical Oncology, Atlanta, GA, 2006. e-Pub 2006.
Al-Refaie WB, Cormier JN, Xing Y, Hunt KK, Fearmonti G, Ghandi R, Kuerer HM, Meric-Bernstam F, Bedrosian I, Lucci A. Initial biopsy procedure for breast cancer diagnosis influences number of surgical procedures and cost of care. American Society of Clinical Oncology, Atlanta, GA, 2006. e-Pub 2006.
Vicini F, Beitsch P, Quiet C, Keleher A, Garcia D, Snider H, Gittleman M, Zannis V, Kuerer HM, Whitacre E, Whitworth P, Fine R, Haffty B, Arrambide S. Two Year Analysis of Treatment Efficacy and Cosmesis by the American Society of Breast Surgeons (ASBS) MammoSite Breast Brachytherapy Registry Trial in Patients Treated With Accelerated Partial Breast Irradiation (APBI). American Society of Clinical Oncology, Atlanta, GA, 2006. e-Pub 2006.
Jeruss JS, Ayers GD, Cristofanilli M, Ross MI, Babiera G, Meric-Bernstam F, Kuerer HM, Feig BW, Yi M, Hunt KK. Positive sentinel nodes after neoadjuvant chemotherapy: what factors predict additional disease in the axilla?. American Society of Clinical Oncology, Atlanta, GA, 2006. e-Pub 2006.
Boughey JC, Peitinger F, Meric-Bernstam F, Perry A, Hunt KK, Babiera GV, Bedrosian I, Buzdar AU, Pusztai L, Kuerer HM. Impact of Pre-operative versus Post-operative Chemotherapy on the Extent and Number of Surgical Procedures in Patients Treated on Randomized Clinical Trials for Breast Cancer. 126th Annual Meeting of the American Surgical Association, Boston, MA, 2006. e-Pub 2006.
Rosenkranz KM, Hartman K, Ghonimi E, Kuerer HM, Singletary S, Hunt K, Meric-Bernstam M, Lucci A, Hwang R, Bedrosian I, Feig B, Ross M, Ames F, Babiera GV. Breast cancer in the very elderly: Treatment patterns in a tertiary cancer center. American Society of Breast Surgeons Annual Meeting, Baltimore, MD, 2006. e-Pub 2006.
Benitez PR, Streeter O, Vicini F, Mehta V, Quiet C, Kuske R, Hayes MK, Arthur D, Kuerer HM, Freedman G, Keisch M, DiPetrillo T, Kahn D, Hudes R. Preliminary results and evaluation of MammoSite balloon brachytherapy for partial breast irradiation for pure ductal carcinoma in situ: A phase II clinical study. American Society of Breast Surgeons Annual Meeting, Baltimore, MD, 2006. e-Pub 2006.
Boughey JC, Hunt KK, Ames FC, Babiera GV, Bedrosian I, Feig BW, Hwang RF, Kuerer HM, Singletary SE, Ross MI. Sentinel Lymph Node Surgery in Locally Recurrent Breast Cancer. Society of Surgical Oncology, San Diego, CA, 2006. e-Pub 2006.
Vicini FA, Beitsch P, Quiet C, Keleher A, Garcia D, Snider H, Gittleman M, Zannis V, Kuerer HM, Whitacre E, Whitworth P, Fine R, Haffty B. One-year analysis of cosmesis and treatment efficacy by the American Society of Breast Surgeons (ASBS) MammoSite breast brachytherapy registry trial in patients treated with accelerated partial breast irradiation (APBI). San Antonio Breast Cancer Symposium, San Antonio, TX, 2005. e-Pub 2005.
Zager JS, Al-Refaie WB, Khakpour N, Yen T, Stephens ELT, Hunt KK, Kuerer HM, Singletary ES, Ross MI, Babiera GV. The Utility Of Ultrasound In The Surgical Management Of Ductal Carcinoma In-Situ. San Antonio Breast Cancer Symposium, San Antonio, TX, 2005. e-Pub 2005.
Al-Refaie WB, Liu D, Feig BW, Hunt KK, Singletary SE, Ames FC, Buchholz T, Kuerer HM, Ross MI, Ghonaimi E, Perry A, Babiera GV. Travel Distance to a Radiotherapy Facility Does Not Predict Mastectomy for Early-Stage Breast Cancer. The Southern Surgical Association Annual Meeting, Hot Springs, VA, 2005. e-Pub 2005.
Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Bernstam F, Ames F, Kuerer HM, Ross MI, Singletary SE, Babiera GV, Feig BW, Hunt KK. Low local-regional failure rates in selected breast cancer patients with tumor-positive sentinel nodes who do not undergo completion axillary dissection. San Antonio Breast Cancer Conference, San Antonio, TX, 2005. e-Pub 2005.
Huflejt M Blixt O, Vuskovic M, Xu H, Shaw L, Reuben J, Kuerer HM, Cristofanilli M. Glycan array identifies specific signatures of anti-glycan autoantibodies in sera of breast cancer patients: diagnostic, prognostic and therapeutic opportunities. San Antonio Breast Cancer Symposium, San Antonio, TX, 2005. e-Pub 2005.
Streeter OE, Vicini FA, Quiet C, Mehta V, Kuerer HM, Strom E, Arthur D, Freedman G, Keisch M, Hayes MK, DiPetrillo TA, Hudes R. A Phase II Multi-Institutional trial evaluating the MammoSite RTS as the sole radiation technique for patients with Ductal Carcinoma In Situ (DCIS). Submitted for presentation at ASTRO's 47th Annual Meeting, Denver, CO, 2005. e-Pub 2005.
Krishnamurthy S, Fackler M, Sukumar S, Hayes K, Hunt KK, Kuerer HM. Emerging insights in the usage of ancillary molecular tests with nipple aspirate fluid cytology. 31st European Congress of Cytology, Paris, France, 2005. e-Pub 2005.
Huflejt M, Blixt O, Vuskovic M, Xu H, Reuben J, Kuerer H, Cristofanilli M. Anti-glycan autoantibodies as markers of malignancy status. The 5th International Symposium on Minimal Residual Cancer, San Francisco, CA, 2005. e-Pub 2005.
Kawase K, Gayed IW, Meric-Bernstam F, Ross MI, Babiera GV, Kuerer HM, Singletary E, Akins J, Yi M, Feig BW, Ames FC, Hunt KK. Lymphatic Drainage Patterns from Breast Cancer: A Large Cancer Center Experience. Annual meeting of the Society of Nuclear Medicine, Toronto, Canada, 2005. e-Pub 2005.
Khakpour N, Lucci A, Ross MI, Kuerer HM, Hunt KK. Sentinel Lymph Node Dissection Is as Effective as Axillary Lymph Node Dissection for Axillary Staging and Control in Patients with Breast Cancer. American Society of Clinical Oncology Annual Meeting, Orlando, FL, 2005. e-Pub 2005.
Adepoju L, Symmans WF, Babiera GV, Singletary SE, Sahin A, Buchholz TA, Hunt KK, Meric-Bernstam F, Ross MI, Ames FA, Kuerer HM. The clinical impact of proliferative high-risk lesions presenting concurrently with ductal carcinoma in situ (DCIS) in patients (pts) treated with breast conserving therapy (BCT). American Society of Clinical Oncology Annual Meeting, Orlando, FL, 2005. e-Pub 2005.
Kronowitz SJ, Kuerer HM, Hunt KK, Buchholz TA, Strom EA, Perkins GH, Meric-Bernstam F, Ross MI, Robb G. Delayed-delayed breast reconstruction. American Association of Plastic Surgeons Annual Meeting, Scottsdale, AZ, 2005. e-Pub 2005.
Johnson P, Gwyn K, Gordon N, Middleton L, Kuerer HM, Perkins G, Yang W, Hortobagyi G, Theriault R. The Treatment of Pregnant Women with Breast Cancer and the Outcomes of the Children Exposed to Chemotherapy In Utero. American Society of Clinical Oncology Annual Meeting, Orlando, FL, 2005. e-Pub 2005.
Sneige N, Gong Y, Lamey J, Valero V, Babiera G, Kuerer HM, Hortobagyi G, Arun B. Baseline proliferation markers and cytopathologic findings in breast epithelium of women at increased risk for breast cancer. Annual Proceedings ASCO, Orlando, FL, 2005. e-Pub 2005.
Li J, Yu X, Zhao J, Kuerer HM, Lane J, Ali S, Schilling E, Krishnamurthy S, Khan SA, Sukumar S, Chan DW. Biomarker discovery for breast cancer in nipple aspiration and ductal lavage fluid. Proceedings of the American Association for Cancer Research, Anaheim, CA, 2005. e-Pub 2005.
Khakpour N, Hunt KK, Ross MI, Kuerer HM, Yi M, Lucci A. Does sentinel lymph node dissection provide axillary control equal to complete axillary dissection in breast cancer patients with lobular histology?. American Society of Breast Surgeons, Los Angeles, CA, 2005. e-Pub 2005.
Al-Refaie WB, Kuerer HM, Khuwaja A, Tseng JF, Hunt KK, Singletary E, Ames FC, Meric-Bernstam F, Ross MI, Feig BW, Babiera GV. Patient Driven Factors Are Determinants In Treatment Choice For Early Breast Cancer: Results from a National Comprehensive Cancer Center. American Society of Breast Surgeons, Los Angeles, CA, 2005. e-Pub 2005.
Khakpour N, Zager JS, Yen T, Stephens T, Kuerer HM, Meric F, Singletary ES, Ross MI, Hunt KK, Babiera GV. The Role of Ultrasound in Surgical Management of Patients Diagnosed with Ductal Carcinoma in-situ of the Breast. American Society of Breast Surgeons, Los Angeles, CA, 2005. e-Pub 2005.
Rao R, Kuerer HM, Khuwaja A, Hunt KK, Singletary E, Ames FC, Meric-Bernstam F, Ross MI, Feig BW, Babiera GV. Surgical intervention for the primary tumor improves progression-free survival in patients initially presenting with Stage IV breast cancer. The Society of Surgical Oncology Annual Cancer Symposium, Atlanta, GA, 2005. e-Pub 2005.
Krishnamurthy S, Fackler M, Sukumar S, Hayes K, Hunt K, Kuerer HM. Intraductal fluid cytology: emerging insight in the use of ancillary genetic tests. Fourth International Symposium on the Intraductal Approach to Breast Cancer, Santa Barbara, CA, 2005. e-Pub 2005.
Lambert LA, Hunt KK, Hwang RF, Ross MI, Ayers GD, Kuerer HM, Singletary SE, Babiera G, Ames FC, Feig B, Krishnamurthy S, Meric-Bernstam F. External Validation of a Breast Cancer Nomogram for Predicting Additional Nodal Metastases After Positive Sentinel Node Biopsy. The Society of Surgical Oncology Annual Cancer Symposium, Atlanta, GA, 2005. e-Pub 2005.
Pawlik T, Fritsche H, Coombes K, Xiao L, Krishnamurthy S, Hunt K, Pusztai L, Arun B, Hung M, Kuerer HM. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by mass spectrometry. Fourth International Symposium on the Intraductal Approach to Breast Cancer, Santa Barbara, CA, 2005. e-Pub 2005.
Shen J, Mirza NQ, Sahin A, Buchholz TA, Meric-Bernstam F, Kuerer HM, Ross MI, Ames FC, Feig BW, Singletary SE, Babiera GV, Hunt KK. Invasive lobular carcinoma: Clinicopathologic factors that impact extent of disease and margin status. The Society of Surgical Oncology Annual Cancer Symposium, Atlanta, GA, 2005. e-Pub 2005.
Streeter OE, Vicini F, Benitez P, Mehta V, Keisch M, Quiet C, Kuerer HM, Strom E, Freedman GM, DiPetrillo T, Arthur D, Hayes MK, Silverstein M. MammoSite Radiation Therapy System (RTS) as the sole radiation technique for DCIS of the breast after lumpectomy: A phase II trial. Proceedings of the 15th Annual National Interdisciplinary Breast Center Conference, Las Vegas, NV, 2005. e-Pub 2005.
Streeter OE, Vicini F, Mehta V, Quiet C, Kuerer HM, Strom E. DCIS monthly update and poster presentation. Primary Therapy and Early Breast Cancer 9th International Conference, St. Gallen, Switzerland, 2005. e-Pub 2005.
Streeter OE, Vicini F, Mehta V, Quiet C, Kuerer HM, Strom E, Freedman G, Arthur D, DiPetrillo T, Keisch M. MammoSite Radiation Therapy System (RTS) as the sole radiation technique for DCIS of the breast after lumpectomy: A phase II trial. The Breast 14(1 (Supplement)):S33, 2005. e-Pub 2005.
Xing Y, Krishnamurthy S, Meric-Bernstam F Cantor SB, Ross MI, Babiera G, Kuerer HM, Singletary SE, Hunt KK, Cormier JN. Is intraoperative touch imprint cytology of sentinel lymph nodes in patients with breast cancer cost-effective?. San Antonio Breast Cancer Symposium, San Antonio, TX, 2004. e-Pub 2004.
Shen J, Hunt KK, Mirza NQ, Buchholz TA, Babiera GV, Kuerer HM, Ross MI, Ames FC, Feig BW, Singletary SE, Cristofanilli M, Meric-Bernstam F. Predictors of systemic recurrence and disease-specific survival following ipsilateral breast tumor recurrence. San Antonio Breast Cancer Symposium, 12/04, San Antonio, TX, 2004. e-Pub 2004.
Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, Pusztai L, Chen JN, Clarke CH, Arun B, Hung MC, Henry HM. Significant differences in ductal fluid protein expression in healthy women versus those with breast cancer identified by time-of-flight mass spectrometry. San Antonio Breast Cancer Symposium, San Antonio, TX, 2004. e-Pub 2004.
Moranbi P, Middleton LP, Mirza NQ, Vlastos G, Kau SW, Perkins GH, Kuerer HM, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M. Occult breast cancer (OBC), a retrospective analysis of clinico-pathological characteristics and long-tern outcome: the University of Texas M.D. Anderson Cancer Center experience. San Antonio Breast Cancer Symposium, 12/04, San Antonio, TX, 2004. e-Pub 2004.
Vicini FA, Beitsch P, Quiet C, Keleher A, Garcia D, Snider H, Gittleman M, Zannis V, Kuerer HM, Whitacre E, Whitworth P, Fine R, Haffty B. First analysis of patient demographics and technical reproducibility by the American Society of Breast Surgeons (ASBS) MammoSite breast brachytherapy registry trial in 801 patients treated with accelerated partial breast irradiation (APBI). San Antonio Breast Cancer Symposium, San Antonio, TX, 2004. e-Pub 2004.
Shen J, Mirza NQ, Babiera GV, Ross MI, Ames FC, Meric-Bernstam F, Feig B, Singletary SE, Kuerer HM, Hunt KK. Feasibility and accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in breast cancer patients with cytologically proven axillary metastases. San Antonio Breast Cancer Symposium, San Antonio, TX, 2004. e-Pub 2004.
Beitsch P, Vicini F, Kuerer HM, Whitaker E, Fine R. Clinical evaluation of the MammoSite Breast Brachytherapy Catheter: An analysis of technical reproducibility, acute toxicity, and patient demographics by the American Society of Breast Surgeons (ASBS). San Antonio Breast Cancer Symposium, San Antonio, TX, 2004. e-Pub 2004.
Cabioglu N, Hunt KK, Mirza N, Sahin A, Singletary SE, Kuerer HM, Babiera GV, Ross MI, Ames FC, Feig B, Meric-Bernstam F. Intraoperative margin assessment in breast-conserving surgery. San Antonio Breast Cancer Symposium, San Antonio, TX, 2004. e-Pub 2004.
Pusztai L, Rouzier R, Rajan R, Hess KR, Gold D, Stec J, Ayers M, Ross JS, Zhang P, Wagner P, Buchholz TA, Kuerer HM, Buzdar AU, Symmans WF, Hortobagyi GN. Microtubule associated protein Tau is a predictive marker and modulator of response to paclitaxel-containing preoperative chemotherapy in breast cancer. San Antonio Breast Cancer Symposium, San Antonio, TX, 2004. e-Pub 2004.
Cabioglu N, Mirza N, Hunt KK, Buchholz TA, Singletary SE, Kuerer HM, Babiera GV, Ross MI, Ames FC, Feig BW, Barry W, Sahin A, Meric-Bernstam F. Improving local control with breast-conserving therapy: A 27-year single institution experience. San Antonio Breast Cancer Symposium, 2004. e-Pub 2004.
Streeter O, Freedom G, Vicini FA, Silverstein M, Kuerer HM, Matek V. MammoSite Radiation Therapy System (RTS) as the radiation technique for DCIS of the breast after lumpectomy. Radiological Society of North America, Chicago, IL, 2004. e-Pub 2004.
Morandi P, Whitman G, Gonzalez-Angulo AM, Revathyh IB, Sneige N, Booser DJ, Kuerer HM, Buchholz TA, Hortobagyi GN, Cristofanilli M. Inflammatory breast carcinoma (IBC): multiple imaging modalities for monitoring response and prediction of pathological residual disease after primary chemotherapy. European Society of Medical Oncology, Vienna, Austria, 2004. e-Pub 2004.
Alpert TE, Kuerer HM, Arthur DW, Haffty BG. Ipsilateral breast tumor recurrence (IBTR) following breast conservation therapy: outcomes of salvage mastectomy (SM) vs. salvage breast conserving surgery (SBCS) and prognostic factors for salvage breast preservation. American Society of Therapeutic Radiology and Oncology, Atlanta, GA, 2004. e-Pub 2004.
Andtbacka RHI, Babiera G, Singletary E, Hunt KK, Meric-Bernstam F, Feig B, Ames F, Ross M, Dejesus Y, Kuerer HM. The incidence, prophylaxis and treatment of venous thromboembolism in patients undergoing breast cancer surgery. American Society of Clinical Oncology Annual Meeting, New Orleans, LA, 2004. e-Pub 2004.
Shen J, Hunt KK, Mirza NQ, Krishnamurthy S, Singletary SE, Kuerer HM, Meric-Bernstam F, Feig B, Ross MI, Babiera GV. Intramammary lymph node metastases are an independent predictor in breast cancer outcomes. American Society of Clinical Oncology Annual Meeting, New Orleans, LA, 2004. e-Pub 2004.
Hennessy BT, Kuerer HM, Sahin A, Buzdar AU, Kau S, Hortobagyi G, Valero V. Long-term outcome of patients with complete eradication of cytologically proven axillary node metastases after primary chemotherapy: The University of Texas M. D. Anderson Cancer Center Experience. Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, 2004. e-Pub 2004.
Xing Y, Ding M, Cox D, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy following preoperative chemotherapy in patients with operable breast cancer. American Society of Clinical Oncology, New Orleans, LA, 2004. e-Pub 2004.
Kronowitz S, Hunt K, Kuerer HM, Robb G. The impact of sentinel node biopsy on the evolution of autologous breast reconstruction. Annual Meeting of the American Association of Plastic Surgeons, Baltimore, MD, 2004. e-Pub 2004.
Cormier JN, Xing Y, Krishnamurthy S, Meric-Bernstam F, Cantor SB, Ross MI, Feig BW, Ames FC, Babiera G, Kuerer HM, Singletary SE, Hunt KK. Is Intraoperative Touch Imprint Cytology of Sentinel Lymph Nodes in Patients with Breast Cancer Cost-Effective?. Society of Surgical Oncology, New York, NY, 2004. e-Pub 2004.
Li J, Zhao J, Kuerer HM, Lane J, Tsangaris T, Ali S, Pedram A, Zhang Z, Sukumar S, Chan DW. Detection of breast cancer by proteomic analysis of breast fluid using SELDI mass spectrometry. 95th Annual Meeting of the American Association of Cancer Research, Orlando, FL, 2004. e-Pub 2004.
Kawase K, Ames FC, Babiera GV, Feig BW, Kuerer HM, Meric-Bernstam, F, Ross MI, Singletary SE, Mirza NQ, Sahin AA, Gayed IW, Buchholz TA, Akins JS, Hunt KK. Lymphatic drainage pattern predicts sentinel lymph node status. American Society of Breast Surgeons, Las Vegas, NV, 2004. e-Pub 2004.
Yen T, Mirza N, Hunt K, Babiera G, Ross M, Singletary SE, Meric-Bernstam F, Feig B, Ames F, Kuerer HM. Selective Sentinel Lymph Node Evaluation in Patients with Presumed Ductal Carcinoma in Situ: Results and Recommendations from a Comprehensive Cancer Center. Society of Surgical Oncology, New York, NY, 2004. e-Pub 2004.
Zhang H, Zhai J, Chagpar A, Mirza N, Kuerer HM, Middleton LP, Whitman GJ, Buchholz TA, Hunt KK, Sahin AA. Amount of Tumor Present In Core Needle Biopsy (CNB) Samples: A Significant Predictor of Margin Status in Subsequent Breast Conserving Surgery (BCS) Specimens in Patients with Ductal Carcinoma In Situ (DCIS). United States and Canadian Academy of Pathology Annual Meeting, Vancouver, British Columbia, 2004. e-Pub 2004.
Goldflam K, Gershenwald JE, Hunt KK, Singletary SE, Mirza N, Arun B, Babiera GV, Kuerer HM, Ross MI, Ames FC, Feig BW, Sahin AA, Meric-Bernstam F. Contralateral Prophylactic Mastectomy: Efficacy and Determinants of Significant Histologic Findings. Society of Surgical Oncology, New York, NY, 2004. e-Pub 2004.
Buchholz TA, Garg A, Esteva FJ, Kuerer HM, Hortobagyi GN, Singletary SE, Sahin AA. Lack of bcl-2 and bax expression correlates with pathological complete response to doxorubicin-based neoadjuvant chemotherapy in breast cancer. San Antonio Breast Cancer Symposium, San Antonio, TX, 2003. e-Pub 2003.
Chen AM, Meric F, Hunt KK, Thamse HD, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig B, Hortobagyi GN, Sahin AA, Perkins GH, Schechter NR, Buchholz TA. Breast –conserving therapy after neoadjuvant chemotherapy: the M. D. Anderson Cancer Center experience. San Antonio Breast Cancer Symposium, San Antonio, TX, 2003. e-Pub 2003.
Buchholz TA, Ang KK, Tu X, Kuerer HM, Esteva FJ, Hortobagyi GN, Singletary SE, Sahin AA. Epidermal growth factor receptor expression is a prognostic but not predictive factor in breast cancer patients treated with doxorubicin-based neoadjuvant chemotherapy. San Antonio Breast Cancer Symposium, San Antonio, TX, 2003. e-Pub 2003.
Chagpar A, Mirza AN, Buzdar AU, Dempsey P, Ames FC, Babiera GV, Feig BW, Hunt KK, Kuerer HM, Meric-Bernstam F, Ross MI, Singletary SE. Accuracy of physical examination (PE), ultrasonography (US) and mammography (M) in predicting residual pathological tumor size in patients treated with neoadjuvant chemotherapy (NAC) for breast cancer. San Antonio Breast Cancer Symposium, San Antonio, TX, 2003. e-Pub 2003.
Hunt KK, Kuerer HM, Meric F, Mirza N, Feig BF, Ames F, Babiera G, Singletary, E, Buchholz T, Akins J, Francis A, Elliott M, Buzdar A, Ross M. Sentinel Lymph Node Biopsy is Accurate for Lymph Node Evaluation Following Preoperative Chemotherapy for Breast Cancer. Southern Surgical Association Annual Meeting, Galveston, TX, 2003. e-Pub 2003.
Kawase K, DiMaio DJ, Tucker SL, Ross MI, Feig BW, Ames F, Kuerer HM, Meric-Bernstam F, Singletary SE, Babiera G, Buchholz TA, Hunt KK. Paget’s disease of the breast: a long-term follow-up study. San Antonio Breast Cancer Symposium, San Antonio, TX, 2003. e-Pub 2003.
Garg A, Strom EA, McNeese MD, Buzdar AU, Hortobagyi GN, Kuerer HM, Perkins G, Singletary SE, Hunt KK, Sahin AA, Schechter N, Valero V, Tucker SL, Buchholz TA. Clinical stage T3 disease and pathologic involvement of four or more lymph nodes predict for local-regional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiation. San Antonio Breast Cancer Symposium, San Antonio, TX, 2003. e-Pub 2003.
Shahar, KH, Hunt, KK, Thames HD, Ross MI, Perkins GH, Kuerer HM, Strom EA, McNeese MD, Meric F, Schechter NR, Sahin AA, Buchholz TA. Factors predictive of having four or more positive axillary lymph nodes in patients with involved sentinel lymph nodes: implications for selection of radiation treatment fields. San Antonio Breast Cancer Symposium, San Antonio, TX, 2003. e-Pub 2003.
Krishnamurthy S, Sneige N, Hunt KK, Marcy S, Babiera GV, Cristofanilli M, Singletary SE, Kuerer HM. Cytology of nipple aspiration fluid (NAF) from breasts in women at high risk of developing breast carcinoma: Report of 88 cases. American Society of Cytopathology, Orlando, FL, 2003. e-Pub 2003.
Shahar KH, Buchholz TA, Delpassand E, Sahin A, Ross MI, Ames F, Kuerer HM, Feig BW, Meric F, Babiera G, Singletary E, Akins J, Mirza N, Hunt KK. Location Correlates with Lymphoscintigraphy Drainage to the Internal Mammary Lymph Nodes in Breast Cancer. The 11th Scientific Session of the Western Surgical Society, Tucson, AZ, 2003. e-Pub 2003.
Kronowitz S, Kuerer HM, Hunt K, Babiera GV, McNeese MD, Buchholz T, Robb G. Delayed immediate breast reconstruction. 72nd Annual Scientific Meeting of the American Society of Plastic Surgeons, San Diego, CA, 2003. e-Pub 2003.
Huang E, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Hortobagyi GN, Buzdar AU, Valero V, Perkins G, Hunt KK, Sahin A, Buchholz TA. Radiation Treatment Reduces Local-Regional Recurrence and Improves Survival In Selected Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Mastectomy. Proc Am Soc Thera Rad Oncol (ASTRO), Salt Lake City, UT, 2003. e-Pub 2003.
Pawlik TM, Strom EA, Singletary E, Babiera GV, Hunt KK, Meric F, Kuerer HM. Effect of Surgical Volume of Resection on Potential Applicability of Balloon Intracavitry Irradiation in Breast Conservation Therapy. American College of Surgeons 89th Annual Clinical Congress, Chicago, IL, 2003. e-Pub 2003.
Buchholz TA, Huang E, Berry D, Strom EA, McNeese MD, Pusztai L, Kuerer HM, Buzdar AU, Hortobagyi GN, Valero V, Perkins G, Sahin AA. Her2-Neu Overexpression Does Not Increase the Risk of Local-Regional Recurrence for Patients Treated with Neoadjuvant Doxorubicin-Based Chemotherapy, Mastectomy, and Radiation. Proc Am Soc Thera Rad Oncol (ASTRO), Salt Lake City, UT, 2003. e-Pub 2003.
Chagpar AB, Middleton LP, Sahin A, Ross MI, Ames FC, Feig BW, Kuerer HM, Valero V, Hunt KK. Clinical outcome of node negative breast cancer patients with micrometastatic disease by immunohistochemistry. Proceedings of the American Society of Clinical Oncology, Chicago, IL, 2003. e-Pub 2003.
Cabioglu N, Krishnamurthy S, Kuerer HM, Hunt K, Singletary SE, Meric F, Feig B, Ross M, Ames F, Babiera GV. The role of breast conserving surgery in women with breast cancer presenting with nipple discharge. Society of Clinical Oncology, Chicago, IL, 2003. e-Pub 2003.
Chagpar A, Yen T, Sahin A, Hunt K, Whitman G, Ames F, Ross M, Meric F, Babiera G, Singletary ES, Kuerer HM. Intraoperative margin assessment reduces re-excision rates in breast conservation surgery for ductal carcinoma in situ. American Society of Breast Surgeons, Atlanta, GA, 2003. e-Pub 2003.
Chagpar A, Evelegh M, Fritsche H, Krishnamurthy S, Hunt K, Kuerer HM. Prospective evaluation of a novel quantitative galactose oxidase-schiff’s reaction in nipple aspirate fluid from women with invasive breast carcinoma. AACR, Toronto, Canada, 2003. e-Pub 2003.
Chandrajit PR, Daley MD, Hunt KK, Akins J, Ross MI, Singletary SE, Marshall GD, Meric F, Babiera G, Feig BW, Ames FC, Kuerer HM. Incidence of anaphylactoid reactions during breast cancer lymphatic mapping following preoperative prophylaxis: Initial results of a prospective clinical practice protocol. Southwestern Surgical Congress, Tucson, AZ, 2003. e-Pub 2003.
Yen T, Hunt K, Mirza N, Thomas E, Meric F, Babiera G, Buchholz T, Singletary E, Feig B, Ross M, Theriault R, Ames F, Kuerer H. Physician recommendations and patient utilization of tamoxifen following surgery for ductal carcinoma in situ at a national comprehensive cancer center. American Society of Breast Surgeons, Atlanta, GA, 2003. e-Pub 2003.
Yen T, Hunt K, Thomas E, Mirza N, Meric F, Babiera G, Buchholz T, Singletary E, Feig B, Ross M, Theriault R, Ames F, Kuerer HM. Tamoxifen (TAM) following surgery for ductal carcinoma in situ (DCIS): Physician perceptions and practices. Society of Surgical Oncology, Los Angeles, CA, 2003. e-Pub 2003.
Chagpar A, Meric F, Hunt K, Cristofanilli M, Singletary S, Buchholz T, Ames F, Marcy S, Babiera G, Feig B, Ross M, Hortobagyi G, Kuerer HM. Chest wall recurrence after mastectomy in early stage node negative patients does not portend dismal prognosis: A ten year multivariate survival analysis. Society of Surgical Oncology, Los Angeles, CA, 2003. e-Pub 2003.
Kuerer HM, Goldknopf IL, Fritsche H, Krishnamurthy S, Coombes KR, Clarke C, Chen JN, Xiao LC, Sheta EA, Hung MC, Hunt KK. Protein Expression Patterns in Bilateral Matched-Pair Breast Ductal Fluid Specimens from Women with Unilateral Invasive Breast Cancer. The 3rd Annual International Symposium on the Intraductal Approach to Breast Cancer, Santa Barbara, CA, 2003. e-Pub 2003.
Newman L, Kuerer H, Hunt K, Ross M, Ames F, Feig B, Buzdar A, Fornage B, Singletary S. Adverse prognostic impact of infraclavicular lymph nodes detected by ultrasound in patients with locally advanced breast cancer. Proceedings of the American Society of Clinical Oncology, Atlanta, GA, 1999. e-Pub 1999.
Sahin A, Kuerer HM, Newman L, Hunt K, Singletary SE. Pathological aspects and prognostic criteria of residual metastases in locally advanced breast cancer patients treated with neoadjuvant chemotherapy. International Academy of Pathology, San Francisco, CA, 1999. e-Pub 1999.
Yemini H, Kuerer HM, Newman L, Singletary SE, Hortobagyi G, Atkinson N, Sneige N. Biological predictors of response to neoadjuvant chemotherapy in locally advanced breast cancer patients. International Academy of Pathology, San Francisco, CA, 1999. e-Pub 1999.
Cohen L, Breslin T, Kuerer H, Sahin A. Identification and evaluation of axillary sentinel lymph nodes (SLN) in patients with breast cancer (BC) treated with neoadjuvant chemotherapy. International Academy of Pathology, San Francisco, CA, 1999. e-Pub 1999.
Breslin T, Fox L, Kuerer H, Fleming J, Delpassand E, Colchin R, Feig B, Ames F, Ross M, Hunt KK. Lymphatic mapping and sentinel node biopsy is accurate following chemotherapy for breast cancer. Proceedings of the Society of Surgical Oncology, Orlando, FL, 1999. e-Pub 1999.
Newman L, Kuerer H, Hunt K, Ames F, Ross M, Theriault R, Fry N, Kroll S, Robb G, Singletary E. Feasibility of immediate breast reconstruction for locally advanced breast cancer. Proceedings of the Society of Surgical Oncology, Orlando, FL, 1999. e-Pub 1999.
Newman LA, Kuerer HM, Hunt KK, Ames FC, Ross MI, Feig BW, Hortobagyi GN, Buzdar AU, Singletary SE. Response to induction chemotherapy in black and white patients with locally advanced breast cancer. 21st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 1998. e-Pub 1998.
Kuerer HM, Sahin A, Hunt KK, Newman LA, Breslin T, Ames FC, Ross MI, Buzdar AU, Hortobagyi GN, Singletary SE. Incidence and impact of occult breast cancer axillary lymph node micrometastases in patients with complete conversion to a histologic negative lymph node status after neoadjuvant chemotherapy. 21st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 1998. e-Pub 1998.
Buchholz TA, Strom EA, McNeese NM, Kueer HM, Buzdar AU, Singeltary E. Second malignancies associated with breast cancer. American Radium Society 80th Annual Meeting, Monte Carlo, Monaco, 1998. e-Pub 1998.
Kuerer HM, Newman LA, Ames FC, Binkley SM, Hunt KK, Buzdar AU, Ross MI, Feig BW, Hortobagyi GN, Singletary SE. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. American Radium Society 80th Annual Meeting, Monte Carlo, Monaco, 1998. e-Pub 1998.
Newman LA, Kuerer HM, Singh G, Buchholz TA, Hunt KK, Ames FC, Singletary SE. Age-related differences in the utilization and impact of multimodality therapy on the survival of black breast cancer patients. Proceedings of the American Society of Clinical Oncology, Los Angeles, CA, 1998. e-Pub 1998.
Kuerer HM, Newman LA, Ames FC, Theriault RL, Hunt KK, Sneige N, Buchholz TA, Singh G, Binkley SM, McNeese MD, Buzdar GN, Hortobagyi GN, Singletary SE. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response (pCR) to doxorubicin based neoadjuvant chemotherapy. Proceedings of the American Society of Clinical Oncology, Los Angeles, CA, 1998. e-Pub 1998.
Kuerer HM, Newman LA, Hunt KK, Ames FC, Buzdar AU, Ross MI, Feig BW, Hortobagyi GN, Singletary SE. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predicts disease-free survival in locally advanced breast cancer patients. The Southwestern Surgical Congress Annual Meeting, San Antonio, TX, 1998. e-Pub 1998.
Kuerer H, Newman L, Binkley S, Buzdar A, Hunt K, Ames F, Ross M, Feig B, Hortobagyi GN, Singletary E. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy. Proceedings of the Society of Surgical Oncology, San Diego, CA, 1998. e-Pub 1998.
Newman L, Kuerer H, Kroll S, Hunt K, Ames F, Ross M, Feig B, Singletary E. Patient outcome afater locoregional recurrence with skin-sparing mastectomy and immediate breast reconstruction. Proceedings of the Society of Surgical Oncology, San Diego, CA, 1998. e-Pub 1998.
Divino C, Kuerer HM, Tartter, PI. Reassessment of the necessity of drainage after lumpectomy and axillary dissection. Proceedings of the Society of Surgical Oncology, Atlanta, Georgia, 1996. e-Pub 1996.
Manasia A, Kuerer HM, Kang H, Hannon E, Oropello J, Stein J, Benjamin E. Effects of low dose intravenously administered synthetic prostacyclin in non-occlusive acute mesenteric ischemia induced by reversible cardiac tamponade. Proceedings of the Society of Critical Care Medicine, New Orleans, Louisiana, 1996. e-Pub 1996.
Farley CR, Bassett R, Meric-Bernstam F, Bedrosian I, Caudle A, DeSnyder S, Hunt KK, Kuerer HM, Singh P, Sun S, Tamirisa N, Teshome M, Hwang R. To Dissect or Not to Dissect: Can we predict the presence of four or more axillary lymph node metastases in postmenopausal women with breast cancer?. The American Society of Breast Surgeons 23rd Annual Meeting.
Kuerer HM. Local-Regional Recurrence and Breast Cancer Survival Vary by Extent of Residual Disease and Tumor Biology – Long-term Outcomes from the Z1071 Trial. San Antonio Breast Cancer Symposium (SABCS).
Woodfin AA, Yam C, Teshome M, Kuerer HM, Hunt K, Meric-Bernstam F, Barcenas C, Sun SX. Surgical Outcomes in Patients Receiving KEYNOTE 522 Regimen for Triple Negative Breast Cancer. The American Society of Breast Surgeons 23rd Annual Meeting.
Woodfin AA, Yam C, Teshome M, Kuerer HM, Hunt K, Meric-Bernstam F, Barcenas C, Sun SX. Surgical Outcomes in Patients Receiving KEYNOTE 522 Regimen for Triple Negative Breast Cancer. American Society of Breast Surgeons.
Lattimore CM, Johnson HM, Kuerer HM, Caudle AS, Giordano SH, Hunt KK, Huo L, Wanis KN. Clipped node pathology as a guide for limited axillary surgery in occult breast cancer. SSO 2026 Annual Meeting.
Johnson HM, Kuerer HM, Martinez AL, Litton JK, Oke OC. Axillary surgery for patients with pregnancy-related breast cancer: Feasibility and safety of sentinel lymph node dissection. SSO 2026 Annual Meeting.

Book Chapters

Black DM, McElroy K, Kuerer HM. Mastectomy. In: Diagnostic Imaging, Breast. Third Edition. Elsevier, 1258, 2019.
Black DM, McElroy K, Kuerer HM. Sentinel Lymph Node Biopsy. In: Diagnostic Imaging, Breast. Third Edition. Elsevier, 1238, 2019.
Refinetti AP, Black DM, Kuerer HM. Targeted Axillary Dissection. In: Diagnostic Imaging, Breast. Third Edition. Elsevier, 1242, 2019.
Black DM, McElroy K, Kuerer HM. Axillary Lymph Node Dissection. In: Diagnostic Imaging, Breast. Third Edition. Elsevier, 1246, 2019.
Mays SR, Hymes SR, Cole KC, Kuerer MK. Dermatologic Emergencies. In: Oncologic Emergencies. Springer New York, 349-370, 2016.
Caudle A, Mittendorf E, Kuerer H. Breast Cancer: Lymphatic mapping and sentinel lymphadenectomy. In: Elective General Surgery: An Evidence-Based Approach. Peoples Medical Publishing House USA, 2015.
Black DM, Kuerer HM. Breast Conserving Surgery. In: Diagnostic Imaging: Breast. 2nd. Amirsys, 2013.
Black DM, Kuerer HM. Axillary Node Dissection. In: Diagnostic Imaging: Breast. 2nd. Amirsys, 2013.
Black DM, Kuerer HM. Mastectomy. In: Diagnostic Imaging: Breast. 2nd. Amirsys, 2013.
Black DM, Kuerer HM. Surgery. In: Diagnostic Imaging: Breast. 2nd. Amirsys, 2013.
Black DM, Kuerer HM. Sentinel Lymph Node Surgery. In: Diagnostic Imaging: Breast. 2nd. Amirsys, 2013.
Akay C, Kuerer HM, Hwang RF. Sentinel Lymph Node Biopsy in Breast Cancer: The MD Anderson Cancer Center Approach. In: Advanced Therapy of Breast Disease. 3rd. People's Medical Publishing House USA, 545-555, 2012.
Arun B, Kuerer HM. Breast Cancer Risk Assessment and Management. In: Breast Cancer. Second Edition. B. C. Decker, Inc, 96-105, 2006.
Kuerer HM. Surgical Considerations for Accelerated Partial-Breast Irradiation. In: Accelerated Partial Breast Irradiation: Techniques and Clinical Implementation. Springer, 2006.
Ehlers R, Kuerer HM, Singletary SE. Sentinel lymph node biopsy for breast cancer: The MD Anderson Approach. In: Advanced Therapy of Breast Disease. Second Edition. B. C. Decker, Inc, 361-67, 2004.
Kuerer HM, Cabioglu N. Nipple Discharge and Ductal Secretions. In: Advanced Therapy of Breast Disease. Second Edition. B.C. Decker, Inc, 37-43, 2004.
Singletary SE, Kuerer HM. Preoperative Systemic Therapy for Operable Breast Cancer. In: American Society of Clinical Oncology Educational Handbook. American Society Clinical Oncology, 526-28, 2001.
Kuerer HM, Ames FC. Utility of overnight migration of high-dose radiocolloid in breast cancer lymphatic mapping. In: Mastery of Lymphatic Mapping. Springer, 2000.
Kaiser S, Kuerer HM. Breast Surgery. In: Handbook of Surgery. First Edition. Williams and Wilkins, 1998.
Kuerer HM. Tumor Biology. In: Handbook of Surgery. First Edition. Williams and Wilkins, 1998.

Books (edited and written)

Kuerer HM. Kuerer's Breast Surgical Oncology. McGraw-Hill, 2010.

Letters to the Editor

Dominici LS, Mittendorf EA, Kuerer HM. Reply to Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer 117: 1783-4, 2011.
Kronowitz SJ, Feledy JA, Hunt KK, Kuerer HM, Youssef A, Koutz CA, Robb GL. Determining the optimal approach to breast reconstruction after partial mastectomy: reply. Plast Reconstr Surg 118: 814-5, 2006.
Kronowitz SJ, Feledy JA, Hunt KK, Kuerer HM, Youssef A, Koutz CA, Robb GL. Determining the optimal approach to breast reconstruction after partial mastectomy. Plastic and Reconstructive Surgery 117: 1-11, 2006.
Raut C, Hunt KK, Kuerer HM. Blue Dye of choice for lymphatic mapping. J Clin Oncol 15: 3648-9, 2005.
Kronowitz S, Kuerer HM. Sentinel lymph node biopsy followed by delayed mastectomy and reconstruction. Am J Surg 189: 251-2, 2005.
Kuerer HM, Julian T, Vicini F. Accelerated partial breast irradiation after conservative surgery for breast cancer. Ann Surg 242: 148-9, 2005.
Jeruss JS, Kuerer HM. Bone Marrow Micrometastases in Breast Cancer. N Engl J Med 353: 2191, 2005.
Kuerer HM, Pawlik TM, Strom EA. Intracavitary Balloon Brachytherapy for Breast Cancer: Surgical considerations. Int J Radiat Oncol Biol Phys 57: 900-2, 2003.
Kuerer HM, Krishnamurthy S, Kronowitz SJ. Important technical considerations for skin-sparing mastectomy with sentinel lymph node dissection. Arch Surg 137: 747, 2002.
Buchholz TA, Kronowitz SJ, Kuerer HM. Immediate breast reconstruction after skin-sparing mastectomy for the treatment of advanced breast cancer: radiation oncology considerations. Ann Surg Oncol 9: 820-1, 2002.
Krishnamurthy S, Kuerer HM. Foam cells in nipple aspiration fluid. Cytopathology 13: 64-6, 2002.
Kuerer HM, Wayne JD, Ross MI. Anaphylaxis during breast cancer lymphatic mapping. Surgery 129: 119-20, 2001.
Kuerer HM, Hwang RF, Esserman LJ. Prophylactic mastectomy in women with a high risk of breast cancer. N Engl J Med 340: 1837-39, 1999.

Patents

Fritsche HS, Kuerer HM. Methods and compositions for detection of breast cancer. Patent Number: 6,855,554.

Less

CV information above last modified November 10, 2025

Henry M. Kuerer, M.D., Ph.D., F.A.C.S., CMQ

About Dr. Kuerer

In the News

Surgery may not be necessary to treat invasive breast cancer

Breast biopsies after neoadjuvant chemotherapy accurately predict presence of residual breast cancer

MD Anderson study evaluates need for biopsies during follow-up care in women with early breast cancer

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Professional Educational Materials

Other Articles

Editorials

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Patents

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop MD Anderson